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ABSTRACT 
 
Tuberculosis, the infectious disease caused by Mycobacterium tuberculosis, is a 
global health problem with approximately two million deaths annually. One-third of 
the world population is chronically infected with Mycobacterium tuberculosis but do 
not show clinical symptoms although there is a 10% risk to development active 
disease, representing an uncontrollable reservoir of tuberculosis. In this 
asymptomatic condition, referred to as latent tuberculosis, Mycobacterium 
tuberculosis is located within granulomatous lesions in the host and is resistant to 
currently available antimycobacterial drugs.  
Two-component regulatory systems in bacteria are a major class of signal 
transduction proteins involved in adaptation to environmental changes. Typical 
system contains a membrane-bound histidine kinase that plays a crucial role in 
sensing environmental stimuli, and a cytosolic response regulator. This pair of 
proteins functions as a molecular switch that controls diverse adaptive 
environmental responses. Mycobacterium tuberculosis has eleven complete two-
component systems. The DosRST system, composed of a response regulator, DosR, 
and two histidine kinases, DosS and DosT, plays a key role in Mycobacterium 
tuberculosis adaptation to latent tuberculosis. DosS and DosT autophosphorylate at 
conserved histidine residues and both proteins transfer this phosphor moiety to 
aspartic acid residue 54 of DosR. The phosphorylation of Asp54 serves as a switch to 
activate DosR and to increase the affinity for its cognate DNA promoters.  
Threonines 198 and 205 of DosR play a crucial role in DosR dimerization and DNA 
binding. The molecular dynamics with wild type and mutant version of DosR show 
different stability in the formation of the active DosR dimer. They also show the 
reduction or the abolishment of protein-DNA interactions because of the repulsions 
generated by negatively charged mutated residues. Moreover, substitutions in 
threonines 198 and 205 of DosR have a relevant effect on the chemical and 
enzymatic phosphorylation of DosR and on its DosS-catalysed dephosphorylation. 
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The DosRST two-component system is a good target for the development of novel 
antimycobacterial drugs against dormant forms of M. tuberculosis. A structure-
based discovery programme of inhibitors of DosR response regulator has been 
initiated with commercially available compounds showing a certain degree of 
similarity with a phenylcoumarin derivative previously described as DosR-DNA 
interfering molecule. 
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Resum 
La tuberculosi, la  malaltia infecciosa causada per Mycobacterium tuberculosis, es un problema de 
salut global que provoca aproximadament 2 milions de morts anuals. Un terç de la població mundial 
es troba crònicament infectada amb Mycobacterium tuberculosis però no mostra símptomes clínics 
encara que té un risc d’un 10% de desenvolupar la malaltia, la qual cosa representa un reservori 
incontrolable de tuberculosi. En aquesta condició asimptomàtica, coneguda com a tuberculosi latent, 
Mycobacterium tuberculosis es localitza en lesions granulomatoses a l’hoste i és resistent als 
medicaments antimicobacterians existents en l’actualitat.  
En bacteris, els sistemes reguladors de dos components son un conjunt de proteïnes implicades en 
l’adaptació a canvis en l’entorn del microorganisme. Un sistema de dos components típic consta 
d’una histidina quinasa unida a membrana que té un paper essencial com a sensor dels canvis 
ambientals i un regulador transcripcional citosòlic que exerceix la seva funció controlant l’expressió 
de gens diana. Aquest parell de proteïnes funciona com un interruptor molecular que controla 
diferents respostes adaptatives a canvis a l’ambient cel·lular. Mycobacterium tuberculosis té 11 
sistemes de dos components complets. El sistema DosRST, composat per un regulador 
transcripcional, DosR, i dues histidines quinases, DosS i DosT, té un paper estel·lar en l’adaptació de 
Mycobacterium tuberculosis a la tuberculosi latent. DosS i DosT s’autofosforilen en residus conservats 
d’histidina i ambdues proteïnes transfereixen aquesta un unitat de fosfat al residu d’àcid aspàrtic en 
posició 54 del regulador DosR. La fosforilació d’Asp54 és un interruptor que  activa DosR i 
incrementa la seva afinitat per als promotors dels gens que regula.  Les treonines 198 i 205 de DosR 
tenen un paper crucial en la dimerització de DosR i en la seva unió al DNA. Les dinàmiques moleculars 
realitzades amb la proteïna salvatge DosR i amb versions mutants mostren diferències notables en la 
formació del dímer actiu. També mostren una reducció o abolició completa de les interaccions 
proteïna-DNA a causa de les repulsions generades pels residus mutants carregats negativament. 
Encara més, les substitucions en Thr198 i Thr205 tenen un important efecte en la fosforilació química 
i enzimàtica de DosR així com també en la seva defosforilació catalitzada per DosS. 
El sistema de dos components DosRST és una bona diana per al desenvolupament de nous 
compostos amb activitat antimicobacteriana contra formes dorments de Mycobacterium 
tuberculosis. S’ha iniciat un programa de recerca dirigit al desenvolupament d’inhibidors específics de 
la proteïna reguladors DosR, usant com a punt de partida compostos comercials estructuralment 
relacionats amb un derivat fenilcumarínic que ha estat descrit com a molècula que interfereix en la 
interacció DosR-DNA.   
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Resumen 
La tuberculosis, la enfermedad infecciosa causada por Mycobacterium tuberculosis, es un problema 
de salud global que provoca aproximadamente 2 millones de muertes anuales. Un tercio de la 
población mundial se encuentra crónicamente infectada con Mycobacterium tuberculosis pero no 
muestra síntomas clínicos aunque tiene un riesgo de un 10% de desarrollar la enfermedad, lo que 
representa un reservorio incontrolable de tuberculosis. En esta condición asintomática, conocida 
como tuberculosis latente, Mycobacterium tuberculosis se localiza en lesiones granulomatosas en el 
huésped y es resistente a los medicamentos antimicobacterianos existentes en la actualidad.  
En bacterias, los sistemas regulatorios de dos componentes son un conjunto de proteínas implicadas 
en la adaptación a cambios en el entorno del microorganismo. Un sistema de dos componentes 
típico consta de una histidina quinasa unida a membrana que tiene un papel esencial como sensor de 
los cambios ambientales y un regulador transcripcional citosólico que ejerce su función controlando 
la expresión de genes diana. Este par de proteínas funciona como un interruptor molecular que 
controla distintas respuestas adaptativas a cambios en el ambiente celular. Mycobacterium 
tuberculosis tiene 11 sistemas de dos componentes completos. El sistema DosRST, compuesto por un 
regulador transcripcional, DosR, y dos histidinas quinasas, DosS y DosT, juega un papel estelar en la 
adaptación de Mycobacterium tuberculosis a la tuberculosis latente. DosS y DosT se autofosforilan en 
residuos conservados de histidina y ambas proteínas transfieren esta unidad de fosfato al residuo de 
ácido aspártico en posición 54 del regulador DosR. La fosforilación de Asp54 es un interruptor que 
activa a DosR e incrementa su afinidad por los promotores de los genes que regula. Las treoninas 198 
y 205 de DosR juegan un papel crucial en la dimerización de DosR y en su unión al DNA. Las dinámicas 
moleculares realizadas con la proteína salvaje DosR y con versiones mutantes muestran diferencias 
notables en la formación del dímero activo. También muestran una reducción o abolición completa 
de las interacciones proteína-DNA a causa de las repulsiones generadas por los residuos mutantes 
cargados negativamente. Más aún, las sustituciones en Thr198 y Thr205 tienen un importante efecto 
en la fosforilación química y enzimática de DosR así como también en su defosforilación catalizada 
por DosS.  
El sistema de dos componentes DosRST es una buena diana para el desarrollo de nuevos 
compuestos con actividad antimicobacteriana contra formas durmientes de Mycobacterium 
tuberculosis. Se ha iniciado un programa de investigación dirigido al desarrollo de inhibidores 
específicos de la proteína reguladora DosR, usando como punto de partida compuestos comerciales 
estructuralmente relacionados con un derivado fenilcumarínico que ha sido descrito como molécula 
que interfiere en la interacción DosR-DNA.  
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Streszczenie 
Gruźlica, choroba zakaźna spowodowana przez Mycobacterium tuberculosis, jest globalnym 
problemem zdrowotnym z dwoma milionami zgonów rocznie. Jedna trzecia ludności świata jest 
przewlekle zakażona Mycobacterium tuberculosis, nie wykazując objawów klinicznych, aczkolwiek z 
10% ryzykiem aktywnego rozwoju choroby, co oznacza niekontrolowany zbiornik gruźlicy. W tym 
bezobjawowym stanie utajonej gruźlicy, Mycobacterium tuberculosis jest usytuowane w 
ziarniniakowych zmianach w gospodarzu odpornym na działanie obecnie dostępnych leków 
przeciwprątkowych . 
Dwuskładnikowe układy wykonawcze (two-component systems) w bakteriach są główną klasą 
białek transdukcji sygnału zaangażowane w adaptację bakterii do zmian środowiskowych. Typowy 
system zawiera kinazę histydynową, która odgrywa kluczową rolę w detekcji bodźców 
środowiskowych i cytozolowy regulator odpowiedzi. Ta para białek funkcjonuje jako molekularny 
przełącznik, który steruje różnymi zmianami adaptacyjnymi w odpowiedzi na środowisko. 
Mycobacterium tuberculosis ma jedenaście kompletnych systemów dwuskładnikowych. System 
DosRST, składający się z regulatora odpowiedzi, DosR oraz dwóch kinaz histydynowych, DosS i DosT, 
odgrywa kluczową rolę w adaptacji Mycobacterium tuberculosis do utajonej gruźlicy. DosS i DosT 
autofosforylują konserwatywne reszty histydyny i oba białka mogą przenieść grupę fosforową do 
reszty kwasu asparaginowego 54 w DosR. Fosforylacja Asp54 służy jako przełącznik, ktory uaktywnia 
DosR oraz zwiększa jego powinowactwo do odpowiedniego promotora DNA. Reszty treoninowe 198 
i 205 DosR odgrywają kluczową rolę w dimeryzacji DosR i wiązaniu DNA. Dynamika molekularna z 
typu dzikiego i zmutowanej wersji DosR wykazuje różnice w trwałości tworzenia aktywnego dimeru 
DosR. Pokazuje ona także zmniejszenie lub zniesienie interakcje białko-DNA ze względu na 
odpychanie generowanych przez ujemnie naładowane reszty zmutowanych aminokwasów. Ponadto 
podstawienia w treoninach 198 i 205 w DosR mają istotny wpływ na chemiczną i enzymatyczną 
fosforylację DosR i na jego defosforylację katalizowaną przez DosS . 
Układ dwuskładnikowy DosRST jest dobrym obiektem dla opracowania nowych leków 
przeciwprątkowych przeciw nieaktywnym formom M. tuberculosis. Strukturalny program oparty na 
wykrywaniu inhibitorów regulatora odpowiedzi DosR został zainicjowany z użyciem dostępnych w 
handlu związków wykazujących pewien stopień podobieństwa z pochodną fenylkumaryny opisaną 
poprzednio jako cząsteczka zakłócająca oddziaływania DosR z DNA. 
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Strategies) project (www.stars-itn.eu) was directed towards the discovery and 
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 INTRODUCTION 
 
1 Tuberculosis 
A more detailed description of epidemiological, clinical and pharmacological aspects 
of active tuberculosis can be found in annex 1. 
 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(M.tuberculosis, Mtb), which most commonly affects the lungs. The World Health 
Organization (WHO) estimates that one third of world’s total population is currently 
infected with Mtb and approximately 10% of these people are expected to develop 
active TB at some point in their lifetime. A new individual is infected every second 
whilst another one dies from the disease every 15 seconds. Furthermore, the 
development of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-
resistant tuberculosis (XDR-TB) strains, together with the spread of risk factors such 
as human immunodeficiency virus (HIV), acquired immunodeficiency syndrome 
(AIDS) and diabetes (Corbett et al., 2003, Restrepo et al., 2007), continue making 
Mtb a health concern in developed countries and strengthened the urge to develop 
new treatment infection strategies. 
WHO Global Tuberculosis Report 2013 (WHO 2013) indicates that in 2012 almost 1.3 
million people died of TB, new cases were estimated at 8.6 million, and the number 
of total TB cases worldwide is about 14 million. These figures are equivalent to 122 
cases per 100,000 population (Fig.  1). Most of the estimated number of cases in 
2012 occurred in Asia (58%) and Africa (27%). 
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Fig.  1 Estimated TB incident rates, 2012 (WHO, 2013). 
 
Mycobacterium tuberculosis mainly infects the lungs and causes a bad coughing. The 
clinical manifestations of tuberculosis can vary depending on the stage of 
tuberculosis, which include latency, primary disease, primary progressive (active) 
disease, and extrapulmonary disease. 
Tuberculosis is primarily transmitted through air and spread by small airborne 
droplets, called droplet nuclei. 
The most frequent method for diagnosing TB worldwide is sputum smear 
microscopy (Hopewell et al., 2006). This test is relatively simple and rapid to 
perform, but it is not specific for tuberculosis as other mycobacteria give the same 
results. However, it does provide a quick method to determine if prevention should 
be taken while more definitive testing is performed. 
Purified tuberculin protein derivative is used in tuberculin skin test (TST, Mantoux 
test). The degree of inflammatory reaction at the site of injection is an indication of 
the individual´s present or past association with the TB bacillus.  
Bacille Calmette-Guerin (BCG), the oldest of the vaccines currently used throughout 
the world, is a commonly used prevention method in TB. New TB vaccines are an 
urgent part of a comprehensive plan to control and ulimately eliminate TB. Over the 
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past decade, researchers have made significant progress in TB vaccine 
development. 
Antitubercular drugs can be divided into first-line drugs, those that generally have 
the greatest bactericidal activity when used for TB treatment, the second-line 
therapeutic-drugs, which are less effective, more expensive and have higher 
toxicities, and experimental drugs. First-line drugs include isoniazid, rifampin, 
pyrazinamide, ethambutol, and streptomycin. Second-line drugs contain ƿ-
aminosalicylicacid, ethionamide, cycloserine, kanamycin, capreomycin, amikacin, 
ciproflaxin, ofloxacin and viomycin. 
Current therapy against tuberculosis is cumbersome, due to its long duration 
(~6months) and often leads to poor patient compliance. There is an urgent need for 
more effective and tolerable treatment of drug-susceptible and drug-resistant 
disease, latent TB infection, and dosing strategies for children. New drugs are 
required to shorten and simplify treatment, to improve the efficacy and tolerability 
of treatment for resistant strains of Mtb and to improve the treatment of TB among 
people living with HIV.  
Multi-drug resistant tuberculosis (MDR-TB) is defined as resistance to the first-line 
drugs isoniazid and rifampin. Extensively drug resistant TB (XDR-TB) is defined as 
MDR-TB plus resistance to a fluoroquinolone, and at least one of three injectable 
second-line drugs. Treating XDR-TB is difficult and requires tailored individual care. 
There are many governmental, multi-lateral and also non-governmental 
organizations  dedicated to TB research. Their role is to accelerate progress on 
access to TB diagnosis and treatment, research and development for new TB 
diagnostics, drugs and vaccines, and tackling drug resistant- and HIV-associated.  
WHO carries global leadership on matters critical to TB by monitoring TB situation in 
the world, including new strategies and standard implementation and measuring 
progress in TB care, control, and financing. WHO shapes the TB research agenda 
and stimulates the generation, translation and dissemination of valuable 
knowledge. 
Main target that unites all TB organizations is The Millennium Development Goal 
(MDG) under which by 2015 the global burden of TB disease (deaths and 
prevalence) will be reduced by 50% relative to 1990 levels, and further, by 2050, the 
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global incidence of TB disease will be less than 1 per million population. By 2012, the 
prevalence rate fell 37% globally since 1990. Current forecasts suggest that the Stop 
TB Partnership target of halving TB prevalence by 2015 compared with a baseline of 
1990 will not be met worldwide (WHO 2013). 
 
2 The Mycobacterium genus 
2.1 Classification and characteristics  
2.1.1 Taxonomy 
In the Bacteria Kingdom, Genus Mycobacterium belongs to the Phylum 
Actinobacteria, Order Actinomycetales (Suborder Corynebacterineae) and Family 
Mycobacteriaceae. 
 
2.1.2 Clinical and epidemiological classification of mycobacteria 
The classification of mycobacteria started in 1896 when Lehmann and Neumann 
proposed for the first time the genus Mycobacterium which included Mycobacterium 
tuberculosis and Mycobacterium leprae species. Phenotypic characteristics and 
biochemical tests have been used to classify mycobacteria into different species; 
more recently genotypic characteristics have been introduced as a tool for 
mycobacterial identification and classification. According to the latest ´´List of 
Bacterial Names with Standing in Nomenclature´´ there are more than 100 
recognized species in the genus Mycobacterium (Bannister et al., 2006).  
Under DNA-based molecular taxonomy, mycobacteria are classified as Gram-
positive bacteria due to genes high similarity with other gram-positive organisms, 
such as Bacillus (Hett & Rubin 2008). 
According to their growth rate, the Mycobacterium genus is usually separated into 
two major groups: i) slow-growing species including M. tuberculosis, M. bovis and M. 
leprae; and ii) fast-growing species such as M. smegmatis. 
Based on their epidemiological features, Mycobacterium includes: i) members which 
widely occur in natural ecosystems decomposing organic matter and due to the 
nitrogen binding activity they are useful and essential inhabitants of the soil and 
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surface waters (Hett & Rubin, 2008) (non-pathogenic or rarely pathogenic 
mycobacteria); ii) species strictly pathogenic to humans and/or animals (strictly 
pathogenic mycobacteria); iii) types usually commensal to humans, but pathogenic 
under certain circumstances (potentially pathogenic mycobacteria) (Brosch et al., 
2001;) (Table 1). 
Among the pathogenic species the most relevant for human health are M. 
tuberculosis and M. leprae, the causative agents of two of the world’s oldest 
diseases, tuberculosis and leprosy, respectively (Hett & Rubin, 2008). 
M. canettii and M. africanum, which also can cause human TB, are most commonly 
isolated from African patients. M. bovis demonstrates the broadest spectrum of 
host infection, affecting humans, domestic or wild bovines and goats. M. microti can 
also cause disease in immunocompromised human patients (Brosch et al., 2002, 
Niemann, 2000) and M. pinnipedii infects seals (Cousins et al., 2003). 
M. kansasii, M. malmoense and M. xenopi represent pulmonary opportunists, while 
M. marinum is the skin pathogen infecting organism by entering through damaged 
or ulcerated skin.  M. ulcerans is the causative organism of buruli (tropical) ulcer 
(Bannister et al., 2006). 
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Table 1 Classification of mycobacteria according to the risk of infection (Brosch et al., 2001). 
Rare pathogens Potential pathogens Strict pathogens 
M. smegmatis M. aurum M. avium M. tuberculosis 
M. phlei M. chitae M. intracellulare M. bovis 
M. fallax M. duvalii M. chelonae M. africanum 
M. thermoresistibile M. gadium M. fortuitum M. ulcerans 
M. parafortuitum M. gilvum M. kansasii M. microti 
M. gastri M. komossense M. malmoense M. canetti 
M. triviale M. lepraemurium M. marinum M. caprae 
M. nonchromogenicum M. neoaurum M. scrofulaceum M. pinnipedii 
M. gordonae M. terrae M. simiae M. leprae 
M. flavescens M. vaccae M. szulgai  
M. farcinogenes M. agri M. xenopi  
M. senegalense M. aichiense M. asiaticum  
M. paratuberculosis M. austroafricanum M. haemophilum  
M. porcinum M. chubuense M. shimoidei  
M. diernhoferi M. obuense   
M. pulveris M. rhodesiae   
M. tokaiense M. moriokaense   
M. poriferae    
 
According to the similarities in genetic and phenotypic characteristics different 
complexes can be differentiate within Mycobacterium genus. 
All of the species of Mycobacterium tuberculosis complex (MTBC), which includes M. 
tuberculosis, M. canettii, M. africanum, M. microti, M. bovis, M. caprae and M. 
pinnipedii, are known to cause TB in humans 
The M. avium complex (MAC) comprises M. avium subspecies responsible for 
disease in birds, but also for disseminated disease in patients with AIDS, causing 
systemic infections late in the progress of AIDS (Tyagi et al., 2004), cervical 
lymphadenitis, and chronic lung disease in immunocompetent or non-HIV patients 
(Turenne et al., 2007). 
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The Mycobacterium fortuitum complex includes M. fortuitum, M. peregrinum, M. 
abcessus and M. chelonae, which are frequently responsible for abscess formation in 
local injection or surgical wounds and can be associated with pulmonary disease 
(Griffith, 2007). 
 
2.1.3 Morphology 
Mycobacteria are typically rod-shaped, non–spore forming, aerobic bacteria, 
classified as acid-fast bacilli. The dimensions of the bacilli have been reported to be 
1-10 µm in length (usually 3-5 µm), and 0.2 -0.6 µm width. Variable morphology can 
be observed when grown on solid media and some species exist as shorter cocci-
bacilli or curved rods on artificial media (Belisle & Brennan 1989).  
The reported morphological variation in M. tuberculosis are classified in two 
categories; i) those which are frequently seen at exponential phase of growth that 
is rod, V, Y-shape, branched or buds (Fig.  2A), and ii) those that are seen 
occasionally under stress or environmental conditions which are round, oval, ultra-
virus, spore like, and cell wall defiant or L-forms (Fig.  2B) (Velayati et al., 2009, 2011; 
Farnia et al., 2010).  
 
 
Fig.  2 Morphological variations in M. tuberculosis. (A). Thin section transmission electron micrograph 
of Mtb (extracted from www.wadsworth.org/databank/mycotubr.htm). (B). Scanning electron 
microscope shows shape variation in Mtb at exponential phase of growth (Ali Akbar Velayati & Parissa 
Farnia, 2012). 
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Mycobacterium tuberculosis is an obligate aerobe. For this reason Mtb complexes 
are always found in the well-aerated upper lobes of the lungs in patient with TB. The 
bacterium is a facultative intracellular parasite, usually of macrophages, and has 
generation time of 15-20 hours, which is extremely slow compared to other bacteria 
with division times measured in minutes (Escherichia coli can divide every 20 
minutes).  
 
2.2 The Mycobacterium tuberculosis genome 
The genome of the virulent strain of Mtb, H37Rv was completely sequenced and 
published in 1998 (Cole et al., 1998) and this allowed to know that the bacterium 
dedicates 8% of its genome to lipid metabolism alone.  
It presents a sequence of 4,411,529 bp and a characteristically high guanine plus 
cytosine (G+C) content (65.5%). Genome analysis revealed an efficient DNA repair 
system with nearly 45 genes related to DNA repair mechanisms (Mizrahi & 
Andersen, 1998). Moreover, despite over 10,000 years of evolution, when 16 
genetically diverse clinical strains were examined for conservation of 24 genes 
known to encode antigenic proteins, minimal variation was observed (Musser et al., 
2000).  
H37Rv and its avirulent counterpart H37Ra strains have been widely used as 
reference strains for studying virulence and pathogenesis of M. tuberculosis 
worldwide since 1940s. H37Ra is used as an adjuvant to boost immunogenicity 
during immunization with BCG. The H37Ra genome is highly similar to that of H37Rv 
with respect to gene content and order (Zheng et al., 2008). However, H37Ra has 
several characteristics that are different from its virulent sister strain H37Rv, 
including: i) a raised colony morphology (Steenken, 1935); ii) loss of cord formation 
(Middlebrook, 1947); iii) loss of neutral red dye binding (Dubos & Middlebrook, 
1948); iv) decreased survival under anaerobic conditions (Heplar, 1954; Dubos, 1955) 
or inside the macrophages (Mackaness et al., 1954); v) impaired ability to disrupt 
phagosomal membranes (Hart & Armstrong, 1974); and vi) loss of virulence in 
guinea pigs (Steenken, 1938; Alsaadi & Smith, 1973) and mice (Pierce et al., 1953; 
Larson & Wicht, 1964). Analyses of the genomes of known avirulent strains, such as 
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the BCG vaccine or the H37Ra, showed mutations in PhoPR two-component system 
resulting in a loss of function, confirming its key role in virulence (Frigui et al., 2008; 
Zheng et al., 2008; Cimino et al., 2012). 
 
2.3 Cell wall 
The cell wall structure of Mtb, unique among procaryotes, is associated with the 
pathogenicity of Mtb (Smith, 2003; Barry et al., 1998; Dubnau et al., 2000; Glickman 
et al., 2000).  The richness in high molecular weight lipids represents the complexity 
of the cell wall (Brennan et al., 1995; Christensen et al., 1999; Daffé et al., 1998; 
Draper, 1998; Jarlier et al., 1994). Unusual impermeable properties of Mtb cell wall 
are thought to be advantageous for the bacilli in stressful conditions of osmotic 
shock (Hett & Rubin, 2008) and the polymers, covalently linked with peptidoglycan 
and trehalose dimycolate, provide a thick layer involved in Mtb resistance to 
antibiotics and the host defense mechanisms (Takayama et al., 2005).  
The mycobacterial cell wall consists of an inner layer and an outer layer that 
surround the plasma membrane (Fig.  3). The outer compartment consists of both 
lipids and proteins. The inner compartment consists of peptidoglycan (PG), 
arabinogalactan (AG), and mycolic acids (MA) covalently linked together to form an 
insoluble complex referred to as the essential core of the mycobacterial cell wall 
(Brennan et al., 2003). 
PG, or murein, external to the bacterial cell membrane, is a major determinant of 
bacteria shape maintenance protecting bacilli from osmotic turgor pressure. The 
structure of PG is unique to bacteria and thus an excellent target for therapeutics. 
AG is important for cell wall integrity and for anchoring the impermeable MA layer 
to the PG layer (Hett & Rubin, 2008). 
Another important component of the cell wall is lipoarabinomannan, a major 
lipoglycan involved in virulence of Mtb (Chan et al., 1991) and in modulating the host 
response during infection (Cox et al., 1999). 
Mycolic acids, the strong hydrophobic molecules that form a lipid shell around the 
organism and affect permeability properties at the cell surface, has been shown to 
be critical for the survival of Mtb (Draper et al., 2005).  
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Cord Factor, a glycolipid most abundantly produced in virulent strains of Mtb, is 
responsible for: i) inducing animal granulomas similar to those characteristic of TB 
infection (Hunter et al., 2006b); ii) increasing cytokine production (Ryll et al., 2001); 
iii) inhibiting the transfer of phagocytosed bacteria to acidic compartments in 
macrophages (Indrigo et al., 2003.); and iv) influencing the morphology of 
mycobacterial colonies (Hunter et al., 2006a). 
The cell wall is a key to the survival of mycobacteria and a more complete 
understanding of the biosynthetic pathways and gene functions and the 
development of antibiotics to prevent formation of the cell wall are areas of great 
interest (Joe et al., 2007). 
 
 
Fig.  3 Schematic of the bacterial cell wall (Abdallah et al., 2007). 
 
2.4 Virulence determinants 
The virulence of Mycobacterium tuberculosis is extraordinarily complex. Although 
the organism apparently does not produce any toxins, it possesses a huge 
repertoire of structural and physiological properties that have been recognized for 
their contribution to mycobacterial virulence and to pathology of tuberculosis. 
Subsequently, virulent Mtb species have developed strategies to avoid or modulate 
the immune response in their favour. 
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Among a great number of virulence factor of Mtb (Table 2), exported proteins are 
one of the most important factors responsible for the virulence (Rajni & Meena, 
2011). Culture filtrate proteins, found in the culture medium in which Mtb grows, are 
actively studied by many researchers, since a great deal of them is recognized by 
the sera of TB patients (Smith, 2003). The virulent components can be assembled in 
different clusters: i) cell envelope proteins, including cell wall proteins, lipoproteins 
and secretion systems; ii) proteins inhibiting antimicrobial effectors of the 
macrophage; iii) gene expression regulators, including two component systems, 
sigma factors and other transcriptional regulators; iv) enzymes involved in general 
cellular metabolism; and v) other proteins, including the ones of unknown function 
(Forrellad et al., 2013; Smith, 2003). 
Mtb has developed highly specialized mechanism to proliferate in the host during 
infection, such as: i) slow generation time, in consequence to which the immune 
system may not readily recognize the bacteria or may not be triggered sufficiently 
to eliminate them; or ii) lipid and fatty acid metabolism, including catabolism of 
cholesterol. It has been also shown that Mtb produces pili during human infection, 
which could be involved in initial colonization of the host (Alteri et al., 2007).
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Table 2 Virulence factors of Mycobacterium tuberculosis.  
Virulence 
factor 
Category Role Virulence characterization Reference 
Antigen 
85 
complex 
Exported 
protein 
Fibronectin-binding 
Possible impact in walling off 
bacteria from the immune 
system and facilitation of 
tubercle formation 
Belisle et 
al., 1997 
HbhA Adhesin 
Heparin-binding 
hemagglutin 
Involvement in binding Mtb to 
epithelial cells 
Delogu & 
Brennan, 
1999 
ESX-1 
Secretion-
associated 
proteins 
Virulence proteins 
delivery during infection 
Avoidance of excessive 
virulence by maintaining ESX-1 
activity that leads to long term 
survival of Mtb 
Raghavan 
et al., 
2008 
WhiB3 
protein 
Putative 
transcription 
regulator 
Implication in sensing 
oxygen tension and 
redox state  
Adaptation of mycobacteria to 
changes in oxygen tension 
Banaiee et 
al., 2006 
Acr1 
(hspX) 
α-crystalline 
protein 
homolog 
Dormancy-associated 
protein 
Inhibition of antimicrobial 
effectors of the macrophage 
Yuan et al., 
2008 
19-kDa 
protein 
Lipoprotein 
antigen 
Blockage of IFN-γ 
signaling through a TLR-
2 dependent 
mechanism 
Inhibition of MHC-II antigen 
processing and presentation in 
macrophages 
Tobian et 
al., 2003 
Sigma 
factors 
Gene 
expression 
regulators 
Help in regulation of 
expression of specific 
genes during stress or 
morphological 
development 
Adaptation to the changing 
environment within the host 
Browning 
et al., 2004 
STPKs 
Serine-
threonine 
protein 
kinases 
Regulation of cell 
shape; macrophages 
modulation 
Regulation of host-pathogen 
interactions and developmental 
changes through signal 
transduction using reversible 
phosphorylation of proteins 
Av-Gay & 
Everett, 
2000; 
Leonard et 
al., 1998 
 
 
3 Latency, dormancy and persistence 
Dormancy, latency, and persistence are related terms used to describe the ability of 
M. tuberculosis to arrest its growth in response to host-imposed stress (Rittershaus 
et al., 2013). The difference between those terms is indistinct in various studies 
regarding tuberculosis.  
Latency refers to an in vivo situation where the bacteria and the host have 
established a balanced state without causing clinical symptoms. Whereas the term 
dormant refers to the state of reduced metabolic activity adopted by many 
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organisms under conditions of environmental stress; organisms slow down their 
metabolic processes to a minimum to retain resources till the conditions are more 
favorable for resuscitation. 
 
3.1 Dormancy among microbes  
Dormancy, a common strategy among natural systems, is regulated by the 
interpretation of environmental indications. Many plant populations can adapt to 
changes in air temperature or photoperiod (Hairston et al., 1990; Vazquez-Yanes & 
Orozco-Segovia, 1990). Frequently, microorganisms are capable of resisting 
stressors such as temperature, desiccation, oxygen tension and antibiotics by 
entering resting states or by forming spores (Roszak & Colwell, 1987;  Whittington 
et al., 2004; Sussman & Douthit, 1973; Lewis, 2007). Not only by constructing 
morphological features such as endospores, cysts, or conidia, microbes can enter 
convertible states of reduced metabolic activity without investment in specialized 
cellular structures (Sussman & Douthit, 1973; Sussman & Halvorson, 1966). 
Futhermore, there is some evidence that dormant and slow-growing populations 
can respond similarly to favorable environmental change (Choi et al., 1999; 
Kjelleberg et al., 1987). 
 
3.2 Dormancy in Mycobacterium tuberculosis 
Once entering the organism, M. tuberculosis has four potential fates: i) it can be 
killed by immune system, which happens in the majority of cases; ii) it can multiply 
causing primary TB; iii) it may become dormant and remain asymptomatic; or iv) it 
may proliferate after a latency period (reactivation disease).  
After entering the host, typically by airborne droplets , bacteria go through a period 
of rapid replication until the host develops an immune response. Latent 
tuberculosis infection (LTBI) occurs when bacilli penetrate into the terminal alveoli 
where they are engulfed by phagocytic immune cells called macrophages. By 
slowing metabolism, spread through granuloma formation (Manabe & Bishai, 2000) 
and becoming dormant, M. tuberculosis adapts to the stressful conditions 
generated by host defense system and becomes as silent to the immune system 
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(Cardona & Ruiz-Manzano, 2004), preventing activation of the disease (Warner & 
Mizrahi, 2007; Rook et al., 1986). The bacterial behavior during the growth phases 
(lag, log, stationary, and death phases) is well known, but the behavior of M. 
tuberculosis in dormant state is poorly understood. 
Hypoxia, nitric oxide and nutrient starvation are some of the conditions which are 
believed to be associated with initiation and maintenance of Mtb dormancy (Wayne 
& Sohaskey, 2001; Betts et al., 2002; Voskuil et al., 2003). Carbon monoxide and 
ascorbic acid have also been implicated in dormancy adaptation (Kumar et al., 2008; 
Taneja et al., 2010). 
Once latent infection with M tuberculosis has been established, viable bacilli may 
persist for decades in a non-replicating state, followed in some cases by reactivation 
(Wayne & Sohaskey, 2001). 
It is commonly estimated that an individual with LTBI has ~10% lifetime risk of 
developing active TB. It is believed that 5% of the infected population will develop 
the disease after 5 years, known as "primary" TB that usually affects children and 
immunosuppressed hosts, and the others will suffer from "post-primary" TB at 
some time during their lives (Grange, 1998).   
 
3.3 Granuloma and immunophysiology of LTBI 
Although very little is known about maintenance of M. tuberculosis inside the host 
during dormant state, the growth pattern across the bacterial population appears 
relatively conserved in animal models. 
M. tuberculosis can persist for decades without causing any clinical symptoms in 
multicellular structure, called granuloma. A granuloma is comprised of 
macrophages (resting, activated and infected), immune effector T cells on the 
periphery, chemokines, cytokines, adhesion molecules, and a caseous necrotic 
center (Lin et al., 2006; Lin & Flynn, 2010).  Granuloma formation is a hallmark of 
LTBI, and provides a microenvironment where interactions between recollected 
cells are facilitated and bacteria are separated from spreading into the host. 
Granulomas can be formed anywhere in the lung, yet 90% of the post‐primary TB 
cases occurs in the upper lobes (Balasubramanian et al., 1994).  
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Inside granuloma in the lungs of mice, immune cells accumulate indifferent sites 
that are most likely associated with their functions in different stages of infection 
and disease (Tsai et al., 2006; Ulrichs & Kaufmann, 2006).  
Granuloma formation reflects the immune response in LTBI (Fig.  4). T cells play an 
important role in the immune response against M. tuberculosis. Both CD4 and CD8 
Tcells participate in control of acute tuberculosis in mice (Flynn & Ernst, 2000). Also 
adequate IL‐12/IL‐23/IFNγ signaling is required for: i) the control of M. tuberculosis 
infections; and ii) the development of mature granulomas (Ottenhoff et al., 2002; 
Casanova & Abel, 2002). Likewise, mice deficient in IFNγ signaling fail to form 
granulomas following M. tuberculosis infection (Pearl et al., 2001).  Cytokines IFN-ɣ 
and TNF-α contribute to resistance to M. tuberculosis whilst in a persistent infection 
pursue to be produced in the lungs of mice, suggesting that continuous 
macrophage activation is important in preventing reactivation of the infection 
(Flynn et al., 1998). 
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Fig.  4 Process of granuloma formation. Extracted from Expert Reviews in Molecular Medicine 
2005; Published by Cambridge University Press.  
 
3.4 Reactivation 
The reactivation of TB, which is the reestablishment of Mtb bacilli metabolic and 
replicative activity, can occur in any organ in which the tubercle bacilli were seeded 
during the primary infection. However, in immunocompetent individuals, the 
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reactivation usually occurs in the upper lobes, where higher oxygen pressure 
supports good bacillary growth (Ahmad et al., 2011). 
Although detailed mechanisms of resuscitation are largely unknown, there is a 
plethora of information regarding the factors increasing the risk for progression 
into active disease. Disruption of organized structures inside granuloma, marked for 
deficiencies related to T-cell number or function, is a typical feature of TB 
reactivation and the most notable cause for that is coinfection with HIV (Dooley & 
Sterling, 2005; Jasmer et al., 2002; McBryde & Denholm, 2012; Klossek et al., 2004; 
Selvyn et al., 1989; Hamdi et al., 2006) . 
Other factors, such as advanced age, uncontrolled diabetes mellitus, sepsis, renal 
failure, malnutrition, smoking, chemotherapy, organ transplantation, and long-term 
corticosteroid usage can trigger reactivation of infection (Frieden et al., 2003; Wells 
et al., 2007; Corbett et al., 2003; Dooley & Chaisson , 2009).  
Resuscitation has been studied at the molecular level in Micrococcus luteus where 
the resuscitation promoting factor (Rpf) has been shown to induce resuscitation. 
The genome of M. tuberculosis comprises five Rpf factors (RpfA to -E) (Mukamolova 
et al., 2002). In vivo and in vitro studies suggest that Rpf proteins are not needed for 
general viability but may be required to respond to conditions specific to a later 
stage of disease, in particular, dormancy (Downing et al., 2005; Tufariello et al., 
2006). Furthermore, an endopeptidase RipA of Mtb has recently been recognized as 
a vital component for revival from latency (Hett et al., 2007; Kana et al., 2008). 
 
3.5 Diagnosis of LTBI 
The diagnosis of LTBI is based on information gathered from the medical history, 
TST or IGRA result, chest radiograph, physical examination, and under certain 
circumstances, sputum examinations (Table 3). 
Radiologic findings associated with risk of subsequent tuberculosis disease may 
include pulmonary scarring and granuloma, particularly in the upper lobes (Joshi et 
al., 2007). Due to some limitations of TST, such as possible false-positive results, 
IGRA test has been alternatively used for LTBI diagnosis (Diel et al., 2008). IGRA 
monitors Mtb-specific proteins, indicating T-cells that have previously been exposed 
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to TB (Lein & Reyn, 1997). Although, with its considerable specificity and predictive 
value, IGRA overcomes TST for LTBI diagnosis, for reasons that include increased 
cost and technological requirements, they are yet to be widely adopted for routine 
LTBI diagnosis in many parts of the world (Vinton et al., 2009). 
 
Table 3 Differentiating between LTBI and active TB disease (CDC). 
LTBI 
 
Active TB Disease 
 
 
 No symptoms or physical findings 
suggestive of TB disease. 
 
 
 
 
 TST or IGRA result usually positive. 
 
 Chest radiograph is typically normal. 
 
 
 
 
 
 If done, respiratory specimens are 
smear and culture negative. 
 
 
 
 
 Cannot spread TB bacteria to 
others. 
 Should consider treatment for LTBI 
to prevent TB disease. 
 
 Symptoms may include one or more 
of the following: fever, cough, chest 
pain, weight loss, night sweats, 
hemoptysis, fatigue, and decreased 
appetite. 
 
 TST or IGRA result usually positive. 
 
 Chest radiograph is usually 
abnormal. However, may be normal 
in persons with advanced 
immunosuppression or 
extrapulmonary disease. 
 
 Respiratory specimens are usually 
smear or culture positive. However, 
may be negative in persons with 
extrapulmonary disease or minimal 
or early pulmonary disease. 
 
 May spread TB bacteria to others. 
 
 Needs treatment for TB disease. 
 
 
 
3.6 In vitro and in vivo models of dormancy 
Studies of dormancy in TB have been hampered by the lack of in vitro and in vivo 
models truly representative of human LTBI. The existing models only reflect 
individual aspects of human TB but are good sources to learn about the metabolic 
state of persistent mycobacteria and host immunity. 
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3.6.1 In vitro models 
Several in vitro models have been developed to model latency or investigate the 
adaptive processes of the M. tuberculosis to non-proliferating conditions. This can 
be achieved by inducing at least one of the stresses to which the tubercle bacilli are 
exposed in the host.  These include: i) hypoxia; ii) starvation of essential nutrients, 
such as carbon, nitrogen, or phosphorus; iii) oxidative and nitrosative stresses; iv) 
iron limitation; and v) exposure to gaseous stresses such as nitric oxide and carbon 
monoxide (Sikri & Tyagi, 2013). 
In vitro models include: i) a nonreplicative persistence oxygen depletion model 
(NRP) (Muttucumaru et al., 2004; Voskuil et al., 2004; Wayne & Hayes, 1996), where 
the culture is gently stirred in a sealed flask, resulting in a slow depletion of oxygen; 
ii) a steady-state reduced oxygen model, which makes use of a chemostat (Bacon et 
al., 2004); iii) a static culture oxygen depletion model (Kendall et al., 2004); iv) an 
aerated stationary-phase model (Voskuil et al., 2004); v) a long-term nutritional 
depletion at high oxygen concentration model (Hampshire et al., 2004); vi) a short-
term oxygen depletion model (Park et al., 2003; Sherman et al., 2001; vii) addition of 
nitric oxide (Voskuil et al., 2003); viii) a short course of complete starvation model 
(Betts et al., 2002); ix) multiple stress model, where bacteria is exposed to the 
combined stresses of low oxygen, high CO2, low carbon and nitrogen nutrients and 
acidic pH (Deb et al., 2009); and x) human macrophage model using vitamin D(3) 
and retinoic acid activated THP-1 macrophages (Estrella et al., 2011). 
 
3.6.2 In vivo models 
A number of animal model systems, including mice, guinea pigs, rabbits, marmoset, 
cynomolgous, and macaque non-human primates, are being adapted to portray 
various aspects of granuloma immunopathology.  
The Cornell model was the first animal model for dormant bacilli. This model 
involves partial clearance of M. tuberculosis infection by incomplete chemotherapy 
to induce the latent state (McCune et al., 1956). 
INTRODUCTION 
 
20 
 
Later LTBI mouse model, known as the chronic or plateau model, involves aerosol 
infection or infection by intravenous routes that lead to a steady accumulation of 
pulmonary damage (Orme, 1988).  
 
3.7 New targets for LTBI  
Current anti-TB therapies are directed against actively replicating bacteria. There is 
no particular treatment for latent form of TB. Identification and validation of 
appropriate targets for designing drugs are critical steps in drug discovery.  With 
different kinds of data that are now available, computational approaches can be 
powerful means of obtaining short-lists of possible targets for further experimental 
validation. Murphy & Brown bioinformatics analysis (Murphy & Brown, 2007) 
selected several physiological roles that can be targeted for therapeutic 
development against LTBI. These  included: i) the significant up-regulation of genes 
controlled by dosR (also named devR); ii) down-regulation of protein and ATP 
synthesis; and iii) the adaptation of two-carbon metabolism to the hypoxic and 
nutrient limited environment of the granuloma. Promising targets for inhibition 
were several regulatory elements (relA, mprAB), enzymes involved in redox balance 
and respiration, sulfur transport and fixation, pantothenate, isoprene, and NAD+ 
biosynthesis.  
Another target identification pipeline for Mtb through an interactome, reactome 
and genome-scale structural analysis (Raman et al., 2008) includes high confidence 
targets that address mycobacterial persistence. Proteins critical for survival of Mtb 
were first identified, followed by comparative genomics with the host, finally 
incorporating a novel structural analysis of the binding sites to assess the feasibility 
of a protein as a target. This work includes a correlation study with expression data 
and non-similarity to gut flora proteins as well as 'anti-targets' in the host. A number 
of novel anti-tuberculous agents are currently in various phases of development 
(Annex 1 Table 11).  Several of these medications such rifapentine, TMC-207 and 
moxifloxacin appear to have potent sterilizing activity and may potentially be of use 
in treatment of LTBI (Andries et al., 2010).   
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The DosR response regulator is an essential protein that controls gene expression in 
latency (Voskuil et al., 2003; Park et al., 2003; Sherman et al., 2001; Cho et al., 2006). 
A plethora of papers (Murphy & Brown, 2007; Raman et al., 2008; Hasan et al., 2006; 
Zhang et al., 2006; Saini et al., 2004, 2005; Wisedchaisri et al., 2005) have identified 
DosR as a strong candidate for therapeutic intervention against LTBI. 
The mechanism of action of dosR targeting molecules may work not by killing 
M.tuberculosis bacilli directly, but by forcing them out of the non-replicative state 
(Wayne & Sohaskey, 2001) leaving them susceptible to the usual antimycobacterial 
agents. 
 
4 Two-component systems 
Two-component systems (TCSs) are widespread signal transduction mechanisms in 
prokaryotes that enable these organisms to sense, respond, and adapt to a wide 
range of environments, stressors, and growth conditions (Stock et al., 2000). They 
were first described when the amino acid sequence of CheY, a response regulator 
involved in chemotaxis in E. coli and other Gram-negative bacteria, was shown to be 
related to regulatory proteins of other cellular processes (Stock et al., 1985). TCSs 
are absent in mammals which makes them potential targets for antimicrobial drug 
design (Watanaber et al., 2008). 
Over three hundred TCSs have been identified in approximately one hundred 
different bacteria and have been catalogued in the P2CS database 
(http://www.p2cs.org) (Barakat et al., 2011). The only bacterium studied to date 
where no TCS have been identified is Mycoplasma genitalium (Barrett et al., 1998). 
Limited metabolic capacities and intracellular lifestyle suggest that M. genitalium 
has little need to respond to its environment by regulating gene expression. 
TCS variants have also been found in yeast (Maeda et al., 1994), plants (Mizuno, 
2005) and in lower eukaryotes, for instance Arabidopsis thaliana (Imamura et al., 
1999), where they regulate hormone responses and circadian rhythms (Table 4A). 
TCSs in bacteria are known to respond to a wide variety of conditions, such as 
nutrient deprivation, cold/heat shock and the presence of antimicrobial compounds 
(Aguilar et al., 2001; Jordan et al., 2008; Sun et al., 1996). They can regulate a wide 
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variety of cellular process, including motility and chemotaxis, sporulation, biofilm 
formation and quorum sensing (Jiang et al., 2000; López et al., 2009; Lyon & Novick, 
2004; Szurmant & Ordal, 2004). TCSs have been shown to play crucial role in 
bacterial virulence (Hoch & Silhavy, 1995; Atkinson & Ninfa, 1999) (Table 4B). 
 
Table 4 TCSs in different bacterial species. (A). Diversity of physiological processes controlled by 
TCSs.  (B). Examples of TCSs involved in virulence. 
A. Diversity of bacterial processes controlled by TCS 
Organism TCS (HK/RR) Function Reference 
Bacillus subtilis VanS/VanR Vancomycin tolerance Evers & Courvalin, 1996 
Bacillus subtilis KinA/SpoOF Sporulation regulation Wang et al., 2001 
Bacillus subtilis ComP/ComA Competence regulation Weinrauch et al., 1990 
Bacillus subtilis DegS/DegU 
Regulation of many cellular processes e.g. 
exoprotease production, catabolism, 
competence development and motility 
Ogura et al., 2001 
Caulobacter. 
crescentus 
CckA/CtrA 
Co-ordination of cell cycle progression and 
polar morphogenesis 
Jacobs et al., 1999; 
Wheeler & Shapiro, 
1999 
Escherichia coli CheA/CheB Chemotaxis Hess et al., 1988 
Escherichia coli EnvZ/OmpR 
Adaptation to environmental osmotic 
changes by controlling expression of 
major outer membrane proteins 
Egger et al., 1997 
Escherichia coli PhoR/PhoB Phosphate regulation Lee et al., 1989 
Rhodobacter 
sphaeroides 
PrrA/PrrB 
Expression of photosynthesis and Calvin 
cycle CO2 fixing operons 
Emmerich et al., 2000 
Rhizobium spp. FixL/FixJ Nitrogen fixation Weinstein et al., 1992 
Staphylococcus 
aureus 
SrhS/SrhR 
Regulation of energy transduction in 
response to changes in oxygen availability 
Throup et al., 2001 
Staphylococcus 
aureus 
YycG/YycF 
Regulation of bacterial cell wall / 
membrane composition 
Martin et al., 1999 
Streptomyces 
coelicolor 
AbsAl/AbsA2 Antibiotic synthesis 
Brian et al., 1996; 
Anderson et al., 2001 
Vibrio fischeri LuxI/LuxR 
Quorum sensing and induction of 
bioluminescent genes 
Salmond et al., 1995 
B. Bacterial TCS involved in the regulation of virulence determinants 
Organism TCS (HK/RR) Function Reference 
Agrobacterium 
tumefaciens 
VirA/VirG Crown gall tumor formation 
Dziejman & Mekalanos, 
1995 
Bordetella 
pertussis 
BvgS/BvgA 
Activation and repression of a range of 
virulence factors 
Akerley et aI., 1992 
Enterococcus 
faecium 
VanR/VanS Vancomycin resistance Arthur et aI., 1992 
Klebsiella 
pneumoniae 
NtrA/NtrC Urease production Collins et al., 1993 
Neisseria 
gonorrhoeae 
PilA/PilB Pilus formation Taha et aI., 1991 
Pseudomonas 
aeruginosa 
PirS/PirR Iron acquisition Rumbaugh et aI., 1999 
 PilS/PilR Pilus formation Rodrigue et aI., 2000 
 FleS/FleR Adhesion 
Dziejman & Mekalanos, 
1995 
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 AlgR2/ AlgR1 Alginate synthesis Balaban et aI., 1998 
Staphylococcus 
aureus 
AgrC/AgrA 
Expression of a range of extracellular 
proteins and toxins involved in various 
aspects of virulence (global expression) 
Yarwood et aI., 2001 
 ArlS/ArlR 
Interaction with other systems to 
modulate virulence factor 
regulation 
Fournier et aI., 2001 
Streptococcus 
pyogenes 
CsrS/CsrR 
Negative regulation of hyaluronic acid 
production and several toxins 
Bernish & Rijn, 1999; 
Engleberg et aI., 2001 
Salmonella spp. PhoQ/PhoP Required for survival in macrophages Groisman, 2001 
Salmonella spp., 
Escherichia coli, 
Shigella spp. 
EnvZ/OmpR 
Outer membrane protein expression for 
nutrient acquisition 
Bernardini et aI., 1989; 
Barrett & Hoch, 1998 
Vibrio cholerae ToxS/ToxR 
Expression of virulence factors e.g. pili and 
toxins 
DiRita, 1992 
 
The prototypical TCS consists of a sensor histidine kinase (HK) that responds to a 
specific signal by modifying the phosphorylated state of its cognate response 
regulator (RR) (Fig.  5). First, upon the perception of environmental or intracellular 
signal, HK autophosphorylates (using ATP as the phosphate source) within a single, 
conserved histidine residue in the carboxyl-terminal region of receiver domain. 
Subsequently the phosphoryl group is transferred in a magnesium-dependent 
manner to an aspartate residue in the aminoterminal region of the partner RR 
protein. Phosphorylation of a RR changes the biochemical properties of its output 
domain, which can participate in DNA binding and transcriptional control, perform 
enzymatic activities, bind RNA, or engage in protein–protein interactions (Gao et al., 
2007; Stock et al., 2000; Galperin et al., 2001; Hoch, 1995,2000; Saito, 2001). 
TCSs are built up from modular units: i) HK sensor domain; ii) HK kinase domain; iii) 
HK transmitter domain; iv) RR receiver domain; and v) RR binding DNA domain. 
The signaling pathway also includes phosphatase activity that dephosphorylates the 
response regulator, returning it to a irresponsive state. The phosphatase activity 
may derive from the histidine kinase, the response regulator, or a separate protein. 
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Fig.  5 A prototypical TCS signalling pathway. 
 
4.1 Structural features 
Biochemical activities and three dimensional structures are known for 
representatives of all conserved core domains of HKs and RRs, as well as for several 
variable input domains of HKs and for most of the subfamilies of output domains of 
RRs. Both proteins consist of (at least) two distinct domains (Mascher et al., 2006). 
 
4.1.1 Histidine kinases 
Histidine kinases, that act as signal receptors, contain an N-terminal input domain 
and a C-terminal transmitter domain (Parkinson & Kofoid, 1992). They are typically 
built up of an extracellular sensing domain, two or more hydrophobic membrane-
spanning segments (Stock et at., 2000), and a transmitter domain localized within 
the cytoplasm (Fig.  6).  
Some histidine kinase sensing proteins are phosphorylate in trans, with the kinase 
domain of one subunit catalysing the phosphorylation of its dimer partner (Cai et al,. 
2003; Dutta et at., 1999) while cis-autophosphorylation (one subunit phosphorylates 
itself) takes place in others (Casino et al., 2010). 
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Due to the great number of stimuli that can be monitored by histidine kinase 
proteins, the regions involved in sensing show the greatest diversity within the 
family. Several conserved regions or boxes, used for identifying members of the 
histidine protein kinase superfamily, are located within the cytoplasmic domain 
(Grebe & Stock, 1999). Such conserved sequences extend for approximately 200 
amino acid residues and are located at the C-terminal end of the protein. All 
histidine kinases share 20-30% sequence homology within this region (Hakenbeck & 
Stock, 1996).  
Sensor domain of histidine kinase can be located in the cytosol, in the membrane, or 
in extracytosolic region. An extracytosolic sensor domain is flanked by two 
transmembrane (TMR1 and TMR2) helices with the N-terminus in the cytosol.  
HKs also possess a dimerization domain which contains the phosphorylable 
histidine residue. The autophosphorylation is carried out in an ATP-dependent 
manner. Catalysis of the autophosphorylation reaction is facilitated by the ATP-
binding domain, which contains conserved sequence motifs (N, D, F and G) (West & 
Stock, 2001).  
The C-terminal cytoplasmic transmitter domain contains  HAMP domain, also known 
as DHp (dimerization and histidine phosphotransfer) or HisKA domain. It is 
commonly found in Histidine kinases, Adenylyl cyclases, Methyl-accepting 
chemotaxis proteins, and Phosphatases (Aravind & Ponting ,1999), hence the name 
HAMP. This domain comprises a sequence with the conserved histidine residue for 
autophosphorylation (the H box). Activity depends on homodimer formation, with 
the dimerisation domains, which have two helices (referred to as Hα1 and Hα2) 
coming together to form a four-helix bundle.  
HAMP domain is pursued by the catalytic domain (HATPase) contains the conserved 
N, D, F, and G boxes with the respective highly conserved amino acid residues. This 
domain catalyzes autophosphorylation of the HKs. 
ATP-binding domain, often abbreviated as CA (for catalytic and ATP-binding 
properties), is located at the carboxyl terminus of the polypeptide and is required 
for kinase activity (Wolanin et al., 2002). This domain binds ATP, which then donates 
its γ-phosphate group to the conserved histidine residue on the DHp domain. The 
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highly conserved N, D, F and G box sequence motifs of the CA domains are 
presumed to play crucial roles in substrate binding, catalysis and/or structure, and 
have also been used to classify the histidine kinases into functional subfamilies. 
 
 
Fig.  6 Domains organization of histidine kinase (explanation in the text). 
 
4.1.2 Response Regulators 
The response regulator (RR) protein harbours the cellular output activity of the 
phosphorelay pathway. Response regulators contain typically two domains: an N-
terminal receiver domain and a C-terminal output domain. The structures of receiver 
domains are well conserved with the sequence of approximately 125 amino acids 
(20-30% homology to other response regulators). Strongly conserved aspartic acid 
(Asp) residue at C-terminal domain accepts the phosphoryl group from the 
phosphorylated histidine kinase. In contrast, output domains show less 
conservation, especially at the sequence level, reflecting specificity and different 
affinity for promoters.   
RR is a transcription factor that binds DNA. Phosphorylation of the RR receiver 
domain alters its affinity toward specific target proteins or DNA sequences and 
induces a conformational change (Lewis et al., 1999), which consequently results in 
activation (Lange et al., 1999) and/or repression of a given set of genes (Hakenbeck 
& Stock, 1996).  
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A significant fraction of RRs have effector domains as enzymes. Many others have 
effector domains for binding RNA, ligands, or proteins to regulate bacterial cellular 
process at post-transcriptional and post-translational levels. There are also single 
domain RRs that have only the receiver domains such as CheY and Spo0F (Galperin 
et al., 2010).  
 
4.2 TCSs as new drug targets 
TCSs might be helpful to provide the basis for structure‐based drug design. Many 
features make them attractive as a potential target for the development of novel 
antimicrobial agents. 
Significant homology is shared among kinase and response regulator proteins of 
different bacteria (Parkinson et al., 1992), which could facilitate the design of a 
broad-spectrum of antimicrobial drug. Similarily, regions unique to individual TCS 
could be targeted to produce drugs specific for a given bacterium.  
Furthermore, since homologous systems have not been found in animals (Hilliard et 
al., 1999), the drugs targeting TCSs may potentially have preferable selectivity.  
Pathogenic bacteria use two-component signal transduction to regulate expression 
of essential virulence factors that are required to enter and survival inside the host 
(Dziejman & Mekalanos, 1995; Groisman & Heffron, 1995; Uhl & Miller, 1995). The 
inhibition of the expression of bacterial virulence factors offers an opportunity for 
specific intervention at the level of host invasion through biochemical processes, 
which are unique to the bacterial cell (Miller et al., 1989).  
Many TCSs play an important role in the emergence of antibiotic resistance or 
tolerance, and inhibition of these systems without killing the host cell may render 
the bacterium sensitive to antibiotics again. 
Targeting the histidine kinases of two-component systems might allow the 
development of antibiotics with a new mode of action.  Current bacterial genomics 
and proteomics will undoubtedly uncover further targets for related structure-
based rational drug design.  
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Elucidated crystal structures of several RRs and HKs make it possible to carry out 
virtual screenings or can serve as a platform for rational design to improve the 
specificity of the lead compounds.  
Additionally, with the increasing wealth of genome sequences available in public 
databases, it is now possible to identify most, if not all, TCS within an organism. 
Data gathered from mutagenesis research can be helpful to evaluate TCSs role in 
the viability and pathogenicity of the bacterium upon which framework for rational 
drug can be designed. This knowledge may be an adequate framework upon which 
rational-designed drug research and development projects could be built. 
 
4.3 TCSs in Mycobacterium tuberculosis 
Genomic analysis indicates that Mtb encodes eleven complete TCSs (Table 5), six 
orphan RRs, and two orphan HKs (Cole et al., 1998; Tekaia et al., 1999). The numbers 
are rather low compared with other bacteria, e.g. E. coli, which has more than thirty 
complete TCSs.  
Several studies have analyzed the expression profiles during Mtb growth in human 
macrophages (Haydel & Clark‐Curtiss, 2004; Zahrt & Deretic, 2001) and mice 
suggesting the biological role for these signal transduction systems in host-
pathogens interactions. 
Evidence suggests that many of the TCSs are engaged in sensing the host 
environment and adjusting bacterial transcription to adapt to the new environment, 
including PrrA (Ewann et al., 2002), DosRST (Malhotra et al., 2004; Roberts et al., 
2004), SenX3-RegX3 (Parish et al., 2003), MprAB (Zahrt et al., 2003), MtrAB (Fol et 
al., 2006), and PhoPR (Perez et al., 2001). The mutagenesis studies support the role 
of TCS in growth and survival (Sassetti et al., 2001), indicating that the senX3 , kdpD , 
and mtrA (Sassetti et al., 2003a) gene products are required for survival in mice and 
that the response regulators PhoP, KdpE, PdtR, and MtrA, as well as the sensor 
kinases MprB, DevS, and Mtr B (Sassetti et al., 2003b) are required for optimal 
growth in vitro. 
Comparative genomic analyses of TCSs in Mtb indicate that homologues of these 
genes exist in other representative of Mycobacterium species, including M. bovis, M. 
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avium, M. leprae, and M. smegmatis (Cole et al., 1998; Zahrt et al., 2003). All of the 
paired TCSs found in Mtb are conserved in their genetic arrangement and location 
within the closely related M. bovis BCG vaccine strain. In contrast, only four TCSs are  
present and predicted to be functional in M. leprae (Bretl et al., 2011).  
 
Table 5 The TCSs identified in Mtb strain (Bretl et al., 2011). 
TCS 
(HK/RR) 
ORF annotation 
Regulation or effect of 
inactivation 
Reference 
SenX3/RegX3  Rv0490/Rv0491 
Regulation of phosphate 
dependent gene expression 
(Himpens et al., 2000) 
U/U/TcrA 
Rv0600c/Rv0601c/ 
Rv0602c 
Un-known 
(Haydel & 
Clark‐Curtiss, 
2006) 
PhoP/PhoR Rv0757/Rv0758 
Implication in regulating 
production of complex cell 
wall lipids 
(Ludwiczak et al., 
2002; Zahrt & Deretic, 
2001) 
NarL/NarS  
 
Rv0844c/Rv0845 Un-known (Parish et al., 2003) 
PrrB/PrrA Rv0902c/Rv0903c 
Involvement in early 
intracellular multiplication 
during macrophage infection 
(Ewann et al., 2002, 
2004) 
MprA/MprB Rv0981/Rv0982 
Regulation of different genes 
engaged in physiology and 
pathogenesis 
(Zahrt et al., 2003) 
KdpE/KdpD Rv1027c/Rv1028c Involvement in virulence (Parish et al., 2003) 
TrcS/TrcR  Rv1032c/Rv1033c Un-known (Haydel et al., 1999) 
DevS/DevR 
(DosS/DosR) 
Rv3132c/Rv3133c 
Involvement in hypoxic 
adaptation 
(Saini et al., 2004) 
MtrB/MtrA Rv3245c/Rv3246c 
Proliferation in macrophages; 
essential for Mtb viability 
(Zahrt & Deretic, 
2000) 
TcrY/TcrX  Rv3764c/Rv3765c Involvement in virulence (Parish et al., 2003) 
 
 
5 DosR/DosS/DosT Two Component System 
Dos (also known as Dev) TCS is composed of two soluble, full-length histidine 
kinases (HKs, DosS and DosT) and a single response regulator (RR, DosR). Dev TCS 
proteins were originally identified as DevR (Rv3133c) and DevS (Rv3132c) in a screen 
for genes differentially expressed in the virulent strain (dev) M. tuberculosis H37Rv 
compared to the avirulent H37Ra strain (Dasgupta et al., 2000).  
Subsequent studies demonstrated that Rv3133c was induced in the tubercle bacillus 
by hypoxia indicating that DevR is a key for adaptation of the bacillus to 
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nonreplicating survival in hypoxic environments. Therefore, the gene was named 
dosR as a regulator of dormancy survival (dos) (Boon & Dick, 2012). Both gene 
designations remain in use today. In this study, the Dos nomenclature has been 
selected. 
In Mtb, dosR and dosS are genetically linked and transcriptionally coupled with each 
other as well as with upstream Rv3134c gene forming operon Rv3134c-devR-devS 
that is transcribed from several promoters (Dasgupta et al., 2000). In contrast, dosT 
does not belong to the core of DosRS operon and is located at the end of a highly 
induced cluster of genes regulated by DosR (Gerasimova et al., 2011). While dosR 
and dosS are conserved and tandemly arranged in many mycobacterial species 
(except M. leprae and M. ulcerans), dosT appears to be less well conserved. DosS 
and DosT are capable of autophosphorylating at conserved histidine residues (DosS 
at His-395 and DosT at His-392), and both proteins can transfer the phosphomoiety 
to Asp-54 of DosR (Roupie et al., 2007, Saini et al., 2004a, 2004b). 
DosRST upregulates a well-defined regulon of ∼48 genes in Mtb following exposure 
to hypoxia, nitric oxide (NO), carbon monoxide (CO), and the cytochrome c 
reductant ascorbate (Boon & Dick, 2002; Honaker et al., 2010; Kumar et al., 2008, 
Taneja et al., 2010; Voskuil et al., 2003). The DosR regulon controls survival of the 
bacilli in an anaerobically-induced state of dormancy and is co-adjuvant in the 
transition of Mtb back to aerobic growth from an anaerobic or nitric oxide-induced 
nonrespiring state (Leistikow et al., 2009; Rustad et al., 2009). 
It is believed that the study of the DosR–DosS signalling pathway will improve our 
understanding of the dormancy response in M. tuberculosis. DosRST two-
component system has been proposed as an attractive target for the development 
of inhibitors against dormant organisms (Lamichhane, 2010; Murphy & Brown, 2007; 
Saini et al., 2004; Vohra, 2006.) 
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5.1 DosRST features 
5.1.1 DosR response regulator  
DosR response regulator controls dormancy adaptation in Mtb. Nearly all Mtb genes 
that are rapidly upregulated in response to low levels of oxygen and nitric oxide 
require DosR for their induction (Voskuil et al., 2003; Park et al., 2003). 
DosR contains conserved amino acid residues that are implicated in its activation 
and that are also present in other TCSs RRs. These include: three aspartates Asp8 
(D8), Asp9 (D9), Asp54 (D54), one Thr/Ser Thr82 (T82), one Tyr/Phe Tyr101 (Y101), 
and one Lys Lys104 (K104) (Dasgupta et al., 2000; Saini et al., 2004; Wisedchaisri et 
al., 2008). It has been demonstrated that the D8 and D9 residues together with D54, 
which likely form an acidic pocket (Stock et al., 2000) and coordinate Mg2
+, are 
functionally important for DosR phosphorylation (Saini et al., 2004). The 
phosphorylation of D54 serves as a switch to activate DosR (Chauhan & Tyagi, 2008; 
Roberts et al., 2004; Saini et al., 2004; Wisedchaisri et al., 2008). 
DosR has been studied by many independent research groups and conflicting 
reports have been published concerning its role in Mtb virulence. Deletion of DosR 
was shown to have an increased (Parish et al., 2003) or neutral effect (Rustad et al., 
2008) on Mtb virulence in mice infected with either wild type Mtb or a dosR deletion 
mutant. However, disruption of dosR was reported to increase the virulence of Mtb 
in mice (Parish et al., 2003) but to lead to attenuation of Mtb virulence in guinea pigs 
(Malhotra et al., 2004). 
 
5.1.1.1 Structural insights 
Crystal structure of unphosphorylated DosR has been solved (Wisedchaisri et al., 
2008) showing that full length DosR is composed of an N-terminal domain (receiver 
domain), a C-terminal domain (DNA-binding domain) and the linker region (Fig.  7). 
DosR belongs to the NarL subfamily of TCSs although this RR has some differential 
features when compared to the rest of proteins of the same family. The N-terminal 
domain of DosR lacks one α/β segment compared to the canonical (βα)5 
arrangement. The C-terminal domain contains four α-helices named α7, α8, α9, and 
α10. This domain has an unusual conformation where the first α-helix in the N-
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terminal domain packs against helix α10 which moves away from the core 
constructed by helices α7 to α9. The linker region consists of helices α5 and α6 with 
high flexibility of the second one. 
 
 
 
Fig.  7 Crystal structure of full-length DosR. The DosR monomer (above). The structure is shown in 
magenta for the N-terminal domain, blue for the linker, and green for the C-terminal DNA binding 
domain. The DosR dimer (below). Subunit A is shown as above. Subunit B is shown in gray. 
 
The crystal structure of the C-terminus DosR (DosRC) in complex with DNA 
oligonucleotides has also been solved (Wisedchaisri et al., 2005). In this structure, a 
DosRC dimer interacts with G4G5G6A7C8T9, a DNA motif present in each half of a 
palindromic consensus sequence (Fig.  8). 
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A helix rearrangement mechanism for DosR activation was proposed (Wisedchaisri 
et al., 2008). In this model, critical helix α10 is in dynamic equilibrium in the closed-
inactive conformation, bound to the N-terminal regulatory domain, burying the key 
Asp54 residue, and in an open-inactive conformation, allowing Asp54 to be solvent-
exposed part of the time and thus available for Asp phosphorylation by DosS or 
DosT. Upon activation by Asp54 phosphorylation, helix α10 provides the DosR 
dimerization interface in an open-active conformation for DNA binding. 
 
 
Fig.  8 Structure of the DosRC–DNA complex. DosRC uses the α10 helices to form a functional dimer 
for DNA binding. Arg196, Thr198, Val202, and Thr205 are residues contributing to this dimerization 
interface. The DNA clearly has a bent conformation, as shown by its helical axis in gray. 
 
5.1.1.2 DosR regulon 
In silico analysis of DosR regulon promoters revealed the presence of one or more 
copies of a consensus binding sequence located in the upstream promoter regions 
of target genes (Park et al., 2003). It has been shown that phosphorylated DosR 
binds cooperatively to specific DNA sequences (Dos boxes) to activate target gene 
expression (Chauhan & Tyagi, 2008, 2009). The DosR regulon is composed of 48 
coregulated genes that are involved in anaerobic respiration and metabolism, 
including genes involved in alternative electron transport pathways (fdxA), nitrate 
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metabolism (narK2 and narX), and deoxynucleoside triphosphate (dNTP) synthesis 
under microaerophilic conditions (nrdZ) (Sherman et al., 2001; Voskuil et al., 2003). 
Furthermore, the Rv3134c-dosR-dosS operon is transcribed from multiple promoters 
and is autoregulated (Bagchi et al., 2005). The protein alpha-crystallin (Acr) is 
repeatedly found to be upregulated in hypoxic conditions (Park et al., 2003; 
Sardiwal et al., 2005). Acr (rv2031c), also known as hspX, encodes a heat shock 
chaperon protein that is also a major cell wall-associated protein during stationary 
phase (Fig.  9). Further, tgs1 is one of the most powerfully induced genes of the 
DosR regulon (Park et al., 2003; Voskuil et al., 2003), and it is divergently transcribed 
from Rv3131. Tgs1 encodes a triacylglycerol synthase that synthesizes triacylglycerol, 
proposed to be an energy source during dormancy (Daniel et al., 2004). Its 
disruption has been shown to prevent triacylglycerol accumulation under inducing 
conditions (Sirakova et al., 2006). Rv3131 codes for a putative classical 
nitroreductase which may be involved in detoxification of nitrogen-containing by-
products in the host (Purkayastha et al., 2002). 
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Fig.  9 Transcriptional regulation of Rv3134c and hspX promoters. (Top panel) Under normoxia, devRS 
operon is transcribed from aerobic promoters (thin wavy arrows) to provide basal levels of DevR and 
DevS. Unphosphorylated DevR does not bind or induce the operon or hspX gene. (Bottom panel) Upon 
induction, DevR~P species is generated. It binds first to the D site and cooperatively recruits another 
DevR∼P molecule to the P site to induce the operon (thick wavy line). At the hspX promoter, DevR~P 
binds first with the P and C sites and then with the D site to induce its transcription. At both 
promoters, DevR~P binds to the P site overlapping the -35 promoter element and also to one or two 
additional upstream sites. The oligomeric status (monomer or dimer) of free and DNA-bound DevR is 
not known and, for simplicity, DevR is represented as an oval (white for unphosphorylated and 
shaded for phosphorylated) (Chauhan & Tyagi, 2008). 
 
5.1.2 Histidine kinases DosS and DosT 
DosS and DosT show high sequence similarity with each other (62.5% sequence 
identity in the full length protein). The N-terminal sensory domains of DosS and 
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DosT contain two tandem GAF domains, which are regulatory domains originally 
named for their association with cGMP-regulated cyclic nucleotide 
phosphodiesterases, adenylate cyclases, and the bacterial transcriptional regulator 
FhlA. C-terminal domains consist of histidine kinase domain (belonging to HisKA_3 
family) and ATP-binding domain. The first GAF domain binds heme and acts as a gas 
sensor (Sardiwal et al., 2005; Ioanoviciu et al., 2007; Sousa et al., 2007; Kumar et al., 
2007), while the function of the second GAF domain remains to be revealed 
(Sardiwal et al., 2005). 
Structural and biochemical analyses have provided important insights into the 
nature of gas ligand binding by histidine kinases DosS and DosT (Cho et al., 2008, 
2009; Ioanoviciu et al., 2007, 2009; Kim et al., 2010; Kumar et al., 2007; Lee et al., 
2008; Podust et al., 2008; Sardiwal et al., 2005; Sousa et al., 2007; Voskuil et al., 2003; 
Yukl et al., 2007, 2008, 2011). Two independent reports proposed a model for DosS/T 
signaling wherein DosS is a redox sensor and DosT is a hypoxia sensor (Cho et al., 
2009; Kumar et al., 2007). It has been suggested that DosT is inactive when bound 
to oxygen under normoxic conditions (Fig.  10). However, during hypoxia, CO and 
NO may displace O2 in DosT, restoring its active form. Similar gas binding can also 
be attributed to DosS. O2 can oxidize the heme group and inhibit DosS. The 
oxidative form Fe3+DosS does not autophosphorylate, while the reduce Fe2+DosS 
does (Cho et al., 2009). Furthermore, NO binds heme but inhibits DosS 
approximately 50-fold less than oxygen (Dunham et al., 2003; Tuckerman et al., 
2002). Likewise, it was demonstrated that flavin nucleotides are capable of reducing 
the heme ion of DosS. 
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Fig.  10 Proposed mechanism for the role of Mtb DosS and DosT in the shift down of tubercle bacilli to 
the persistent state. The sense-and-lock model proposes that during disease progression hypoxia NO 
and CO are being sensed, independently or in conjunction, to induce the persistent state. Hypoxia, 
NO, and CO induce reductases to generate active ferrous DosS, whereas deoxygenation generates 
active ferrous DosT. Both ferrous DosS and DosT is now capable of binding NO and CO to generate 
NO–DosS, CO–DosS, NO–DosT, and CO–DosT, which keep the Dos regulon in a locked (active) state 
(Kumar et al., 2007). 
 
Few studies have focused on the biological relevance of DosT and DosS and their 
roles in adaptation to hypoxia and anaerobic conditions. It has been shown that 
after two hours under 0.2% oxygen conditions, dosT and dosS single mutants are 
only able to induce DosR regulon expression at 40 to 45% of normal levels, and 
bacteria that lack both sensors are completely unable to induce the expression of 
DosR-regulated genes (Roberts et al., 2004). Another study reported that the dosS 
deletion mutant had no apparent effect on acr (a member of the DosR regulon) 
induction in an overnight settled culture model or after two hours in 0.2% oxygen 
(Sherman et al., 2001). A study that used the Wayne model indicated that the dosS 
mutant had a 15-fold decrease in survival by day 40 (Boon & Dick, 2002). The dosS 
mutant, at day 5 of the model, maintains protein expression levels of DosR regulon 
proteins, indicating that at this time point in this particular model, DosT is able by 
itself to induce the expression of the DosR regulon. Another research showed that 
only versions of DosT and DosS lacking heme (by deletion of their N-terminal region 
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or treatment with denaturants) can phosphorylate themselves or DosR in vitro 
(Roberts et al., 2004; Saini et al., 2004a,b). 
The three dimensional structures of GAF-A and GAF-B from DosT have been 
determined (Podust et al., 2008). The heme is embedded into the GAF-A domain, 
which is composed of five strand anti-parallel β-sheet and four α-helices. The heme 
is positioned nearly perpendicular to the β-sheet (Fig.  11). 
 
 
 
Fig.  11 Overall structure of GAF DosT. Topology diagram of GAF DosT is shown above. Below, ribbon 
representation of the two orthogonal views of GAF DosT. The O2 ligand is represented by red spheres, 
and the heme (orange), and H137, H147, and Y169 are shown as sticks. 
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6 Drug discovery & development pipeline 
Before any potential new medicine can be discovered, the first step is to gather the 
knowledge about the disease to be treated. The key points are to understand how 
the genes are altered, how that affects the proteins they encode and how those 
proteins interact with each other in living cells, how those affected cells change the 
specific tissue they are in and finally how the disease affects the entire patient.  
Target drug discovery focuses on evaluating a disease hypothesis through the 
process of discovery and clinical testing of a molecule designed to interact with a 
specific target believed to be involved in the disease pathogenesis.  
With the sequencing of the human genome (Hopkins & Groom, 2002), the 
emergence of system biology and the development of many high throughput 
technologies, target-based drug discovery has emerged as the primary strategy of 
many pharmaceutical companies during past 20 years. This approach has advanced 
thanks to the development of computational and informatics tools that aid 
scientists in the design, selection and optimization of molecules for specific 
medications. Target selection is a critical task, sub-optimal target selection has 
become a very common cause of failure in the clinics. A multifactorial disease 
cannot be efficiently approached by a target located downstream or an up-stream 
target can fail if there is an efficient alternative pathway. System biology and its 
associated simulation technologies used to be on the basis of a right target 
selection. 
Pharmaceutical research and development (R&D) of a drug consists of several 
stages (Fig.  12). It begins with drug discovery followed by preclinical drug 
development where thousands of candidate chemicals maybe screened for 
attractive therapeutic, pharmacological, and toxicity properties (Rowberg, 2001). 
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Fig.  12 Stages in the drug discovery and development (R&D)  process.  
 
6.1 Drug discovery 
Typically, at this stage, chemical compounds, either naturally occurring or synthetic, 
are investigated for their potential to bind to and modify molecular targets 
(Rowberg, 2001). The sections in this chapter refer only to the drug discovery 
process of low-molecular weight chemical molecules, omitting different types of 
drugs, such as biological, cellular and gene-derived.  
 
6.1.1 Target identification and validation 
Drug discovery usually begins with the identification of potential drug targets, 
whose action or absence of actions result in a disease condition (Aldridge, 1998). 
For this purpose, it is important to understand how the disease occurs at the 
molecular, cellular and genetic levels. The actual process of drug discovery is 
characterized by a search for molecules that can bind to targets and result in an 
action that produces a therapeutic result. Presently, high-throughput screening is 
used to test a wide range of potential targets against thousands of diverse chemical 
compounds. This leads to the identification of promising lead compounds which 
interact with the target and show the potential to either neutralize or slow the 
disease process. The alternative method of rational drug design involves the design 
and synthesis of compounds based on the known structure of either a specific 
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target (target based drug design) or one of its natural ligands (ligand based drug 
design). 
 
6.1.2 Hit identification 
There are few important features to validate before the molecule could be 
considered for drug development: i) target selectivity, to ensure that it only or 
mainly acts on the disease protein; ii) target toxicity; and iii) target distribution in 
the body in a way that ensures it reaches the disease site. 
Pharmaceutical companies, especially the “big pharma”, have large small molecule 
compound libraries, which can include Food and Drug Administration (FDA) 
approved drugs, non FDA-approved drug candidates with known activity from 
previous screenings and compounds with unknown activity. One of the most 
important challenges at this point is to reduce the number of compounds to test, as 
chemical libraries can be very large (10,000-2,000,000 compounds) and testing is 
expensive but maintaining the maximal chemical diversity. Computational chemistry 
first helps to inform small molecule library classification and activity prediction. 
 
6.1.3 Lead identification: hit to lead (H2L) phase 
A successful hit identification phase usually yields several hit compounds (i.e. 10-
200) with relatively weak affinities for the target. They can be promiscuous, but, 
definitively, they can add chemical diversity to the discovery process. Those hit 
compounds with an affordable chemistry can be selected to generate a number of 
independent chemical series of analogues. The aim is to obtain derived lead 
compounds with a higher affinity (potency) for the target and a reasonable degree 
of selectivity versus off-targets. In addition, in vitro metabolic and PK predictive 
tests (i.e. PAMPA, CACO, etc) are run at this stage to predict and subsequently 
discard those chemical structures with poor in vivo performance.  
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6.1.4 Lead optimization 
This phase involves rigorous testing and optimization of the selected compounds to 
identify the  candidate drug/s to development. This phase starts with some (i.e. 2-
20) lead compounds and yield a few number of candidates to enter in the regulatory 
phase. Compound optimization mostly includes in vivo data in one or more animal 
species.  
In vivo assays include animal models of disease as well as side effects/safety models 
and models of drug disposition (Absorption, Distribution, Metabolism, Excretion 
and Toxicity–ADMET). Candidate identification stage is required to study many 
processes, including metabolism, absorption into tissues and passage from the 
tissues back into circulation, excretion through the kidneys and liver, and, for 
volatile agents, exhaled from the lungs. Ideally, the dynamic kinetics of drug 
exposure will correlate with the appearance and decay of efficacy 
(pharmacodynamics) and toxicity (toxicokinetics). This information can guide drug 
dose schedules (Rydzewski, 2008).  
 
6.2 Preclinical studies 
Once promising drug candidates have been identified, they enter the preclinical 
research stage, starting the so called ‘preclinical regulatory phase’. Usually this 
means to start the relationship with the Regulatory Agencies asking for a Scientific 
Advice (i.e. FDA Pre-IND meeting) to agree the development plan. The candidates 
undergo laboratory and animal testing focusing on the pharmacological aspects of 
drug development. During this phase, the pharmacological concerns of toxicity, 
bioavailability and efficacy are investigated (Aldridge, 1998). Safety testing takes 
place in animals that are administered increasing doses to look for onset of toxicity. 
Another feature of this stage is to determine the best method of delivery (e.g., oral, 
intravenous, etc.). Other tests include determining a drug candidate’s shelf lifetime 
and shipping durability. 
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6.3 Clinical Drug development 
Clinical trials, which constitute the most time consuming and costly portion of drug 
development, consist of three phases, each more complex than the preceding. 
Before clinical trials can begin, the sponsoring pharmaceutical company must have 
approval from the Regulatory Agencies involved about trial protocols. 
In the clinic, there is a sequential evaluation in healthy human volunteers of 
tolerability, efficacy and dose range in patients, followed by widespread trials in 
thousands of appropriate patients to develop a broad database of efficacy and 
safety. New therapies typically enter the clinic through Phase I trials, which are 
often followed by subsequent phases. However, both the European Medicines 
Agency (EMA) and the US Food and Drug Administration (FDA) allow the  Phase 0 
trials which may enhance Phase I. Phase 0 trials will study the distribution of the 
drug in the human body with the usage of applications such as PET imaging, using 
very small non-therapeutic doses that are tagged with radiolabels.  
 
6.3.1 Phase I 
Phase I trials establish the safety of a compound; identify its behaviour and possible 
side effects. Further goal at this stage is to establish a dose range where the 
compound is safe. This is determined by testing a range of doses. Study participants 
initially receive a low dose of the drug; this is gradually increased as long as the drug 
appears to be safe. The participants in this study are healthy volunteers (rather than 
people who have the target disease), and they usually number between 10 and 100. 
Typically, a phase I trial will last about 1.5 year and cost about $10 million (Zivan, 
2000). 
 
6.3.2 Phase II 
The goal of this phase is to obtain preliminary data on the effectiveness (also known 
as efficacy) of the test drug. The phase II trials determine the parameters for the 
final test (phase III trials). These parameters, among others, are the class (e.g., age, 
gender) and condition of the patients to include in the trial, what end points to 
measure, and what constitutes an effective dose (dose-range studies) and duration 
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of treatment. End points are those conditions that yield an unambiguous indication 
of the drug’s success or failure. Phase II involves the use of a control group, a test 
group of patients to whom a placebo or another drug is given, which allows the 
clearest means of proving whether the drug is successful and of determining its side 
effects. At this point affected patients are tested in relatively small number (100 to 
300 participants). They are usually randomised, double-blind studies to ensure 
objectivity. Typically, phase II lasts about two years, and cost about $20 million. 
 
6.3.3 Phase III 
The goal of the phase III trial is authoritative demonstration of a drug’s 
effectiveness as defined by the end points determined in the phase II trials. Phase III 
seeks definitive proof of a molecule's efficacy and safety profile in a large number of 
patients who have the disease (from several hundred to several thousand). This 
extensive data provides a basis for extrapolating results to the general population 
and for the labelling information that will be provided with the product. In Phase III 
studies, the new drug is often compared to current standard therapy. Phase III trials 
may take several years.  
During the clinical trials, companies are required to follow certain standards and 
procedures, like the informed consent by the particpants, to ensure good clinical 
practice.  
 
6.3.4 Regulatory review and approval  
At this stage, applications with all the necessary information, including quality, 
preclinical and clinical data collected during development of the product, are 
submitted to the relevant regulatory authorities in order to obtain approval to 
market the drug in their jurisdictions [e.g., a New Drug Application (NDA) in the US, 
and a Marketing Authorisation Application (MAA) in the EU].  
Figure 13 (Fig.  13) gives an overview of this regulatory review and approval process. 
The red arrows refer to variations on the approval route that may be used when 
there is an identified unmet medical need or there is pressure to allow the drug for 
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use, even while it is being studied. These variations have specific requirements and 
are only applicable in limited situations. 
 
 
Fig.  13 Regulatory review and approval process. (Extracted from: 
http://www.fda.gov/cder/handbook/develop.htm) 
 
6.3.5 Marketing 
The last phase in the drug development process is the marketing or 
commercialization of the drug once it has been approved. The drug manufacturer 
must submit marketing authorization applications in every country or territory 
where it wants to sell the drug. 
 
6.3.6 Life cycle management 
Once the trials are completed, the treatment can be approved for general use. If 
approval is granted, post-marketing surveillance is carried out to monitor the drug 
for additional safety concerns that may not have appeared during the preapproval 
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clinical trials. These studies occur as post-marketing Phase IV trials. Examples are 
the safety and efficacy of varying doses, how the drug interacts with other drugs, or 
how it works in people with other diseases. Phase IV trials may include small or large 
numbers of subjects and may reveal uncommon side effects that are too rare to 
show up in Phase II or III studies. 
 
6.4 Drug discovery and development cost 
According to the Pharmaceutical Research and Manufacturers of America (PhRMA), 
it takes 10-17 years (Fig.  14) from disclosure to the approved medication at an 
average investment of $1.3- $1.7 billion (Fig.  15), where clinical trials consume the 
major share of the costs. Historical data, although figures are quickly evolving, point 
out that for every 5,000 – 10,000 potential drugs that are initially tested in an animal 
model of disease only 250 will progress to pre-clinical development. Of these 5 will 
move forward into first-in-man studies (Phase I) of which only a single compound 
will achieve regulatory approval (www.fda.gov). 
Funding for a trial can come from various sources, with the majority sponsored by 
pharmaceutical companies. In addition, public funds, like the National Institutes of 
Health or the European Framework Programmes, venture capital, venture 
philanthropy, NGOs. Investigators may also receive research money from the public, 
from industry and from other private sources. 
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Fig.  14 Drug Development Time and Attrition Rate. Adapted from the Pharmaceutical Research and 
Manufacturers of America (PhRMA) 2000 Industry Profile. 
 
 
Fig.  15 R&D Cost allocations by stage, PhRMA. 
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OBJECTIVES 
This work has two main objectives: 
1. The structural and functional characterization of the DosRST two-component 
system with a focus on: i) the relay of phosphate groups from DosS and DosT 
histidine kinases to DosR response regulator; and ii) the activation of DosR as 
specific DNA binding protein. 
Its specific objectives are: 
 to clone, express and purify wild-type and mutant forms of DosR, DosS and 
DosT  
 to solve the structure of active wild-type and mutant versions of DosR using 
X-ray crystallography  
 to in silico model DosS-DosR interface, analyse the key residues implicated in 
HK-RR interaction and to quantify this interaction by isothermal calorimetry 
 to check the autophosphorylation of DosS and DosT 
 to investigate the capability of histidine kinase DosS and DosT to 
phosphorylate wild-type DosR and its mutant versions 
 to analyse potential DosS phosphatase activity on DosR~P 
 to evaluate the role of key residues of DosR in its activation and in DNA 
binding efficiency 
2. The initiation of a structural-based discovery programme of inhibitors of DosR 
response regulator. 
Its specific objectives are:  
 to select a set of structurally diverse inhibitors of DosR based on the initial 
work described by Gupta et al (Gupta et al., 2009) 
 to test and implement in vitro assays for the analysis of the inhibitor-protein 
target interaction  
 to analyse the activity and spectrum of the potential inhibitors of DosR 
through whole-cell growth inhibition assays with a set of bacterial species 
 to check the selectivity of the DosR inhibitors using in vitro cellular assays 
with eukaryotic cell lines 
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MATERIALS & METHODS 
 
1. Materials 
 
1.1 Bacterial strains 
 
Species Strain Purpose Reference/source 
    
E. coli  DH5α Cloning Novagen-Merck 
E. coli  
BL21-
CodonPlus(DE3)-RIL 
(RIL) 
Protein expression Stratagene 
E. coli  BL21 (DE3) Protein expression Gibco 
E. coli  Rosetta (DE3) Protein expression Novagen-Merck 
K. pneumoniae Trevisan Antimicrobial  activity ATCC® 
E. coli 
Castellani and 
Chalmers 
Antimicrobial activity ATCC® 
M. smegmatis 
(Trevisan 1889) 
Lehmann and 
Neumann 1899 
Antimicrobial  activity DSMZ, Germany 
 
 
1.2 Eukaryotic cell lines 
 
 
Cellular line Cell type Purpose Reference/source 
 
HepG2 
 
Human hepatocytes   
Compounds 
selectivity 
ATCC® 
CHO-K1 
Chinese hamster 
ovary cells 
Compounds 
selectivity 
ATCC® 
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1.3 Cloning vectors, genomic DNA and constructed plasmids 
 
Name Purpose Reference/source 
pET21d(+) Cloning Novagen-Merck 
pPEU7 Cloning  IRB Barcelona 
Mycobacterium tuberculosis 
H37Ra genomic DNA  
Template for DosR, DosS and DosT 
cloning 
ATCC® 
DosR- pET21d(+) Protein expression This study 
DosS- pET21d(+) Protein expression This study 
DosT- pET21d(+) Protein expression This study 
DosS 350-578 - pPEU7 Protein expression This study 
DosS 380-578 - pPEU7 Protein expression This study 
DosT 349-573 - pPEU7 Protein expression This study 
DosT 380-573 -pPEU7 Protein expression This study 
 
 
1.4 Oligonucleotides 
The oligonucleotides used in this work were purchased from Sigma-Aldrich and are 
listed in the table below. The oligonucleotides’ sequence is depicted and the 
restriction sites used for cloning are underlined. The codons used to generate 
mutant proteins are in bold in their corresponding oligonucleotides.  
Fw-forward primer, Rv-reverse primer.  
 
Table 6 Oligonucleotides used In this study. 
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Name Sequence 5´-3´ Purpose Reference 
DosR Fw CTGCCATGGTAAAGGTCTTCTTGGTCGATGAC DosR full lenght 
amplification 
Roberts et al., 
2004 
DosR Rv AATACTCGAGTGGTCCATCACCGGGTG DosR full lenght 
amplification 
Roberts et al., 
2004 
DosS Fw TGTCCATGGCTCACCACCACCACCACCACATGA
CAACAGGGGGCCTCG 
DosS full lenght 
amplification 
This study 
DosS Rv TCTGGATCCCTACTGCGACAACGGTGCTGAC DosS full lenght 
amplification 
This study 
DosT Fw ATTAGCTAGCGTGACACACCCTGACAGGGCG DosT full lenght 
amplification 
This study 
DosT Rv AATACTCGAGTGCGCAGCGGTGCAGACCA DosT full lenght 
amplification 
This study 
DosS350-578 Fw AAGTTCTGTTTCAGGGCCCGGACGAACAACTC
GAGATGATG 
DosS 350-578aa 
fragment amplification 
This study 
DosS380-578 Rv  AAGTTCTGTTTCAGGGCCCGGAACTCGACGTA
CTGACCGAC 
DosS 380-578aa 
fragment amplification 
This study 
DosT349-573 Fw AAGTTCTGTTTCAGGGCCCGGACAAACAGCTC
GATATGATGGC 
DosT 349-573aa 
fragment amplification 
This study 
DosT380-573 Fw AAGTTCTGTTTCAGGGCCCGATCCTGACCGATC
GCGACCG 
DosT 380-573aa 
fragment amplification 
This study 
DosR D54A-Fw CAGATGTCGCGGTGCTGGCAGTCCGGTTGC DosR mutagenesis This study 
DosR D54A-Rv GCAACCGGACTGCCAGCACCGCATCTG DosR mutagenesis This study 
DosR [T198A, 
T205A]-Fw 
GAACGTCGGGCGCAAGCCGCGGTATTCGCGG
CGGAGTTGAAGC 
DosR mutagenesis This study 
DosR [T198A, 
T205A]-Rv 
GCTTCAACTCCGCCGCGAATACCGCGGCTTGC
GCCCGACGTTC 
DosR mutagenesis This study 
DosR [T198D, 
T205D]-Fw 
GAACGTCGGGATCAAGCCGCGGTATTCGCGGA
TGAGTTGAAGC 
DosR mutagenesis This study 
DosR [T198D, 
T205D]-Rv 
GCTTCAACTCATCCGCGAATACCGCGGCTTGAT
CCCGACGTTC 
DosR mutagenesis This study 
DosR [T198E, 
T205E]-Fw  
GAACGTCGGGAGCAAGCCGCGGTATTCGCGG
AGGAGTTGAAGC 
DosR mutagenesis Chao et al., 
2010 
DosR [T198E, GCTTCAACTCCTCCGCGAATACCGCGGCTTGCT DosR mutagenesis Chao et al., 
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1.5 Chemicals 
T205E]-Rv CCCGACGTTC 2010 
EMSA-Fw  GGCCCGCGCTTTGGGGACTAAAGTCCCTAACC
CTGGCCACG 
EMSA Wisedchaisri 
et al., 2005 
EMSA-Rv   CGTGGCCAGGGTTAGGGACTTTAGTCCCCAAA
GCGCGGGCC 
EMSA Wisedchaisri 
et al., 2005 
Acetate kinase Sigma 
Acetyl phosphate Sigma 
Acetonitrile  Merck 
Acrylamide  Bio-Rad, Sigma 
ADP Sigma 
Ammonium persulfate BioRad 
AMPPNP Jena Bioscience 
ATP Roche 
BactoTM Agar Panreac 
Beryllium sulfate tetrahydrate Sigma 
Bio-Safe Coomasie Stain BioRad 
Boric acid Panreac 
Bovine serum albumin (BSA) Sigma 
Bromophenol blue BioRad 
BugBuster Ni-NTA His Bind Purification Kit Novagen-Merck 
Carbamoyl phosphate disodium Sigma 
Coomassie brilliant blue G250 Pierce, Fluka 
Coomassie brilliant blue R-250 Bio-Rad 
Desthibiotin Sigma 
DNA ladder 100bp Biolabs 
DTT Boehringer 
EDTA Fluka 
Ethidium bromide Boehringer 
Glicerol  Merck 
HEPES Sigma 
Imidazole Sigma 
Iodoacetamide (IAA) Sigma 
IPTG Sigma 
Lambda DNA/HindIII Marker Promega 
Lysozyme from hen egg white Fluka 
Matrices for MALDI analysis Bruker Daltonics 
Mercaptoethanol Bio-Rad 
MES potassium salt Sigma 
MgSO4 New England 
Phenylmethanesulfonyl fluoride (PMSF) Sigma 
Polid(I)d(C)  Sigma 
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1.6 Laboratory equipment 
ÄKTA FPLC 
Fractions collector  
Amersham 
Amersham 
Laboratory balances Mettler 
COBOS 
VULCANO 
Autoclave Selecta 
Scales Labclinic 
Centrifuge 
      RC5C, Tubs Corex 
      Eppendorf 5810R, 5415 d 
      SIGMA 1-14 
      SIGMA 3-16K 
      Centrifuges rotor GSA, SS34 
 
Du PONT 
Eppendorf 
Sigma 
Sigma 
DU PONT 
Column FF His·trap VWR INTERNATIONAL EUROLAB 
Column Strep·trap GE Healthcare 
Columns Superdex 75, 200 GE Healthcare 
Dry bath TB15105 Fisher Scientifics 
Electroporator Eppendorf 
Freezer 
       -80°C 
      -20°C 
 
JOUAN 
ZANUSSI 
Fridge WHIRPOOL 
Zanussi 
French Press Cell Disrupter  Constant Systems Ltd 
Gel electrophoresis equipment Bio-Rad 
Ecogen 
Incubator Selecta  
Barnstead international 
INNOVA 
iTC200 microcalorimeter Microcal 
Precision Plus Protein® Dual Color Standards BioRad 
Protamine sulfate Sigma 
PureYield Plasmid Midiprep and Miniprep systems Promega 
Red Safe, Nucleic Acid Staining Solution iNtRON Biotechnology 
Restriction enzymes Promega 
SYBR Safe DNA gel stain Invitrogen S. A. 
T4 ligase Novagen-Merck 
T7 promotor and terminator primers Novagen-Merck 
TEMED BioRad 
Tris(2-carboxyethyl)phosphine hydrochloride Sigma 
Trypsin Sigma 
UREA Merck 
ZipTip C18 Millipore 
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Laminar cabin AV100, BV100 TELSTAR 
PCR PTC-200 Peltier Thermal Cycler  MJ Research 
PCR System, 7500 Fast Real-Time  Applied Biosystems 
Pipettes GILSON 
pH meter CRISON 
Shaker Selecta 
Spectrophotometer Thermo Scientific 
NanoDrop™ 1000 Thermo Scientific 
Sonicator BRANSON 
Thermocycler PTC-150, PTC-200 MJ research 
Transilluminator UVP 
UV lamp Grogen 
Vortex REAX , REAX 2000, REAX control Heidolph 
Water bath Huber 
COLORA 
Selecta 
 
 
1.7 Growth media 
Antibiotics were purchased from Sigma-Aldrich. Ampicilin (Amp) stock solutions 
(100 mg/ml) were prepared in distilled sterile water, and filtered with 0.2 μm syringe 
filters. Chloramphenicol (Chl) solution (34 mg/ml) was prepared in ethanol sterilely. 
 
LB broth (Luria-Betrani) 
10 g/L bacto-tryptone 
5 g/L bacto-yeast extract 
10 g/L NaCl pH 7.2 
LB was used to grow E. coli cells in the presence of the appropriate antibiotic. To 
prepare solid medium, 15 g/L bacto agar was added to LB and poured on Petri 
dishes.  
 
Nutrient broth medium 
5 g/L peptone 
3 g/L meat extract 
Nutrient broth medium was used to grow Mycobacterium smegmatis for 
antimicrobial activity assays. 
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Müeller-Hinton broth (MHB)  
2 g/L beef extract  
17.5 g/L acid hydrolysate of casein  
1.5 g/L starch  
pH 7.3 
Müeller-Hinton medium was used as medium for E.coli and K. pneumoniae growth in 
antimicrobial activity assay. 
 
Autoinduction medium  
6 g/L Na2HPO4 
3 g/L KH2PO4 
20 g/L tryptone 
5 g/L yeast extract 
5 g/L NaCl2, pH 7.2 
0.2% lactose 
0.6% glycerol 
0.05% glucose 
The autoinduction medium was used for inducible protein expression. 
 
HepG2 cells growth medium 
1.87 mM MEM with GlutaMAXTM I 
1 mM sodium pyruvate 
1 mM non-essential aminoacids 
10% Fetal Bovine serum (FBS) 
100 U/ml penicillin 
100 µg/ml streptomycin 
 
CHO-K1 cells growth medium 
1176 mg/l F-12 Nutrient Mixture (Ham) 
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2 mM glutamine 
10% Fetal Bovine serum  
100 U/ml penicillin 
100 µg/ml streptomycin 
 
Cryoprotectant medium for HepG2 and CHO-K1 cells 
Complete growth medium 
10% DMSO 
 
1.8 Software 
 The basic local alignment search tool (BLAST) was used to compare 
sequences of interest against various gene and genome databases, such as 
NCBI (http://www.ncbi.nlm.nih.gov).  
 The web-based DNA calculator (Sigma) was used to check and avoid the 
secondary structure and primer dimmer of designed primers 
(http://www.oligoevaluator.com/). 
 TMPred was used to predict possible transmembrane regions of the proteins 
(http://www.expasy.org/). 
 ApE-A plasmid Editor v2.0.37 was used for planning the plasmid 
constructions (http://biologylabs.utah.edu/jorgensen/wayned/ape/). 
 HADDOCK software was used for molecular modelling 
(http://haddock.science.uu.nl/). 
 Structural information about proteins was obtained from Protein Data Bank 
(http://www.rcsb.org/pdb/home/home.do). 
 PROSITE was used for helix–turn–helix motif prediction in DosR structure 
(http://prosite.expasy.org/). 
 Multi Gauge software (version 2.1) (Fujifilm) was used to analyse images 
from EMSA and in vitro phosphorylation assays (http://fujifilm.jp/lsr/). 
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 In MALDI-TOF, proteins and peptide fragments were examined with the 
MASCOT program (www.matrixscience.com) using following parameters: 
NCBI and/or Swiss-Prot sequence database. 
 
2. Methods 
 
2.1 Eukaryotic cell lines culture and cytotoxicity assay 
2.1.1 Eukaryotic cell line culture  
The cells HepG2 and CHO-K1 were frozen and thawed according to the 
manufacturer´s instruction. First, the cells were trypsinised with trypsin-EDTA 
(0.025% trypsin, 0.002% EDTA) in phosphate buffered saline (PBS). The number of 
cells/ml was couned with Neubeuer´s chamber and the number of vials to freeze to 
have 2 x 106 cell/vial was adjusted. Falcon tube with cells was centrifuged 3 min at 
1000 rpm at 4°C. The cells were resuspended in cryoprotectant medium (1.5 ml/vial), 
transferred to freezing vials and froze in Mr. Frosty (NalgeneTM Cryo 1°C Freezing 
container) filled with absolute ethanol. Mr. Frosty was placed at -80°C for minimum 
2 hours. For thawing the cells, the culture medium was warmed at 37°C. The frozen 
vials were thawed rapidly and centrifuged 3 min at 1000 rpm at 4°C. Next, the cells 
were resuspended with 1 ml of culture medium per vial and seeded in a culture dish 
(1 dish/vial). The cells were cultured at 37°C incubator with 5 %CO2. 
 
2.1.2 Cytotoxicity assay 
Cytotoxicity of selected compounds was analysed in HepG2 human hepatocytes and 
CHOK1 Chinese hamster ovary cells, using CellTiter-Glo® Luminescent Cell Viability 
Assay. The cells were incubated for 24 h at 37°C with 5% carbon dioxide. Control 
wells containing medium without cells to obtain a value for background 
luminescence were prepared. The test compounds (final concentration:  10 µM, 30 
µM, 100 µM) were added to the cell-containing wells and incubated for 24 h at 37°C 
with 5% carbon dioxide. 15 µl Celltiter- Glo 3/7 was added to each well and incubated 
at RT for 1 h, before reading the luminescence. 
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2.2 Microbiological methods 
2.2.1 Glycerol stock preparation 
Glycerol stocks of all bacterial strains were prepared by growing a bacterial culture 
from a single, colony to mid-exponential phase (OD6oo 0.5-0.6). Glycerol was added 
to a final concentration of 12% (v/v). 1 ml aliquots were prepared and frozen at –80°C 
in cryotubes 
 
2.2.2 Bacterial growth in LB medium 
The cells were grown overnight at  37° C, 250 rpm in LB medium and diluted 200 fold 
to obtain starting main culture.  
 
2.2.3 Preparation of electrocompetent cells 
A single colony of E. coli was inoculated into 2 ml LB medium and incubated at 37°C 
o/n, 250 rpm. The o/n culture was then used to inoculate 200 ml LB. Cells were 
grown to OD600 of ~0.4, placed on ice for 20 min and then harvested by 
centrifugation at 5000 g for 10 min at 4°C. The pellet was washed two times with 
250 ml of ice-cold distilled water, harvested by centrifugation as described above 
and gently resuspended in 50 ml dH20, containing 10% glycerol. After the final 
centrifugation the cells were resuspended in 0.5 ml dH20, containing 10% glycerol. 
The aliquots were stored at -80°C prior snap freezing in liquid nitrogen. 
 
2.2.4 Preparation of heat shock competent cells 
A single colony of E. coli was inoculated into 10 ml LB medium and incubated at 37°C 
o/n, 250 rpm. The o/n culture was then used to inoculate 500 ml LB. Cells were 
grown to OD600 of ~0.4, placed on ice for 20 min and then harvested by 
centrifugation at 3000 g for 10 min at 4°C. Cell pellets were gently resuspended in 30 
ml of ice-cold 100mM CaCl2 and incubated on ice for 30 min. Cells were harvested by 
centrifugation as described above and gently resuspended in 8 ml 100 mM CaCl2, 
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containing 15% glycerol. The aliquots were stored at -80°C prior snap freezing in 
liquid nitrogen. 
 
2.2.5 Antimicrobial activity 
Compounds were screened for their antibacterial activity against M. smegmatis, 
E.coli and K. pneumoniae using a high-throughput, turbidometric bacterial growth 
assay. In this assay, Müeller-Hinton agar (MHB) was used as medium for E.coli and K. 
pneumoniae growth and nutrient agar medium was used to Mycobacterium 
smegmatis growth. 
Compounds were added at a final concentration of 10 μM. In all plates, the OD612 
was measured before and after 18 h (E. coli and K. pneumoniae) or 40 h (M. 
smegmatis) incubations at 35°C. Negative controls (1% DMSO vehicle) and positive 
controls (Ciprofloxacin, 3.0 µg/mL) were run in each plate. The experiment was 
repeated three times and the results given were the mean of three independent 
reads.  
 
2.3 DNA analysis 
2.3.1 Primers design 
Primers for PCR experiments were designed according to the following standard. 
The length of most primers was ranged from 18-25 nucleotides with a >50% of 
guanine/cytosine (GC) content greater than 50% in order to result in a melting 
temperature (Tm) from 50-65˚C.  
 
2.3.2 Plasmid construction 
2.3.2.1 Insert and vector preparation 
The primers used in this work are described in (Table 6). Plasmid construction was 
planned using ApE-A plasmid Editor. Amplification reactions for all M. tuberculosis 
gene targets were designed and optimized to be used under standardized set of 
thermocycling parameters. 
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Cloning the full-length of DosR, DosS and DosT 
The dosR and dosS genes were amplified from Mycobacterium tuberculosis H37Ra 
genomic DNA using KOD XL DNA polymerase.  Amplification was carried out in a 50 
µl final volume reaction mixture containing nuclease-free water, PCR buffer, 2 mM 
PCR nucleotide mix deoxynucleoside triphosphates (dNTPs) (0.2 mM final 
concentration for each dNTP), 2.5 U/µl KOD XL DNA polymerase (0.05 U/µl final 
concentration), and genomic DNA from Mycobacterium tuberculosis H37Ra. A 3 min 
initial denaturation at 95°C was followed by 30 cycles: 95°C 15 sec, 65°C 20 sec 
(DosR) or 25 sec (DosS, DosT), 72°C 50 sec (DosR) or 2.5 min (DosS, DosT) and a 10 
min final extension at 72°C. Cloning primers incorporated restriction sites for 
directed cloning. Both amplified fragment and vector were digested with 
appropriate endonucleases following the manufacturer’s instructions. To inhibit 
restriction enzymes, the digested mixtures were heated at 65ºC for 10 min in the 
case of heat labile enzymes. For heat resistant enzymes, the DNA fragments 
resulting from the digestion were purified from an agarose gel after 
electrophoresis. PCR products were mixed with 6x DNA loading buffer (360 mM 
Tris-HCl, pH 8.8, 9% SDS, 0.9% bromophenol blue, 15% β-mercaptoethanol, 30% 
glycerol) and electrophoresed on a 1% agarose gel. Electrophoretic separation of 
products was carried out for 60 min at 0.8 mV/cm2 in 1x TAE buffer (40 mM Tris 
base, 20 mM glacial acetic acid, 1 mM EDTA pH 8.0). Amplicons were visualized 
under UV transillumination, and size estimation was made using Lambda 
DNA/HindIII Ladder. Both, fragment and vector were purified using a commercially 
available purification kits; fragment DNA (GenElute TM PCR Clean-Up Kit, Sigma) 
and vector (QIAquick® Gel Extraction Kit, Qiagen), according to manufacturer´s 
instructions. 
 
Ammonium acetate purification 
For purification of low concentrated DNA fragments, 0.5 volumes of 2.5 M 
ammonium acetate solution was added, and the samples were mixed and chilled on 
ice. The samples were then centrifuged for 30 min (10,000xg, 4°C) and the 
supernatant was transferred to a clean tube. In order to precipitate the DNA, two 
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volumes of absolute ethanol was added to the samples and the contents were 
mixed by inversion and stored for 20 min at –20°C. The DNA pellet was subsequently 
collected by centrifuging for 10 minutes at 5000 g, 4°C, washed in 70% ethanol and 
allowed to dry. The final pellet was dissolved in required volume of dH2O or TE 
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and stored at –20°C till further use. 
 
Cloning the truncated forms of DosS and DosT 
Truncated forms of histidine kinases DosS and DosT were PCR-amplified from 
Mycobacterium tuberculosis H37Ra genomic DNA using the appropriate primers (see 
Table 6) and were cloned into the pPEU7 vector. The clones were obtained by using 
the CloneEZ® PCR Cloning Kit (GenScript) according to manufacturer´s instructions. 
 
2.3.2.2 Ligation and transformation 
Ligation was carried out in a 20 µl final volume reaction mixture containing 
nuclease-free water, 2 µl of 10x ligation buffer (500 mM Tris HCl pH 8.0, 100 mM 
MgCl2, 0.5 mg/ml acetylated BSA), 2.5 U/μl T4 DNA polymerase , 2 µl of 25 mM dATP, 
1 µl 100 mM DTT (DNA-ligation kit, Novagen-Merck). The ligation reaction was 
allowed to proceed 18 hours at 16°C. A control ligation was set up without insert. 
DNA ligase inactivation was performed by heating the reaction mixture 10 min at 
70°C. 
 
Heat shock transformation 
Competent cells were incubated on ice for 30 min in 20 µl ligation reaction. Then 
they were heat shocked at 42°C for 2 min. Tubes were placed back on ice for a 
further 5 min. 500 µl of LB media was added and cells were incubated for 1 h at 37°C, 
with shaking (250 rpm). Transformation mixtures were spread onto LB agar plates 
containing adequate antibiotic for transformants selection. Plates were incubated 
o/n at 37°C.  
 
Electroporation  
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Electrocompetent bacteria were thawn on ice for 5–10 min. For a single 
transformation 50 μl of bacterial suspension were mixed in a cold transformation 
cuvette with 1-8 μl of the ligation reaction, equalling approximately 1–10 ng of 
circular plasmid DNA. Immediately after the electroporation (U = 1.7 kV; time pulse = 
5 ms) 500 μl of LB-medium were added and this suspension was transferred to an 
Eppendorf tube. After incubating the cells at 37°C for 1 h, 100 μl were plated on an 
agar plate containing the appropriate selection antibiotic and incubated at 37°C o/n. 
 
Selection of recombinant clones 
To screen for recombinant plasmids, colony PCR was performed. Insert-specific 
primers or vector-specific primers were used for amplifying a portion of the 
plasmid. Plasmid DNA from positive clones was isolated and sequence integrity was 
checked by automatic sequencing. Following sequencing confirmation, purified 
plasmids were used to transform E.coli Rosetta (DosR and DosS full lenght) or BL21 
(truncated forms of DosS and DosT) for the proteins expression. 
 
DNA sequencing  
DNA sequencing was performed for each new clone using PCR to amplify the DNA 
region of interest prior to Sanger sequencing.T7 forward and reverse primers were 
used. PCR reactions were sent to Technical and Scientific Services of University of 
Barcelona to be automated sequenced by the fluorescent Sanger method.  
 
2.4 Construction of mutant clones 
Mutagenesis of specific residues of DosR was carried out using the QuikChange XL 
site-directed mutagenesis kit following the manufacturer’s instructions. In this 
method, mutations were generated by PCR using a pair of oligonucleotide primers 
designed with mismatching nucleotides at the centre of the primers (Table 6). 
Mutations were confirmed by DNA sequencing and the final constructs were used 
to transform Rosetta or Bl21 E. coli cells. 
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2.5 Purification and analysis of proteins 
2.5.1 Protein expression 
E.coli Rosetta (for DosR, DosS and mutant proteins of DosR) or Bl21 (for truncated 
forms of DosS and DosT) cells were transformed with the recombinant clones and 
grown in plates with LB medium with the appropriate antibiotics. The pre-inoculum 
was inoculated with one colony, grown o/n at 37°C (250 rpm) and then used to 
inoculate flasks containing 1L of LB medium with the appropriate antibiotics. 
Protein expression was induced by the addition of isopropyl-1-thio-β-D-
galactopyranoside (IPTG) or with autoinduction system. In the first case, cells were 
grown in LB medium with adequate antibiotics at 37°C until OD600 ~0.6. Protein 
expression was induced with 1 mM IPTG at 37°C for 3-18 h. Cells were centrifuged at 
4,000 rpm for 20 min at 4°C and stored at -80°C before use. In autoinduction system, 
cells were grown in auto induction medium with adequate antibiotics at 37°C until 
OD600 ~1.5 and shifted at 20°C for 18 h. The cells were harvested by centrifugation at 
4,000 rpm for 20 min at 4°C and stored at -80°C before use. 
 
2.5.2 Denaturating poly-acrylamide gel electrophoresis (SDS-PAGE) 
For the separation and analysis of proteins, SDS-polyacrylamide gel electrophoresis 
technique was used (Laemmli, 1970). Resolving gels (125 mM Tris-HCl, pH 6.8, 0.1% 
SDS, 10-20% ammonium persulfate, 0.5-1% TEMED) of either 12% or 15% acrylamide 
(acrylamide:bis-acrylamide 29:1) and a stacking gel (375 mM Tris-HCl, pH 8.8, 0.1% 
SDS, 10-20% ammonium persulfate, 0.5-1% TEMED) of 6% were prepared and casted 
in the electrophoresis apparatus according to the manufacturer’s instructions. 
Protein samples were mixed with an appropriate amount of loading buffer (63 mM 
Tris-HCl, 10% glycerol, 2% SDS, 5% ß-mercaptoethanol, 0.0025% bromophenol blue, pH 
6.8) and boiled for 5 min before loading onto the gel. The gels were run in running 
buffer (25 mM Tris-HCl pH 8.3, 190 mM glycine, 0.1% SDS). Coomasie buffer was used 
for visualising the proteins in the gel. Gels were immersed in Coomassie Blue stain 
for 30-60 min on a shaking platform. Gels were subsequently rinsed several times in 
metanol:AcOH:H2O (5:1:4) to destain for 1-2 hours, rinsed in dH2O and analysed. 
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2.5.3 Cell disruption and crude extract production 
After protein expression, induced cultures were thawed on ice and resuspended in 
buffer (150 mM NaCl, 100 mM Tris-HCl, pH 8.0 and 1 mM EDTA for Strep-tagged 
proteins) supplemented with 1% protamine sulfate and lysed. Cells were disrupted 
by repeated sonication cycles (12 μm amplitude, 15 sec on, 45 sec off for 25 cycles), 
or using a French press Cell Disrupter (21,000 psi pressure). Protein integrity was 
accomplished by keeping the cell suspension and the subsequent crude extract 
cooling on ice.  
The insoluble fraction was isolated by centrifugation at 16,000 g for 40 min.  
Presence of induced recombinant protein in soluble and insoluble cell fractions was 
determined by SDS-PAGE with Coomassie staining. 
 
2.5.4 Protein purification and quantification 
Immobilized Metal Ion Affinity Chromatography (IMAC) is based on the interaction 
of certain protein residues (histidines, cysteines, and to some extent tryptophans) 
with cations of transition metals. The Nickel Chelating Resin is specifically designed 
for the purification of recombinant proteins fused to the 6 x histidine (6XHis) tag. 
Ni-Affinity Chromatography uses the ability of His to bind nickel.  
The strep-tag purification system is based on the highly selective binding of 
engineered streptavidin, called strep-tactin, to strep-tag fusion proteins. 
The proteins were purified under denaturating conditions using liquid 
chromatography system ÄKTA. Proteins were fractionated by automatic collector 
and detected in the eluent by determination by UV absorbance at 280 nm. 
The cell lysate was applied to a 5 ml pre-equilibrated affinity column (His•trap or 
Strep•tractin) with washing buffer  (150 mM NaCl, 100 mM Tris-HCl, pH 8.0 and 
1mM EDTA for Strep-tagged proteins composition) at a rate of 1 ml/min. The 
nonspecifically bound proteins were eluted with washing buffer. Recombinant 
proteins were eluted from the column with elution buffer (washing buffer with 
addition of 500 mM imidazole or washing buffer with addition of  2.5 mM 
desthiobiotin for His•tag or Strep•tag proteins, respectively). Protein fractions 
MATERIAL & METHODS 
 
65 
 
were analyzed by SDS-PAGE, pooled and further purified by size exclusion 
chromatography. 
For size exclusion chromatography, pooled fractions from the affinity 
chromatography were injected onto a Superdex 75 or 200 gel filtration column 
equilibrated in washing buffer used with affinity columns. Fractions were collected 
and analyzed by SDS-PAGE. Gels were stained with Coomassie staining.  
For crystallization trials or ITC, fractions containing protein were dialysed against 
washing buffer. Proteins were concentrated using Amicon Centriplus spin 
concentrators. The protein content for all proteins was determined by Bradford 
method or with Thermo Scientific NanoDrop™ 1000 Spectrophotometer. 
  
2.5.5 Matrix-assisted laser desorption/ionization-time-of-flight mass 
spectrometry (MALDI-TOF) 
Matrix-assisted laser desorption/ionization (MALDI) is a “soft” ionization  technique 
used in mass spectrometry, allowing the analysis of biomolecules (e.g. proteins, 
peptides or sugars) and large organic molecules (e.g. polymers, dendrimers or other 
macromolecules), which tend to be fragile and fragment when  ionized by more 
conventional ionization methods.  The utility of MALDI-TOF for protein analyses lies 
in its ability to provide highly accurate molecular weight information on molecules. 
The ability to generate such accurate information can be extremely useful for 
protein identification and characterization (e.g. post-translational modifications). 
Typical MALDI protocols for protein modification characterization begin with the 
enzymatic digestion of the protein sample, resulting in a complex mixture of 
peptides. When a protein’s primary structure is known, the molecular weight of a 
peptide can be used to corroborate the presence of any modification by its specific 
molecular-weight difference between the observed mass of peptide and that 
calculated on the basis of the sequence. 
The identity of all the proteins produced in this thesis was verified by MALDI-TOF. 
MALDI-TOF/TOF analysis was performed with the Microflex system 
spectrophotometer (Bruker Daltonics). 
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The dried extract of protein band excised from SDS-PAGE was dissolved in 10 µl of 
0.1% trifluoroacetic acid (TFA) and purified by ZipTip C4 tips prior to MS analysis. The 
eluate was mixed with 50% acetonitrile and 0.1% TFA in water for spotting onto 
sample plate, and dried for MALDI-TOF/TOF MS analysis. For phosphoprotein 
characterization, proteins, previously pretreated with either 20 mM AcP, 100 mM 
CmP or 5 mM BeF3
-, were incubated with 100 ng/L trypsin (50 mM , pH 8.3) on ice. 
Phosphopeptides were dissolved, purified and eluted as above using ZipTip C18. The 
solution was spotted on a polish stainless steel MALDI target plate. Linear Detector 
was used for samples 5-100 kDa (proteins), while reflector detector was used for 
samples 0-5 kDa (peptides). Proteins and peptide fragments were examined with 
the MASCOT program using following parameters: NCBI and/or Swiss-Prot sequence 
database.  
 
2.5.6 Regeneration of columns 
Columns regeneration was performed when different proteins were isolated or 
when there was a significant loss in the yield of protein. Columns used in 
polyhistidine-tagging were regenerated with nickel sulfate (NiSO4). His•Trap 
column was striped by washing with 5–10 column volumes of stripping buffer (20 
mM sodium phosphate, 0.5 M NaCl, 50 mM EDTA, pH 7.4). Next, it was washed with 
5–10 column volumes of washing buffer and 5–10 column volumes of distilled water 
before re-charging the column with nickel sulfate. The water-washed column was 
re-charged by loading 0.5 ml or 2.5 ml of 0.1 M NiSO4 in distilled water on column. 
Again, the column was washed with 5 column volumes of distilled water, and 5 
column volumes of washing buffer for pH adjustment before storage in 20% 
ethanol. 
To regenerate Strep•Tactin column, an excess of a yellow azo dye 1 mM hydroxyl-
azophenyl-benzoic acid (HABA) was added to the column. HABA displaces the 
desthiobiotin from the binding pocket on the Strep•Tactin and being removed by 
adding 1 x Strep•Tactin washing buffer before using the column.  
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2.5.7 Proteins crystallization and diffraction trials 
Protein structural characterization was attained by crystallization and diffraction 
trials. Pure protein preparations were used to obtain protein crystals by the sitting 
drop vapor diffusion method. This technique employs special 96-well plates with 
reservoir solution (Fig.  16). Crystallization of the purified protein was initially 
performed at 21ºC with commercially available screens: JBScreen Classic HTS I, II 
(Jena Bioscience, Germany) and JCSG+ (Qiagen, Netherlands) using a robotic 
system. Subsequent modifications of conditions were performed for crystals 
optimization. DosR and DosR mutant proteins (10 mg/ml) were treated with BeF3
- 
(7mM MgCl2, 30 mM NaF, 5 mM BeSO4) before setting up the crystallization plates. 
Crystals appeared between 2 hours and 2 weeks and reached their maximum size 
after 1 week to 1 month. Crystals were subsequently transferred to a cryo-
protectant solutions and flash frozen under liquid nitrogen. Diffraction trials were 
performed at the European Synchrotron Radiation Facility (ESRF), Grenoble, France.  
 
 
Fig.  16 An illustration of 96-well crystallization plate with diagram of sitting drop vapor diffusion 
method. In this method, the protein drop sits on a pedestal above the reservoir solution. 
 
2.6 Analysis of protein interactions 
2.6.1 Electrophoretic mobility shift assay (EMSA) 
The gel electrophoretic mobility shift assay (EMSA) was used to detect the 
formation of protein-DNA complexes. A double-stranded oligonucleotide containing 
the palindromic consensus promoter sequence of hypoxic response genes was used 
as a DNA probe. EMSA-Fw and EMSA-Rv 5’-fluorescein labelled oligonucleotides 
(Table 6) were annealed (incubation at 85ºC for 5 minutes and gradually reduction 
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of the heat until room temperature) and used as DNA probe. Binding of protein to 
DNA fragments was carried out by incubation on ice for 30 min in a 20 μl reaction 
mixture. The mixture was composed of labelled probe (5-10 ng), 1–10 μg of protein 
DosR, 50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 40 mM KCl, 12 mM MgCl2, 1 µg/μl poly-
(dI–dC) and 10% of glycerol. After incubation, the reaction was resolved in a 15% non-
denaturing polyacrylamide gel in 1 x Tris-borate-EDTA (TBE) buffer (Tris base 89 mM, 
boric acid 89 mM, EDTA 2 mM). The positions of the fluorescein labelled DNA in the 
gels were detected using a flatbed scanner that detects fluorescence (Fujifilm FLA-
5000 machine) or with transiluminator. Cell extracts contain many DNA-binding 
proteins that are capable of interacting with DNA in a sequence-independent 
manner and thus they may compete with the protein of interest for binding to a 
specific DNA. Nonspecific competitor DNA, poly-(dI–dC), was included in the 
binding reaction to minimize nonspecific interactions by facilitating detection of the 
complexes of interest. The assay was accomplished in the presence or absence of 
phosphoryl donors, such as carbamoyl phosphate (100 mM) and acetyl phosphate 
(20 mM), or Asp-phosphate mimetics like BeF3
- (5 mM). The analysis of these 
experiments was carried out using Multi Gauge Fujifilm software (version 2.1).  
Apart from protein-DNA binding, EMSA can also measure the ability of the small 
molecules to inhibit the DNA-binding or change the conformation of examined 
protein. The inhibitors screening was performed with EMSA to validate the 
inhibitory properties of the compounds and provide additional criteria for 
eliminating the least effective compounds. 
 
2.6.2 In vitro phosphorylation assay 
2.6.2.1 Autophosphorylation of DosS and truncated forms of DosS and DosT 
For autophosphorylation assay, DosS full length, DosS and DosT truncated forms 
were incubated with 0.5 µCi [γ-32P]ATP in 10 ml reaction buffer (500 mM Tris/HCl, pH 
6.8, 1M KCl, 100 mM MgCl2, 1 mM ATP) at 24ºC and aliquots were withdrawn at 
different time points and the reaction was stopped by SDS buffer  (120 mM Tris-HCl, 
pH 6.8, 20% glycerol, 4% SDS, 10% -mercaptoethanol, and 0.2% bromphenol blue). 
Unincorporated [γ-32P]ATP was removed by applying the reaction mixture to a 
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Centricon Centrifugal Filter Devices (Amicon Millipore). All aliquots were analyzed 
by SDS-PAGE and blotted to polyvinylidene difluoride membrane. The membranes 
were exposed to film o/n at 25°C and visualised with Fujifilm FLA-5000 machine.   
 
2.6.2.2 Phosphotranfer from DosS and truncated forms of DosS and DosT to DosR 
Phosphotransfer was accomplished by adding DosR to autophosphorylated DosS 
sample to in the same buffer, maintaining a molecular ratio of 1:1. The reaction was 
carried out at 24ºC and stopped at different time-points with SDS-sample buffer. 
Proteins were separated by 15% polyacrylamide gel, which was dried and visualized 
through autoradiography.  
 
2.6.2.3 Phosphorylation of DosR and mutant proteins by acetyl phosphate 
[32P]-acetyl phosphate was prepared using 1.5 unit of acetate kinase in buffer (2.5 
mM Tris-HCl, pH 8.0, 6 mM CH3CO2K, 1 mM MgCl2). 
Freshly prepared [32P]-AcP was used to phosphorylate DosR and mutant proteins.  
For each reaction 0.25 mg/ml of protein was incubated with [32P]-AcP in 
phosphorylation buffer (2,5 mM Tris-HCl pH 8,0, 6 mM CH3CO2K, 1 mM MgCl2) at 
24ºC at different times. The reaction was stopped with SDS-sample buffer and 
products were separated on 15% SDS-PAGE. After drying, detection was performed 
by autoradiography. 
2.6.2.4 Phosphatase Activity of DosS 
DosR was phosphorylated by [32P]-AcP as described above and DosS was added to a 
final reaction. The reaction mixture was incubated for various time points at 24°C. A 
control reaction was prepared in parallel, where DosS was replaced with buffer. The 
reaction was stopped with SDS- buffer and products were separated on 15% SDS-
PAGE. After drying the gels, detection was performed by autoradiography. 
 
2.6.3 Isothermal titration calorimetry (ITC) 
Isothermal titration calorimetry (ITC) is a physical technique that measures the heat 
changes associated with the interactions occurring between components in 
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solution, and thus it is useful to measure thermodynamic parameters between 
interacting biomolecules. ITC measures all binding parameters in a single label-free, 
in-solution experiment. ITC is used for characterization of mechanism of the 
molecular interaction, confirmation of intended binding targets in small molecule 
drug discovery and determination of binding specificity and stoichiometry. 
ITC was used to examine protein-protein interactions and to measure the affinity of 
a set of potential inhibitors for DosR. The assays were performed at 21ºC with 
purified proteins by using iTC200 microcalorimeter. All solutions were dialysed into 
washing buffer (with the addition of DMSO for protein-ligand interaction) to 
minimize the noise and thoroughly treated by vacuum stirring before loading into 
the syringe and the cell of the calorimeter. For protein-protein interaction 
measurement, a solution containing various protein concentrations was used as 
titrant, whereas solutions containing various concentration of other protein were 
used in the calorimetry cell. For protein-ligand interaction measurement, a solution 
containing various compound concentrations was used as titrant, whereas solutions 
containing various concentration of protein were used in the calorimetry cell. The 
machine was settled to inject 27 successive aliquots of 1.5 μl samples from the 
syringe with a 150 seconds interval into the cell under continuous stirring at 100 
rpm. The binding data were collected according to the heat effects (heat of reaction 
per injection) measured in microcalories per second and analysed by non-linear 
regression using a simple one-site binding model. The fitted data yielded the 
association constant (KA), number of binding sites on the protein (N), the enthalpy 
of binding (ΔH) and the entropy of binding (ΔS) by Origin software (version 7.0).  
 
2.7 Molecular modelling DosR-DosS complex 
The three dimensional structure of the HisKA_3 domain of M. tuberculosis DosS 
(aminoacids 382 to 446) was modelled with MODELLER software (Sali & Blundell, 
1993) using the B. subtillis DesK crystal structure (PDB accession code: 3EHF) as a 
reference template. A ‘slow’ refinement of the structure was performed during the 
modelling. Five different models were generated, and the one with better DOPE-
score was selected for analysis and further calculations. The structure of the 
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DosR:DosS complex was predicted with HADDOCK software (Dominguez et al., 
2003). The M. tuberculosis DosR structure was obtained from the PDB (accession 
code: 3C3W). Only the response regulator domain was considered (aminoacids 1 to 
99) as the receptor in the docking algorithm. The M. tuberculosis DosS structure was 
directly taken from the previous modelling. Two structural units of DosS were 
considered as two independent ligands. Structural information from the homolog T. 
maritima HK:RR complex (PDB accession code: 3DGE) was used to set-up a list of 
distance restrains between receptor and ligands aminoacids to reduce the protein-
protein docking search space. One thousand structures were generated by rigid 
body docking. The two-hundred best structures were then refined by a semi-flexible 
simulated-annealing protocol in explicit water as implemented in HADDOCK. 
Structures were visualized and analyzed with Visual Molecular Dynamics (Humphrey et 
al., 1996). 
 
2.8 Molecular dynamics simulations 
The starting coordinates for the simulation of the DosR-DNA complex were taken 
from the Protein Data Bank (PDB accession code: 1ZLK). The system was prepared 
for simulation using the GROMACS 4.5.3 simulation package. Molecular dynamics in 
explicit solvent at an atomic resolution were performed using a TIP3P water model 
(Jorgensen et al., 1983) and the CHARMM force-field (MacKerell et al., 1998) to 
describe the bonding and non-bonding interactions of the whole system. The 
system is embedded in a 111.5 x 68 x 57 A3 volume box and it was equilibrated 
following standard procedures (structure optimization followed by temperature 
and volume equilibration). All bonds were constrained with the LINCS algorithm 
(Hess et al., 1997) after optimization and the simulation time-step set to 2 fs. The 
production simulation used for analysis was performed in the micro-canonical 
ensemble at 300K using the PME treatment of long range electrostatic interactions 
(Essmann et al., 1993) with a distance cut-off of 8 Å for updating the neighbouring 
list. Separate NOSE-HOOVER thermostats (Evans & Holian, 1985) were used for 
protein, DNA and water atoms. The simulation was extended for 3.5 ns, and non-
solvent structures were sampled every 1 ps. 
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2.9 Compounds selection 
All compounds used as inhibitor candidates were purchased from Specs Compound 
Handling BV (http://www.specs.net/snpage.php?snpageid=home), except for 
compound 10 that was purchased from ChemBridge (www.chembridge.com). These 
two companies are suppliers of screening compounds and building blocks to the 
Life Science industry. Compounds dilutions were freshly prepared before each 
experiment.
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RESULTS 
 
For the study of DosRST two-component system, recombinant protein production 
methods were applied. Those methods offer the possibility of attaching purification 
tags to the proteins which facilitates the purification procedures. Hexahistidine tag 
(His-tag) was chosen for easy affinity chromatography (Hoffmann & Roeder, 1991) 
when designing the constructs for expressing the full length DosR, DosS and DosT 
proteins. Compared to other affinity tags like glutathione-S-transferase which is a 
protein on its own, the small size of a hexahistidine tag does not interfere with 
function and crystallisation ability of many recombinant proteins, and therefore 
shortens the protein preparation procedures of having to cleave the tag.  
Another advantage of using recombinant proteins is that their production can be 
boosted by the use of an efficient expression system, which is normally a better 
alternative to protein extraction from the native source, if the goal is to produce 
proteins in a large quantity to meet the need of crystallisation. Additionally, proteins 
belonging to a pathogenic bacteria (Mycobacterium tuberculosis), which demands 
P3 containment safety level, could be produced in different strains of non-
pathogenic Escherichia coli, the expression system of choice in this study. 
 
1. Cloning 
1.1 Cloning of DosR 
1.1.1 Cloning of wild type DosR 
The dosR gene of M. tuberculosis H37Rv was amplified using Mtb H37Ra genomic 
DNA as template. The DosR amino acid sequence of Mtb virulent strain H37Rv is 
identical to that of avirulent strain H37Ra (see Annex 2). 
The cloning oligonucleotides (Table 6) incorporated restriction sites at their 5’ end 
for directed cloning: the forward primer included NcoI cleavage site and the reverse 
primer contained XhoI site. The selected cloning vector was pET21d(+), which allows 
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the cloning and expression of recombinant proteins with a C-terminal six histidine 
tag (His6-tag). The amplified DNA fragment and circular vector were digested with 
NcoI and XhoI endonucleases. The digested fragments were ligated and the ligation 
reaction was transformed into E. coli DH5α competent cells. Transformants were 
selected on LB-Amp agar plates and analysed by colony-PCR. Plasmid DNA from 
positive clones was isolated and sequence integrity was checked by automatic 
sequencing.  
 
1.1.2 Cloning of mutant forms of DosR 
The mutagenesis research was performed in order to gather the data which could 
be helpful to evaluate the molecular switches leading to DosRST TCS activation, 
upon which a framework for rational drug project can be initiated.  
It has been shown that phosphorylation of Asp54 serves as a switch to activate 
DosR and it occurs through phosphorylation in a reaction catalysed by DosS and 
DosT(Chauhan & Tyagi, 2008; Roberts et al., 2004; Saini et al., 2004a; Wisedchaisri et 
al., 2008).  
It has been also demonstrated that DosR is a substrate of Ser/Thr kinase PknH (Chao 
et al., 2010). PknH phosphorylates DosR in residues threonine 198 (Thr198) and 
threonine 205 (Thr205), located in the key regulatory helix 10, involved in the 
activation and dimerization of DosR. PknH and DosS phosphorylation of DosR 
cooperatively enhance DosR binding to cognate DNA sequences (Chao et al., 2010). 
To assess the role of phosphorylation in DosR activity a series of mutants in residues 
Asp54, Thr198 and Thr205 was constructed in this study and their roles in the Dos 
TCS signal transduction pathway (i.e. phosphorylation, dephosphorylation and DNA 
binding) compared to the wild-type response regulator protein were evaluated.  
Asp-54 residue of DosR was mutated to alanine. Three different double mutants 
were constructed at Thr198 and Thr205 residues of DosR: i) mutation to alanine, 
DosR [T198A, T205A]; ii) mutation to aspartic acid, DosR [T198D, T205D]; and iii) 
mutation to glutamic acid, DosR [T198E, T205E]. Triple mutant DosR [D54A, T198D, 
T205D] was also constructed. A schematic representation of DosR with mutant 
derivatives residues is shown in Fig.  17. 
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Mutagenesis of specific residues of DosR was carried out with the QuickChange XL 
site-directed mutagenesis kit using DosR-pET21d(+) construct as template. 
Mutations were confirmed by DNA sequencing and the final constructs were used 
to transform Rosetta E. coli cells for the expression and purification of mutant 
recombinant proteins. 
 
 
Fig.  17 Schematic outline of DosR of M. tuberculosis wild type and mutant proteins domains 
structure. Mutated amino acid residues are indicated in one-letter code. Helix–turn–helix motif (H-T-H) 
was predicted by PROSITE. 
 
1.2 Cloning of DosS 
1.2.1 Cloning of full length DosS 
The dosS gene of M. tuberculosis H37Rv was amplified using Mtb H37Ra genomic 
DNA as template. The DosS amino acid sequence of Mtb virulent strain H37Rv is 
identical to that of avirulent strain H37Ra (see Annex 2). 
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Cloning oligonucleotides (Table 6) incorporated restriction sites at their 5’ end for 
directed cloning: the forward primer included NcoI cleavage site with an additional 
N-terminal six histidine tag (His6-tag) and the reverse primer contained BamHI 
cleavage site. The selected cloning vector was pET21d(+). The amplified DNA 
fragment and circular vector were digested with NcoI and BamHI endonucleases. 
The digested fragments were ligated and the ligation reaction was transformed into 
E. coli DH5α competent cells. Transformants were selected on LB-Amp agar plates 
and analysed by colony-PCR. Plasmid DNA from positive clones was isolated and 
sequence integrity was checked by automatic sequencing.  
 
1.2.2 Cloning of truncated forms of DosS 
By sequence similarity comparison with known proteins belonging to two-
component systems, the conserved His residue at position 395 in DosS was 
predicted to be the site of phosphorylation (Dasgupta et al., 2000). Its involvement 
in the phosphorylation reactions was confirmed by the analysis of mutant proteins 
(Roberts et al., 2004; Saini et al., 2004a, b). In Saini et al, for instance, the mutation 
to glutamine (unable to receive phosphodonor) at His395 resulted in abolishment of 
DosS autophosphorylation, confirming that phosphorylation occurs at the 
conserved His395 residue.  
Furthermore, the histidine kinases are membrane-bound sensor kinases, which 
denote the probable complexity in protein purification. TMPred prediction of the 
DosS revealed possible transmembrane (TM) regions that flank predominantly at 
the N-terminus of the protein (Fig.  18). The C-terminus of DosS protein contains all 
the domains required for phosphorelay and signal output. Taking into account the 
above mentioned structural and functional considerations, diverse truncated forms 
of histidine kinase DosS were constructed (Fig.  19). To avoid the difficulties in 
protein solubility and subsequent purification problems that could be encountered 
with full length of DosS, the predicted transmembrane regions were detached. In 
order to be used in in vtro phosphorylation assays, in each truncated form of 
protein the conserved histidine residue was preserved. One of the truncated forms 
carries the histidine kinase domain exclusively (DosS380-578). In the other truncated 
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form (DosS350-578) few additional amino acids at N-terminal of HisK domain were 
included to elude possible disruption in secondary structure of protein.  
 
 
Fig.  18 TMPred prediction of the DosS revealed possible transmembrane (A). The prediction of 
transmembrane regions. (B). The orientation of transmembrane regions of DosS. Anything above zero 
on the scale is considered to be a possible TM. 
 
The truncated forms of dosS gene were amplified using M. tuberculosis H37Ra 
genomic DNA as template and the corresponding cloning oligonucleotides (Table 
6). The pPEU suite of vectors have been developed in the IRB Barcelona Protein 
Expression Core Facility for HTP cloning and expression of proteins in a number of 
affinity tag/fusion protein/expression host combinations. The selected cloning 
vector was pPEU7, which has t7/lacO promoter/operon combination for inducible 
expression in E. coli strains and N-terminal StrepII-Cherry tag. The clones were 
obtained using the CloneEZ Kit according to manufacturer´s instruction.  
The digested fragments were ligated and the ligation reaction was transformed into 
E. coli DH5α competent cells. Transformants were selected on LB-Amp agar plates 
and analysed by colony-PCR. Plasmid DNA from positive clones was isolated and 
sequence integrity was checked by automatic sequencing. 
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Fig.  19 Schematic outline of DosS of M. tuberculosis wild type and truncated proteins domains 
structure prepared in this work. Indicated amino acid residue represents conserved histidine residue 
(H395) in single-letter code. 
 
1.3 Cloning of DosT 
1.3.1 Cloning of full length DosT 
The dosT gene of M. tuberculosis H37Rv was amplified using Mtb H37Ra genomic 
DNA as template. The DosT amino acid sequence of Mtb virulent strain H37Rv is 
identical to that of avirulent strain H37Ra (see Annex 2). 
Cloning oligonucleotides (Table 6) incorporated restriction sites at their 5’ end for 
directed cloning: the forward primer included NheI cleavage site and the reverse 
primer contained XhoI site. The selected cloning vector was pET21d(+), which allows 
the cloning and expression of recombinant with  a C-terminal His6-tag. The amplified 
DNA fragment and circular vector were digested with NheI and XhoI endonucleases. 
The digested fragments were ligated and the ligation reaction was transformed into 
E. coli DH5α competent cells. Transformants were selected on LB-Amp agar plates 
and analysed by colony-PCR. Plasmid DNA from positive clones was isolated and 
sequence integrity was checked by automatic sequencing.  
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1.3.2 Cloning of truncated forms of DosT 
The conserved His residue at position 392 in DosT was predicted to be the site of 
phosphorylation of DosT (Dasgupta et al., 2000). Its involvement in the 
phosphorylation reactions was confirmed by the analysis of mutant proteins 
(Roberts et al., 2004), like in the case of DosS. TMPred prediction of DosT revealed 
possible transmembrane (TM) regions that flank predominantly at the N-terminus 
of the protein with strong transmembrane helice at position 238-256aa (Fig.  20). 
The C-terminus of DosT protein contains all the domains required for phosphorelay 
and signal output indicating that this region is cytoplasmic. For in vitro 
phosphorylation and EMSA assays, the diverse truncated forms of histidine kinase 
DosT were constructed (Fig.  21). Alike for truncated forms of DosS, in each 
truncated form of DosT the conserved histidine residue was preserved and 
predicted possible transmembrane regions detached. The truncated forms of dosT 
gene were amplified using M. tuberculosis H37Ra genomic DNA as template and the 
cloning oligonucleotides (Table 6). Cloning was performed as it is described in 
chapter 1.2.2. 
 
 
Fig.  20 TMPred prediction of the DosT revealed possible transmembrane (A). The prediction of 
transmembrane regions. (B). The orientation of transmembrane regions of DosT. Anything above zero 
on the scale is considered to be a possible TM. *The probable strong transmembrane helice of DosT is 
indicated by the large peak at aa 238-256.  
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Fig.  21 Features of DosT of M. tuberculosis. Full length and truncated forms prepared in this work. 
Indicated amino acid residue represents conserved histidine residue (H392) in single-letter code. 
 
1.4 Expression and purification of proteins 
Induction of recombinant protein expression was performed either by the addition 
of IPTG to cells growing on LB or by autoinduction in cells growing in autoinducing 
medium.  
 
IPTG induction 
The T7 expression system is widely used for the production of inducible target 
proteins from cloned genes in E. coli. T7 polymerase is so selective, active and 
processive that most resources of the cell can become directed to producing a 
great variety of target proteins (Studier & Moffatt, 1986). The expression of 
recombinant proteins was achieved by IPTG induction of a chromosomally 
integrated cassette in which the T7 RNA polymerase is expressed from the lacUV5 
promoter.  
 
Autoinduction 
The autoinduction bacterial expression method (Studier, 2005) is based on the 
presence of medium components that are metabolized differentially to promote 
culture growth to high cell densities and subsequently induce protein expression 
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from lac-based promoters. The method allows high cell densities and spontaneous 
gene induction without monitoring cell growth. 
Autoinduction systems often increase cell mass and target-proteins yield 
substantially compared to conventional IPTG induction in E. coli cell cultures 
(Grabski et al., 2003). In some studies autoinduction produced 5-20 fold increase in 
target protein per volume of culture compared to IPTG induction (Studier, 2005).  
 
Expression trials 
The expression trials were performed for each protein with both autoinduction 
system and with the use of IPTG as inducing agent. For IPTG induction, proteins 
expression levels were optimized by adjusting the amount of inducing agent used, 
time allowed for expression and temperature. 
As an example of these trials, DosS overexpression was analysed by SDS-PAGE (Fig.  
22). Here, the experiment with different IPTG concentrations (from 0.5 to 2.0 mM), 
temperatures (20ºC, 30ºC, 37ºC) and induction times (2 h, 4 h, o/n) was performed.  
The lower IPTG concentration (0.5 mM) resulted in lower levels of recombinant 
protein (data not shown). Comparable amounts of recombinant protein were 
produced in 2 h and o/n cultures, induced at 20ºC or 30ºC.  The best conditions for 
expression of this protein were selected: 4 h, 37ºC, where the protein is 
overexpressed in high yield. 
The trials carried out with autoinduction system showed proteins expression higher 
in the soluble yield of most proteins, comparing to IPTG induction (data not shown). 
 
 
RESULTS 
 
82 
 
 
Fig.  22 DosS protein expression trials with 1 mM IPTG. Cell lysates of DosS were analysed. Different 
conditions (time and temperature) were analysed in this experiment. MW lanes show protein 
molecular weight marker (kDa); Non-induced cultures: lanes 1, 3, 5, 7, 9, 11, 13, 15, 17; induced 
cultures: lanes 2, 4, 6, 8, 10, 12, 14, 16, 18.  
 
1.4.1 DosR 
1.4.1.1 Expression and purification of wild type DosR and mutant forms of DosR 
Overexpressed (IPTG or autoinduction) DosR WT or DosR mutant proteins were 
purified by IMAC chromatography with 500 mM imidazole in buffer (150 mM NaCl, 
100 mM Tris-HCl, pH 8.0). SDS-PAGE analysis revealed that proteins migrated as 
diffuse bands with the predicted molecular mass of approximately 26 kDa (Fig.  23). 
All the constructions were expressed as soluble proteins.  
The average yields of DosR WT, D54A, [T198A, T205A], [T198D, T205D], [T198E, 
T205E] proteins were 10 mg/ml, 8 mg/ml, 8 mg/ml, 10 mg/ml and 18 mg/ml, 
respectively. All the proteins were considered to be >90% pure by Coomassie 
staining after SDS-PAGE.  
The identity of wild-type DosR and mutant proteins DosR were verified by MALDI-
TOF. 
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Fig.  23 SDS-PAGE analysis purified DosR D54A mutant protein. Purification fractions: lane 1, 
concentrated DosR fractions after HisTrap column purification; lanes 2, 4-6, contaminant proteins 
eluted from column; 7-9, purified DosR; lane 3, protein molecular mass marker. 
 
1.4.2 DosS 
1.4.2.1 Expression and purification of full length DosS  
Overexpressed (IPTG induction or autinduction) recombinant protein was purified 
by IMAC chromatography with 500 mM imidazole in buffer (150 mM NaCl, 100 mM 
Tris-HCl, pH 8.0). SDS-PAGE analysis revealed that proteins migrated as diffuse 
bands with the predicted molecular mass of approximately 65 kDa. Despite 
presenting many difficulties in purification (e.g. high aggregation in solution), DosS 
was expressed as soluble protein with average yield of 15 mg/ml (Fig.  24). 
RESULTS 
 
84 
 
 
Fig.  24 DosS purification trial. Chromatograms and SDS-PAGE analysis of E. coli lysates and purified 
protein DosS. DosS purified with Ni-affinity column (on the left) was loaded onto size exclusion 
column. The aggregate and contaminants were separated and purified fractions of DosS were 
collected. 
1.4.2.2 Expression and purification of truncated forms of DosS 
Truncated forms of DosS were overexpressed in E. coli Bl21 cells by induction with 
IPTG or by autoinduction. The soluble fractions were purified by IMAC 
chromatography with 2.5 mM desthiobiotin in buffer (150 mM NaCl, 100 mM Tris-
HCl, pH 8.0, 1 mM EDTA).  SDS-PAGE analysis revealed that proteins migrated as 
diffuse bands with the predicted molecular mass of approximately 37 kDa. The 
average yields of DosS350-578 and DoS380-578 were 1.6 mg/ml and 3.4 mg/ml, 
respectively. All the proteins were contaminated by the overexpressed protein ~23 
kDa and the contamination was impossible to remove neither by Strep-tactin 
column nor by size exclusion chromatography. In spite of the contaminants, the 
proteins were checked for their autophosphorylation capacity. 
The identity of full length DosS and truncated forms DosS were verified by MALDI-
TOF. 
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1.4.3 DosT 
1.4.1 Expression and purification of full length DosT 
Overexpressed (IPTG induction or autoinduction) recombinant protein were 
purified by IMAC chromatography with 500 mM imidazole in buffer (150 mM NaCl, 
100 mM Tris-HCl, pH 8.0). SDS-PAGE analysis revealed that proteins migrated as 
diffuse bands with the predicted molecular mass of approximately 65 kDa. DosT 
was expressed as insoluble protein, and refolding trials were unsuccessful (Fig.  25).  
 
 
Fig.  25 DosT purification trial. Expression trial of DosT with IPTG (left) shows band ~65kDa indicating 
that IPTG has induced DosT.  
 
1.4.2 Expression and purification of truncated forms of DosT 
Truncated forms of DosT were overexpressed in E. coli Bl21 cells by induction with 
IPTG or by autoinduction. The soluble fractions were purified by IMAC 
chromatography with 2.5 mM desthiobiotin in buffer (150 mM NaCl, 100 mM Tris-
HCl, pH 8.0, 1 mM EDTA). SDS-PAGE analysis revealed that proteins migrated as 
diffuse bands with the predicted molecular mass of approximately 37 kDa. The 
average yields of DosT349-573 and DosT380-573 were 2.9 mg/ml and 4.6 mg/ml, 
respectively. Alike with truncated forms of DosS , the proteins from this experiment 
were contaminated by the overexpressed protein ~23kDa. Even though the 
contamination was impossible to be removed neither by Strep-tag column nor by 
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size exclusion chromatography, the proteins were checked for their ability to 
autophosphorylate. 
The identity of full length DosT and truncated forms DosT was verified by MALDI-
TOF. 
 
1.4.4 DosR phosphorylation  
Response regulators phosphorylate at their active aspartic acid residue, i.e. Aps54 in 
the case of DosR, in the presence of phosphoryl donors, such as acetyl phosphate 
or carbamoyl phosphate. BeF3
- is reported to mimic phosphorylation on active 
aspartate residues in response regulators (Cho et al., 2001). To determinate DosR 
WT phosphorylation the protein was treated with different phosphoryl donors and 
prepared for MALDI screening as described in M&M chapter (2.5.5.). The MALDI-TOF 
spectrum of non-treated protein showed a broad peak centred at m/z 24.3664, 
indicating a molecular mass of DosR of approximately 24 kDa in accordance with the 
predicted molecular mass (Fig.  26). Analysis of DosR pre-treated with BeF3
- (Fig.  
27A), AcP (Fig.  27B) or CmP (Fig.  27C), revealed other peaks with different 
molecular masses (Table 7), suggesting the modification of DosR at certain residues.  
 
 
Fig.  26 MALDI spectrum obtained for untreated DosR WT protein. 
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Fig.  27 MALDI spectrum obtained for DosR WT protein pre-treated with BeF3
- (A), AcP (B) and CmP (C).  
 
Table 7 Proteins recognized by MALDI-TOF. Molecular size (Da): DosR WT: 23261.9; DosR WT in 
pET21d+, containing His•tagx 6: 24360; BeF3
-
: 103.95; PO4
3-
: 94.97. The weights of the main peaks are 
highlighted in yellow. 
 DosR DosR + BeF3
- DosR+AcP DosR+CmP 
     
Molecular 
weights of 
detected 
proteins (kDa) 
24366.4 24460.6 24454.1  24460.2  
24520.9 24362.4 24348.3 24356.1 
24540.2 24520.5 24432.6 24565.5 
24640.3 24560.8 24536.1  
24684.4    
 
To reveal if the residues of interest had been phosphorylated, the pre-treated 
proteins were digested with trypsin in order to obtain peptides profile by MALDI-
TOF screening. DosR pre-treated with BeF3
- could not be estimated due to the lack 
of recognition of peptide carrying residue Asp54 by MALDI MS (Fig.  28A). In case of 
DosR pretreated with AcP (Fig.  28B) or CmP (data not shown), the peptide with the 
residue of interest Asp54 was recognized, but the molecular weight of the peptide 
was the exact as of the sample non-treated sample. 
The signals from the trypsinised peptides did not result in target phosphopeptides 
identification. It is often difficult to observe phosphopeptides in protein enzyme 
digests and map them by MALDI-TOF. Signal intensity from the phosphopeptide is 
often lower than that of most other peptides due to its low abundance and high 
instability, so disappearance of such a weak peak after phosphatase treatment is 
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more difficult to detect. After additional trials of phosphopeptide detection by 
MALDI TOF and subsequent failures, no further experiments were performed. 
 
 
Fig.  28 MALDI-TOF peptides analysis of DosR pre-treated with BeF3
- (A) or AcP (B). 
 
1.5 Structural determination of active form of DosR 
1.5.1 Protein crystallization and diffraction trials 
The crystal structure of full-length unphosphorylated (inactive) DosR has already 
been reported (Wisedchaisri et al., 2008). In this study the production and structural 
characterization of the phosphorylated (activated) DosR crystal protein has been 
attempted. The crystal structures of other TCS response regulators in active 
conformations have been reported before in the presence of BeF3
- ( Yan, 1999; Lee 
2001), For this reason, DosR wild type and mutant variants were pre-treated with 
BeF3
- prior to being submitted to crystallization trials.  
Crystals were obtained using the sitting drop vapour diffusion method. Each 
experiment consisted of mixing protein solution with reservoir solution and then 
equilibrating it against reservoir solution.  
Only crystals of variants of DosR proteins were obtain when proteins were pre-
treated with BeF3
-. Many crystals of different symmetry were obtained, but few 
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crystals were reproducible. The best crystals chosen for diffraction trials (Fig.  30, 
Fig.  33), diffracted very poorly (7-10 Å). Diffraction trials were performed at the 
European Synchrotron Radiation Facility (ESRF), Grenoble, France. 
 
1.5.1.1 Wild type DosR 
In an intensive crystallization screen for wild type DosR many crystal of different 
forms were obtained: hexagonal, rhombic and needle-like crystals. The best crystals 
were obtained in the pH range varies from 4 to 8.5.  
Small crystals were obtained after ~48 h incubation and accomplished maximum 
size after ~2 weeks.  
 
 
Fig.  29 DosR WT crystals obtained in the crystallization plates. (A). 5 mM BeF3
-, 2.6 M sodium chloride, 
0.15 M ammonium phosphate, 0.1 M Bis-Tris, pH 7.8. (B). 5 mM BeF3
-, 4% isopropanol, 2.5 M sodium 
chloride, 0.1 M Bis-Tris, pH 7.8. (C). 5 mM BeF3
-, 4% isopropanol, 2,5 M sodium chloride, 0.1 M MMT, 
pH 4.0. 
 
The best crystal was transferred to a cryoprotectant solution and flash frozen in 
liquid nitrogen. The crystal diffracted to 10 Å ressolution. 
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Fig.  30 DosR crystal chosen for diffraction trial. 5 mM BeF3
-
, 4% isopropanol, 2.75 M NaCl, 0.1 M MMT, 
pH7.4. 
 
1.5.1.2 DosR [T198A, T205A] 
Very few crystals were obtained for DosR [T198A, T205A] and most of them were 
not reproducible. 
 
 
Fig.  31 Example of DosR [T198A, T205A] crystal. 5 mM BeF3
-, 1.6 M magnesium sulfate, 0.1 M MES 
sodium salt, pH 6.5.  
 
1.5.1.3 DosR [T198D, T205D] 
DosR [T198D, T205D] crystallized rapidly and in wide range of different conditions. 
Different crystal forms were observed. The best crystals were obtained in the pH 
range varies from 6.5 to 8.0. Needle-shaped crystals appeared after ~2 h incubation.  
Hexagonal crystals were obtained after ~24 hours and accomplished maximum size 
after ~1 week. 
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Fig.  32 DosR [T198D, T205D] crystals obtained in the crystallization plates (A). 5 mM BeF3
-, 8% PEG 
8000 MME, 0.2 M lithium chloride, 0.05 M magnesium sulphate. (B). 5 mM BeF3
-, 0.1 M potassium 
chloride, 4% PEG 6000, 0.1 M Bis-Tris pH 6.5. (C). 5 mM BeF3
-, 0.15 M magnesium chloride, 10% PEG 
2000 MME, 0.1 M MES pH6.8. (D). 5 mM BeF3
-, 0.1 M magnesium chloride, 8% PEG 6000, 0.1 M Tris pH 
8.0. €. 5 mM BeF3
-, 0.1 M potasium chloride, 3% PEG 6000, 0.1 M Tris-HCl pH 8.0. (F). 5 mM BeF3
-,  0.2 
M Sodium acetate, 15% PEG 8000, 0.1 M MES sodium salt, pH6.5  
 
The best crystal was transferred to a cryoprotectant solution and flash frozen in 
liquid nitrogen. The crystal diffracted to 7 Å ressolution. 
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Fig.  33 DosR [T198D, 205D] chosen for diffraction trial. 5 mM BeF3
-
, 15% PEG 8000, 0.2 M sodium 
acetate, 0.1 M MES sodium salt, pH 6.5. 
1.6 DosR-DosS interaction 
Protein–protein interaction between DosR and DosS were analysed through ITC and 
in vitro phosphorylation assays. 
 
1.6.1 ITC  
ITC was used to analyse protein-protein interactions between DosR and DosS. The 
assays were performed at 21ºC with purified proteins dialyzed against the same 
buffer.  
ITC technique is very sentitive to little changes in the protein environment and even 
though various conditions and proteins concentrations were examined, the 
interaction between response regulator DosR and correspond histidine kinase DosS 
was not potent enough to be clearly observed with ITC. In experiment shown in Fig.  
34, a solution containing 5 mM of DosR was used as titrant, whereas solution 
containing 25 µM of DosS was used in the calorimetry cell. 
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Fig.  34 DosR-DosS interaction measured by ITC. 5 mM of DosR and 25 µM DosS was used. Figure 
represents raw binding heats (on the right) and the integrated heat data (on the left). 
 
1.6.2 Autophosphorylation of DosS and truncated forms of DosS and DosT 
The first steps in two-component signal transduction are the signal recognition by 
the sensor histidine kinase followed by dimerization and autophosphorylation at a 
specific His residue (Hoch & Silhavy, 1995). Purified DosS was incubated at room 
temperature with 0.5 μCi [γ-32P]ATP, and aliquots of the reaction were removed for 
analysis at 5, 30 and 120 min. The aliquots were electrophoresed in 12% SDS-PAGE 
gels, which were subsequently dried and visualized by autoradiography (Fig.  35). 
The autophosphorylation assay showed that full-length DosS was able to 
autophosphorylate and that it incorporated the maximum amount of radiolabelled 
ATP at 2 hour time point (data not shown). In a time course phosphorylation assay 
(1 to 120 min) DosS was rapidly labelled with [γ-32P]ATP: about 85% and 97% of the 
maximum radioactivity incorporated in the protein was detected at 60 min and 90 
min, respectively (Fig.  35). 
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Fig.  35 Time-dependent autophosphorylation of DosS. Protein was incubated in reaction buffer as 
described and samples were removed at indicated time points and analysed by 12%  SDS-PAGE.  
 
To investigate whether full length of histidine kinases is required for 
autophosphorylation, truncated versions of histidine kinases were tested for their in 
vitro autokinase activity in the same manner as full length DosS. DosS350-578, DosT349-
573 and DosT380-573 autophosphorylated in the presence of [γ-
32P]ATP, which proved 
their autophosphorylation activity (Fig.  36). The truncated form DosS380-578 did not 
autophosphorylate, which might be due to possible disruption in the secondary 
structure caused by too short amino acid sequence when designing the truncation. 
Taking into account these activity results and the degree of protein purity obtained 
with full-length and truncated protein samples, only full length DosS was used for 
further enzymatic phosphorylation assays. 
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Fig.  36 In vitro autophosphorylation of truncated forms of DosS and DosT. Truncated forms of proteins 
DosS and DosT: DosS350-578, DosT349-573, DosT380-573 and DosS380-578 were incubated in reaction buffer as 
described and samples were removed at indicated time points and analysed by 15% SDS-PAGE. 
 
1.6.3 Phosphotransfer from histidine kinase to response regulator 
In TCS signalling cascades, once HK is autophosphorylated, HKs transfer the 
phosphate moiety from His-P to the active aspartic acid residue of their cognate RR. 
This phosphotransfer was analysed for wild type and mutant versions of DosR using 
full length of DosS protein. 
 
1.6.3.1 Phosphotransfer from DosS to wild-type DosR 
To assess phosphotransfer from DosS to DosR, wild type DosR was added to the 
autophosphorylated DosS. A fast phosphotransfer from DosS to DosR (0.5 min) was 
observed with a maximum of DosR phosphorylation at 1 min and quick decrease to 
nearly complete dephosphorylation of both proteins within 20 min (Fig. 37).  
To rule out the possibility that DosR phosphorylation was due to 
autophosphorylation, a control phosphotransfer reaction was performed, where 
DosR was incubated with [ɣ-32P]ATP in the absence of DosS. No phosphorylation of 
DosR was observed under those conditions as no labelling was observed (data not 
shown). 
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Fig. 37 Phosphotransfer from DosS~P to wild-type DosR. DosS was incubated with 0.5 μCi [γ-
32
P]ATP 
for 60 minutes and added to DosR. Samples were removed at indicated time points and analysed by 
15% SDS-PAGE. It is observed that DosS~P transfers the phosphate donor to cognate response 
regulator DosR. 
 
1.6.3.2 Phosphotransfer from DosS to DosR D54A 
Aspartic acid residue Asp54 in Mtb DosR has been described to be the receiver 
residue of DosS histidine kinase phosphatase activity. Mutagenesis of the Asp54 
residue to Val (Saini et al., 2004a) or Glu (Roberts et al., 2004), the residues 
incapable of receiving the donor phosphate, rendered DosR protein unable to 
accept the phosphoryl moiety from DosS~P. That result determined that the 
phosphorelay proceeded in a manner consistent with two-component response 
regulators.  
To confirm the specificity of the phosphorelay from DosS to DosR proteins of this 
study, phosphotransfer assays using DosR D54 mutant was performed.  
Autophosphorylated DosS could not transfer the phosphate moiety to DosR D54A 
(Fig. 38), in agreement with Asp54 being the acceptor residue of DosR for 
phosphotransfer. 
 
1.6.3.3 Phosphotransfer from DosS to DosR double mutants  
As it was mentioned before, DosR can be phosphorylated by PknH in residues 
Thr198 and Thr205. To evaluate the implication of Thr198 and Thr205 residues in the 
phosphotransfer from DosS to DosR, three double mutant proteins at these 
residues were constructed. The change of threonines to aspartic acid and glutamic 
acid residues was chosen because these negatively charged amino acids are 
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considered to function as phosphomimetic substitutions. The mutation to alanines 
was selected as control of silencing substitutions (Wang & Klemke, 2008). 
To evaluate the synergism of DosS phosphorylation with PknH we carried out 
phosphotransfer assays form DosS to the different DosR Thr mutant proteins.  In 
the presence of DosR double mutants, (DosR [T198A, T205A], DosR [T198D, T205D] 
and DosR [T198E, T205E]) phosphorylated DosS transfered the phosphor moiety to 
each response regulator (Fig. 38). DosR [T198A, T205A] behaved similarly to the 
wild type responseIn contrast, the threonine phosphomimicking versions, DosR 
[T198D, T205D] and DosR [T198E, T205E] were more efficiently phosphorylated by 
DosS, since both the level of phosphorylation (2-fold higher level of phosphorylation 
at time point 10 minutes) and the speed (almost 100% of the DosS-associated 
phosphosignal is being transferred within 1 min of reaction) increased This 
significant finding is discussed in details in the discussion section. 
 
 
Fig. 38 Phosphotransfer from DosS~P to DosR and DosR mutant proteins. DosS was incubated with 0.5 
μCi [γ-
32
P]ATP for 60 minutes and added to DosR. Samples were removed at indicated time points and 
analysed by 15% SDS-PAGE. 
 
1.6.3.4 Phosphotransfer from DosS to triple mutant DosR 
To analyse if the increased and more stable phosphorylation in DosR [T198D, T205D] 
and DosR [T198E, T205E] was due to a more efficient phosphotransfer from DosS to 
DosR’s Asp54 or to phosphotransfer to other potential HKs phosphoaccepting 
groups (i.e. aspartate or glutamate residues along the response regulator protein), 
a triple mutant, DosR [D54A, T198D, T205D] was constructed. There was no 
observable phosphotransfer throughout the 10-min time course, with the triple 
mutant behaving as the DosR D54A mutant (Fig.  39). These results indicated that 
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Asp54 was still the DosS specific phosphoacceptor in DosR [T198D, T205D] and 
DosR [T198E, T205E] mutants. 
 
 
Fig.  39 Phosphotransfer from DosS~P to DosR [D54A, T198D, T205D]. DosS was incubated with 0.5 μCi 
[γ-32P]ATP for 60 minutes and added to DosR. Samples were removed at indicated time points and 
analysed by 15% SDS-PAGE.  
 
1.6.3.5 Acetyl-phosphate  phosphorylation  
To study if the observed higher efficiency in phosphorylation was DosS-dependent, 
we compared phosphorylation of wild-type DosR, DosRT198A/T205A, 
DosRT198D/T205D and DosRT198E/T205E using [32P]-acetyl phosphate as the 
phosphodonor. Low-molecular-weight compounds such as acetyl phosphate (AcP) 
have been described to serve as phosphodonors for response regulators 
phosphorylation both in vitro and in vivo (Lukat et al., 1992; Kenney et al., 1995; Klein 
et al., 2007).  The phosphorylation pattern of wild-type DosR, DosR [T198A, T205A], 
DosR [T198D, T205D] and DosR [T198E, T205E] using [32P]-acetyl phosphate as 
phosphodonor was analysed. Radioactive [32P]-AcP and DosR WT or mutant 
proteins were incubated for up to 120 min. The experiment showed that DosR 
[T198A,T205A], phosphorylated in the presence of acetyl phosphate slightly more 
efficiently than wild-type. However, the AcP-dependent phosphorylation of DosR 
[T198D, T205D] and DosR [T198E, T205E] were clearly enhanced compared to wild 
type DosR protein (Fig.  40). Quantification of phosphorylation level showed that 
DosR [T198A,T205A], DosR [T198D, T205D] and DosR [T198E, T205E] 
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phosphorylated 2-fold, 4-fold and 5-fold faster than WT, respectively. Mutant DosR 
D54A was not phosphorylated when treated with 32P-acetyl phosphate (data not 
shown). 
 
 
Fig.  40 DosR and DosR mutant proteins phosphorylation by [32P]-acetyl phosphate. Radioactive [32P]-
AcP and DosR WT or mutant proteins were incubated for up to 120 min. DosR. Samples were removed 
at indicated time points and analysed by 15% SDS-PAGE. 
 
1.6.4 Phosphatase activity of DosS 
Histidine kinases can exhibit phosphatase activity towards their cognate response 
regulators.  
The phosphatase activity of DosS has not been described before, so in this study it 
was investigated if DosS has the capacity to dephosphorylate DosR~P. To rule out 
the potential phosphatase activity coming from DosR itself, negative control 
reaction were set up in the absence of DosS. First, we checked the stability of 
DosR~P phosphorylated by AcP in Asp54. DosR~P was highly stable with an 
apparent half-life of 30 min. When DosS was added, the radiolabelled signal on 
DosR started to disappear after 5 min and it was almost completely eliminated after 
30 min (Fig.  41). Therefore, DosS has a significant phosphatase activity that 
accelerates 6 fold the dephosphorylation of DosR. However, DosS did not show 
phosphatase activity on phosphorylated DosR [T198E, T205E]. 
Phosphatase activity of DosS against DosR~P is extensively debated in the 
discussion section. 
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Fig.  41 Phosphatase activity of DosS on phosphorylated wild type DosR (A) and mutant DosR [T198E, 
T205E] (B). Wild-type DosR and DosR [T198E, T205E] previously phosphorylated with [
32
P]-AcP were 
treated for 30 min time course with unphosphorylated DosS. Samples were removed at indicated time 
points and analysed by 15% SDS-PAGE. 
 
1.6.5 Modelling HK-RR interaction 
Disclosure of protein-protein interaction is crucial for the investigation of 
intracellular signaling pathways. Using in silico molecular modeling, the mechanism 
of intermolecular phosphotransfer between response regulator DosR and histidine 
kinase DosS was proposed in this study. The key residues involved in this interaction 
were studied. 
Structures of some response regulators have been revealed and can be used as 
templates to predict the 3D structure of other regulators by homology modelling. 
The known structures of response regulators have receiver domains composed of 
alternating α-helices and β-sheets. The 3D shape resembles a barrel composed of 
five α/β sequential segments [(αβ)5], with parallel β-sheets surrounded by the α-
helices. The aspartate residue that is phosphorylated occurs at the tip of one of the 
internal β-sheets, almost in the loop that connects it to the next α-helix. These 
structural feature appear to be conserved in the receiver domains of the majority of 
response regulators whose structure has been determined or modelled so far 
(Alves et al., 2003). 
Crystal structure of non-phosphorylated inactive DosR has been solved 
(Wisedchaisri et al., 2008) showing that full length DosR is composed of an N-
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terminal domain (receiver domain), a C-terminal domain (DNA-binding domain) and 
the linker region. DosR belongs to the NarL subfamily of TCSs although this RR has 
some differential features when compared to the rest of proteins of the same 
family. The N-terminal domain of DosR lacks one α/β segment compared to the 
canonical (αβ)5 arrangement. The C-terminal domain contains four α-helices named 
α7, α8, α9, and α10. This domain has an unusual conformation where the first α-
helix in the N-terminal domain packs against helix α10 which moves away from the 
core constructed by helices α7 to α9. The linker region consists of helices α5 and α6 
with high flexibility of the second one. Sequence alignments of DosR with other 
RRs, for example RR468 from Thermotoga maritima, confirmed that M. tuberculosis 
DosR lacks one αβ segment (Fig.  42). 
The crystal structure of the C-terminus DosR (DosRC) in complex with DNA 
oligonucleotides has also been solved (Wisedchaisri et al., 2005). In this structure, 
DosRC uses the α10 helix to form a functional dimer for DNA binding. These 
available structures were considered in this study, when modelling DosR-DosS 
complex with HADDOCK software. 
DosS structure has not been reported hitherto. Previously solved structure of 
histidine kinase HK853 in complex with its cognate response regulator RR468 of 
Thermotoga maritima (Casino et al., 2009) was also used to construct DosR-DosS 
model. Interfacing residues in T. maritima HK853-RR468 complex were proposed 
and identified by site-directed mutagenesis (Casino et al., 2009). In HK853 they 
were: Thr267, Tyr272, and in response regulator they were: Ile17, Phe20.  
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Fig.  42 Sequence and structural alignments of M. tuberculosis DosR and T. maritima RR468. (A). 
Sequence alignment of M. tuberculosis DosR and T. maritima RR468. The red box denotes the missing 
αβ segment in DosR. Similarities in aminoacids are marked with colours. The star indicates the 
conserved aspartic residue in receiver domain of response regulators: Asp54 in DosR and Asp53 in 
RR468. (B). Structural alignment of DosR (green) and RR468 (grey). Conserved Asp residue is 
highlighted in gold.  
 
Mtb DosS and T. maritima HK853 histidine kinases consist of two GAF domains and 
histidine kinase domain. There are seven families in clan His_Kinase_A of histidine 
kinase domains. Histidine kinase domain from T. maritima HK853 belongs to HisKA 
family while histidine kinase domain from M. tuberculosis DosS belongs to HisKA_3. 
Moreover, sequence comparison show that phosphate donor site (conserved 
histidine) is shifted one amino acid position in the sequence alignment with respect 
to other subfamilies (Fig.  43). 
These proteins are mainly built up from alpha-helices, this shift in sequence was 
translated into a rotation about 60 degrees in the 3D structure. In the model of 
DosS structure, the conserved histidine residue is rotated 60 degrees when 
compared to the structure of the histidine kinase from T. maritima HK853. The 
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location of phosphoacceptor in DosS and subsequent rotation of DosR caused T. 
maritima model unhelpful for DosR-DosS structural prediction. 
 
 
Fig.  43 Sequence comparison of HisKA and HisKA_3 families. The phosphate donor site (conserved 
histidine) are highlighted in purple and annotated with arrows. 
 
Upon BLAST search of DosS homologous genes (HisKA_3) with known protein 
structure, DesK from B. subtilis was identified. The sequence comparison of DosS 
and DesK showed that both proteins are homologous with a 90% of sequence 
identity (5e-12 E-value) in the histidine kinase domain (Fig.  44). Thus, the solved 
structure of histidine kinase of DesK served in this study, apart from T. maritima 
complex, as a template for modelling DosS in DosS-DosR complex. 
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Fig.  44 Sequence alignment and structure of histidine kinase domains. (A). Sequence alignment of 
histidine kinases domains of M. tuberculosis DosS and B. subtillis DesK. The star indicates the 
conserved His residue in histidine kinase domains (His395 in DosS and His188 in DesK). Similarities in 
aminoacids are marked with colours. (B). Structure of histidine kinase domain of DesK. His188 is 
highlighted in gold. 
 
For modelling the structure of the complex, protein-protein virtual docking was 
performed with HADDOCK software. Only those models in which histidine H395 
(from DosS) and aspartate D54 (DosR) were facing each other at an interacting 
distance lower than 3 Å were considered.  
Prediction model of DosR-DosS complex upon the structures of non-
phosphorylated response regulator DosR from Mtb and histidine kinase DesK from 
B. subtillis showed the rotation about 60 degrees of response regulator DosR 
against histidine kinase DosS (Fig.  45). A genuine overlap between hydrophobic 
and polar aminoacids (Val12 of DosR with Gln400 of DosS and Ala404 of DosS; Leu20 
of DosR with Leu407 of DosS, Glu88 of DosR with Gln410 of DosS, Phe403 of DosS 
with Val13 of DosR and Leu17 of DosR) was maintained at the DosR-DosS interface, 
generating His395 directly pointing at Asp54 ready for proper phosphoryl transfer.  
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Fig.  45 The complexes of HK-RR. (A). Reported structure of HK853-RR468 complex of T. maritima. (B). 
Predicted model for DosR–DosS complex. Conserved aspartic residues (RR) and histidine residues (HK) 
are highlighted in gold. Histidine kinases are shown in green and response regulators are shown in 
blue. 
 
The analysis of the interfaces of DosR and DosS showed good overlap of amino acid 
types and allowed detection of key residues for the proteins interactions. Exposed 
hydrophobic amino acids were: Val12 and Leu20 in DosR; Phe403 and Leu407 in 
DosS. 
 
 
Fig.  46 The interfaces of DosR (left) and DosS (right) with exposed hydrophobic amino acids: Val12 and 
Leu20 in DosR; Phe403 and Leu407 in DosS. Polar amino acids are highlighted in green, non-polar in 
white, positive in blue and negative in red. 
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1.7 DosR-DNA binding  
The electrophoretic mobility shift assay (EMSA) was developed based on the 
observation that a DNA fragment mobility is retarded in a gel when it complexes 
with a DNA-binding protein (Garner and Revzin, 1981). DNA binding efficiency of the 
DosR and its mutant counterparts were examined using this technique. It had been 
previously determined that DosR recognizes variations of a 20-bp palindromic 
sequence that precedes nearly all of the Mtb genes initially upregulated by hypoxia 
(Park et al., 2003; Florczyk et al., 2003). Furthermore, the crystal structures of the 
DosR C-terminal domain in complex with DNA sequence including the proper 
consensus was reported (Wisedchaisri et al., 2005). This precise DNA sequence 
containing a 20 bp consensus motif was used as probe for EMSAs. 
It has been reported that phosphorylation of DosR in Asp54 promotes its DNA-
binding capacity (Roberts et al., 2004) and that phosphorylation in Thr198 and 
Thr205 by PnkH enhances this ability (Chao et al., 2010). In this study, exploiting 
DosR mutant forms, EMSAs were performed to evaluate the role of key residues of 
DosR in its activation and in DNA binding efficiency. 
 
1.7.1 Wild-type DosR binding to DNA 
To analyse the interaction of DosR with its cognate DNA, EMSAs were carried out 
using purified wild-type DosR protein with or without pre-treatment with different 
phosphoryl donors, such as acetyl phosphate (AcP) or carbamoyl phosphate (CmP) 
to induce protein phosphorylation. BeF3
-, which has been reported to serve as a 
phosphate analogue in proteins phosphorylated on aspartate residues (Cho et al., 
2001) was also used (Fig. 50). DosR-DNA binding was observed in the presence of 
0.5 µM of DosR (Fig. 47). 
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Fig. 47 Wild-type DosR binding to their cognate DNA fragment. EMSA was performed in the absence of 
DosR (lane 1) or in the presence of 10 nM, 50 nM, 100 nM, 250 nM, 0.5 µM, 1 µM, 2 µM DosR (lanes 2-
8).  
 
The specificity of DosR-DNA binding was demonstrated by competition assays with 
increasing amounts of non-labelled DNA probe (Fig. 48). 
Addition of excess cold DNA (self-specific competitor) effectively reduced binding 
by DosR to labelled DNA. Furthermore, incubation with non-specific competitor 
showed no interruption in the binding, which demonstrates specificity of this 
binding interaction. 
 
Fig. 48 Specificity of DosR-DNA binding. Competition was performed with 5 ng of DNA without (lane1) 
or with DosR (2 µM) with no competitor (lane 2) or with 50x, 250x, 500x of self-competitor (lanes 3-5) 
and 100x, 500x of non-specific competitor (lanes 6,7). 
DosR bound to the DNA probe in the absence of phosphorylation. However, when 
DosR was pre-treated with AcP enhanced DosR binding was observed (Fig. 49). 0.2 
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µM of DosR was sufficient to observe DosR-DNA complex, whilst 0.5 µM of non-
phosphorylated DosR was required for DosR-DNA binding. The enhancement in the 
affinity of DosR~P (pre-treated with AcP) to bind to cognate DNA has been shown 
also in other studies (Roberts et al., 2004; Chauhan et al., 2008). Increased DosR-
DNA binding was also seen for DosR pre-treated with CmP (data not shown). There 
was no enhancement of DosR binding to DNA when the protein was previously pre-
treated with BeF3
- (Fig. 50).  
 
 
Fig. 49 Phosphorylated DosR binding to their cognate DNA fragment. EMSA was performed in the 
absence of DosR (lane 1) or in the presence of: 0.2 µM, 0.7 µM, 1.38 µM, 2.75 µM DosR pre-treated 
with AcP (lanes 2-5). 
 
Fig. 50 DosR and DosR pre-treated with BeF3
- binding to their cognate DNA fragment. EMSA was 
performed in the absence of DosR (lane 1) or in the presence of: 0.2 µM, 0.5 µM, 0.7 µM DosR (lanes 
2-4) or DosR pre-treated with BeF3
- (lanes 5-7). 
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1.7.2 DosR D54A binding to DNA 
The lack of phosphotransfer from DosS to DosR D54A (Fig. 38) pointed at Asp54 as 
the only amino acid that can be specifically phosphorylated by DosS. EMSA was 
performed in order to examine if the phosphorylation impairment had an effect on 
DNA binding. Wild-type DosR and DosR D54 were incubated with labelled DNA and 
the reaction was resolved in a non-denaturing polyacrylamide gel. DosR D54A 
bound poorly to DNA compared to DosR WT protein (Fig. 51). 
 
 
Fig. 51 DosR and DosR D54A DNA binding. EMSA was performed in the absence of protein (lane 1) or 
in the presence of 2 µM DosR or DosR D54A (lanes 2 and 3 respectively). 
 
1.7.3 DosR double mutants binding to DNA 
To evaluate the effect of mutations in residues Thr198 and Thr205 on DosR-DNA 
binding, the ability of wild-type, DosR [T198A, T205A], DosR [T198D, T205D] and 
DosR [T198E, T205E] to bind to their cognate DNA was analysed. At 1 µM of wild-
type DosR, almost all DNA was bound to the protein. The binding was also observed 
between DNA and DosR [T198A, T205A] even though the mutant protein bound 
more weakly than the wild type. Most notably, the DosR [T198D, T205D] and DosR 
[T198E, T205E] mutants were unable to bind to cognate DNA at any of the assayed 
protein concentrations (Fig. 52). 
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Fig. 52 Wild-type DosR and mutant proteins binding to cognate DNA. EMSA was performed in the 
absence of protein (lane 1) or in the presence of 0.5 µM, 0.75 µM, 1 µM wild-type DosR (lanes 2-4), 0.5 
µM, 0.75 µM, 1 µM DosR [T198A, T205A] (lanes 5-7), 0.5 µM, 0.75 µM, 1 µM DosR [T198D, T205D]  
(lanes 8-10), 0.5 µM, 0.75 µM, 1 µM DosR [T198E, T205E] (lanes 11-13) . 
 
To analyse if the enhancement of protein-DNA binding induced by DosR 
phosphorylation occurred with DosR mutants, EMSA was performed with proteins 
pre-treated with BeF3
-, acetyl phosphate (Fig. 53) or carbamoyl phosphate. The 
assay showed that the pattern of DNA binding did not change by the pre-treatment 
with phosphoryl donors or phosphomimetic.  
 
 
Fig. 53 Wild-type DosR and mutant proteins binding to cognate DNA in the presence of 20 mM AcP. 
EMSA was performed in the absence of protein (lane 1) or in the presence of 0.2 µM, 0.4 µM, 0.8 µM 
wild-type DosR (lanes 2-4), 0.2 µM, 0.4 µM, 0.8 µM DosR [T198A, T205A] (lanes 5-7), 0.2 µM, 0.4 µM, 
0.8 µM DosR [T198D, T205D] (lanes 8-10). 
 
1.7.4 Molecullar modelling of DosR-DNA interaction 
The effect of the double mutations at positions Thr198 and Thr205 on the structural 
stability of the DosR dimer and the complex it forms with DNA was analysed by 
means of molecular dynamics simulations. The structure of the wild-type DosR-DNA 
complex remained stable fluctuating around the initial X-ray coordinates for the 
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total simulation period. On the other hand, when the double mutant DosR [T198E, 
T205E] was introduced into the structure, two important effects occurred. Firstly, 
the DosR dimer started bending and breaking apart (Fig. 54A), showing an average 
RMSD of 2.7 Å with respect to the initial structure (the RMSD is kept low at 1.5 Å for 
the wild type DosR) after 4 ns of simulation. This is mainly due to the fact that 
position 198 and 205 are actually located at the dimerization interface formed by 
alpha-helix 10. A small threonine to a voluminous and negatively charged glutamate 
substitution in these positions notably disfavoured the protein-protein interactions. 
Secondly, and as a consequence of the DosR dimer rearrangement, the interaction 
with DNA was progressively lost with an initial separation of 4 Å between the center 
of masses of DosR and DNA (Fig. 54B). Moreover, the DosR [T198E, T205E]-DNA 
complex was further destabilized by the T198E substitution because a strong 
negative electrostatic potential was formed at the deeper site of the DNA binding 
pocket (data not shown). 
 
 
Fig. 54 Molecular dynamics simulations for DosR and DosR [T198E, T205E]. (A). Superposition of the 
wild-type DosR (white) and DosR [T198E, T205E] mutant (green) in complex with DNA (orange) at the 
end of the molecular dynamics simulation. (B). Evolution of the distance between DosR dimer and 
DNA strand along the simulation of the complex for different DosR variants. 
 
1.8 Screening for potential inhibitors of DosR-DNA binding 
This thesis was initiated because of the attractiveness of Mtb Dos TCS of as a novel 
antitubercular drug target. The mechanism of action of DosRST targeting molecules 
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may work not by killing M. tuberculosis bacilli directly, but by forcing them out of the 
non-replicative state leaving them susceptible to currently available 
antimycobacterial agents. Response regulators had been suggested to be good 
targets for this and a significant number of molecules targeting response regulators 
as a strategy for the development of novel broad-spectrum anti-infectives had been 
reported. In this work a group of small-molecules were designed as potential 
inhibitors of DosR TCS. 
 
1.8.1 Compounds selection 
During bacterial adaptation to hypoxia and other stress signals, DosR response 
regulator mediates the induction of 48 genes that constitute the DosR regulon.  
In view of the role of DosR in dormancy regulation and in hypoxic survival, the 
identification of compounds that inhibit the ability of DosR to bind to its target 
genes is likely to provide novel antitubercular chemotherapeutic agents against 
persistent bacilli. DosRST two-component system has been proposed as an 
attractive target for the development of inhibitors against dormant mycobacteria 
(Lamichhane, 2010; Murphy & Brown, 2007; Saini et al., 2004; Vohra, 2006).  
In Gupta et al, a homology-based model of DosR was generated to be used as a tool 
for the rational design of potential inhibitor compounds. The model was based on 
the structure of NarL response regulator of E. coli as the primary template for the N-
terminal region, whereas the known crystal structure of C-terminal DosR was used 
as the template for the C-terminal region. In that study, a phenylcoumarin derivative 
molecules named as compound 10 (Fig. 55) showed its ability to abrogated DNA-
protein interaction with an IC50 < 26.2 μg/ml (45 µM). Compound 10 showed its 
ability to prevent DosR binding to target DNA without inhibiting its 
phosphorylation. Exposure of Mtb to this compound prevented the upregulation of 
genes from the DosR regulon. Furthermore, exposure to this compound reduced 
the ability of Mtb to establish nonreplicating dormancy in vitro following gradual 
oxygen depletion. Thus, compound 10 appeared like a good starting point for the 
development of small molecules inhibiting DosR-DNA binding. 
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Consistent with results from Gupta and colleagues, for this study ten commercially 
available small molecules (compounds 1-9, 11, Table 8), structurally similar to 
compound 10, were selected for biological and chemical screenings in order to 
search for potential DosR-DNA binding inhibitors. Fig. 55 shows the chemical 
structure of compound 10 and the three different regions on which the design of 
the chosen compounds was based are highlighted. All the compounds were freshly 
prepared in DMSO for every experiment. 
 
 
Fig. 55 Chemical structure of compound 10 (phenylcoumarin derivative) (ChemBridge, 7862123) 
(Gupta et al., 2009). The shapes of different colours represent the chemical structures on which the 
selection of other screening compounds for this study was based. 
 
Table 8 The compounds 1-9 and 11 used in this study. 
Compound 
number 
Name & 
Formula 
ID 
number 
(SPECS) 
Chemical structure 
1 
N-{4-[(2-
chlorobenzoyl)
amino]-3-
methoxyphenyl
}-3,5-
dimethylbenza
mide 
C23H21ClN2O3 
AP-
970/42250
064 
 
2 
2-chloro-N-(3,4-
dimethoxyphen
yl)benzamide 
C15H14ClNO3 
 AO-
548/10416
031 
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3 
2-chloro-N-[4-
(2-oxo-2H-
chromen-3-
yl)phenyl]benz
amide 
C22H14ClNO3 
AG-
690/36105
015 
 
4 
N-{4-[(2-
chlorobenzoyl)
amino]-3-
methoxyphenyl
}-1,3- 
benzodioxole-
5-carboxamide 
C22H17ClN2O5 
 AP-
970/42736
696 
 
5 
2,3-dichloro-N-
[3-methyl-4-(2-
oxo-2H-
chromen-3-
yl)phenyl]benz
amide 
C23H15Cl2NO3 
AG-
670/11901
084 
 
6 
3-methoxy-N-
[4-(2-oxo-2H-
chromen-3-
yl)phenyl]benz
amideC23H17N
O4 
AK-
778/37026
083 
 
7 
2-chloro-5-iodo-
N-[4-(2-oxo-2H-
chromen-3-
yl)phenyl]benz
amide 
C22H13ClINO3 
 AK-
778/36975
010 
 
8 
N-(3,4-
dimethoxyphen
yl)-4-
methylbenzami
de 
C16H17NO3 
AO-
548/10416
025 
 
9 
4-(2-oxo-2H-
chromen-3-
yl)benzoic acid 
C16H10O4 
 AN-
465/25105
015 
 
RESULTS 
 
115 
 
11 
N-(3,4-
dimethoxyphen
yl)[1,1'-
biphenyl]-4-
carboxamide 
C21H19NO3 
AO-
548/11903
037 
 
 
 
1.8.2 Activity assays 
1.8.2.1 ITC 
ITC analysis was carried out to determine the binding ability of each compound to 
wild-type DosR. The assays were performed at 21ºC with solutions dialyzed into 
buffer (150 mM NaCl, 100 mM Tris-HCl, pH 8.0 and 10% DMSO). A solution containing 
different compound concentrations was used as titrant, whereas solutions 
containing 100 µM of DosR were used in the calorimetry cell. Compound 10 and 
compound 2 showed affinity to DosR (Fig.  56). Compounds 1, 5 and 9 displayed 
very weak binding. Compounds 3, 4, 6, 7, 8 and 11 showed no affinity to DosR (Table 
9). 
Table 9 Displayed affinity of compounds 1-11 to DosR measured by ITC. Strong binding (+++), weak 
binding (+) and no binding (-) were observed. 
compound # 1 2 3 4 5 6 7 8 9 10 11 
Affinity to DosR + +++ - - + - - - + +++ - 
 
 
Fig.  56 Compounds binding to DosR. (A). Compound 10. (B). Compound 2. The right upper part of each 
figure shows the raw binding heats and the left part represents the integrated heat data. The aliquots 
of a compound (500 µM) were injected into the cell containing DosR (100 µM) solution. 
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Fig. 57 Compounds binding to DosR [(A): compound 1, (B): compound 3, (C): compound 4, (D): 
compound 5, (E): compound 6, (F): compound 7, (G): compound 8, (H): compound 9, (I): compound 
11). The top part of each figure shows the raw binding heats and the bottom the integrated heat data. 
The aliquots of a compound (500 µM) were injected into the cell containing DosR (100 µM) solution. 
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1.8.2.2 EMSA 
EMSA trials have been shown to be a good experimental approach to test potential 
inhibitors (Gupta et al., 2009). The compounds showed good solubility in DMSO and 
for each experiment they were freshly prepared in this solvent. To set up the 
experimental conditions, different concentrations of DMSO were added to each 
sample to analyse its potential influence on the binding of DosR to DNA and on the 
migration of the free DNA probe (Fig.  58). Although some effect on DNA binding 
was observed at concentrations higher than 5% DMSO, the compromise between 
product solubility and a DMSO concentration where DNA shift was observable 
made us select 10%  DMSO as the final concentration in each reaction. 
 
 
Fig.  58 DMSO influence on DosR-DNA binding estimated by EMSA. DosR (2 µM) was incubated with 
different concentration of DMSO: 0, 2.5%, 5%, 7.5%, 10%, 15% (lanes 2-7, respectively). DNA (5 nM) 
incubated with 15 µM DMSO, lane 8, only DNA, lane 1. 
 
ITC analysis showed affinity of compounds 2 and 10 for DosR protein. To evaluate if 
those compounds had influence on DosR-DNA binding, EMSA was performed 
initially for those two compounds. Decreased binding of DosR to DNA was showed 
in the presence of compound 2 in all the assayed concentrations. Decreased binding 
of DosR to DNA was showed in the presence of compound 10 already at 500 µM and 
an increase in compound concentration caused higher decrease in binding. 
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Fig. 59 The effect of the compounds 2 and 10 on DosR binding to DNA. (A). Compound 2. (B). 
Compound 10. EMSA was carried out without (lane 5) or with 2 µM DosR (lanes 1-4). The compounds 
were added at 0.125 mM 0.25 mM, 0.5 mM, 1 mM (lanes 1-4). 5 nM of DNA was used. 
 
The compounds 1, 3, 9-11 were tested with EMSA at concentrations 250 µM (lanes b 
in Fig.  60) or 500 µM (lanes a in Fig.  60) with the protein DosR alone (Fig.  60A) or 
pre-treated with 20 mM AcP (Fig.  60B). Any of the tested chemicals showed 
significant inhibitory effect on the DNA-binding properties of the response 
regulator DosR. In the presence of DosR pre-treated with AcP, compound 5 
inhibited DosR-DNA binding at 250 µM. Hypothesis about these findings are 
presented in discussion section. 
 
Fig.  60 Effect of test compounds on DosR (2 µM) binding to DNA (5 nM).  EMSAs were carried out with 
compounds 1-11 at 500 µM (a) and 250 µM (b) in the absence (-) or presence (+) of wild-type DosR 
protein. (A). Non phosphorylated DosR. (B). DosR pretreated with 20 mM AcP. 
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1.8.2.3 Whole cell antimicrobial activity 
Compounds were screened for antibacterial activity against E.coli, K. pneumoniae 
and M. smegmatis using a high-throughput, turbidometric assay of bacterial growth 
in a 384-well plate format. In this assay, Müeller-Hinton broth (MHB) was used as 
medium for E.coli and K. pneumoniae growth and nutrient medium was used to M. 
smegmatis growth. Compounds were added at a final concentration of 10μM. In all 
plates, the OD612 was measured before and after 18 h (E. coli and K. pneumoniae) or 
40 h (M. smegmatis) incubations at 35°C. Negative controls (1% DMSO vehicle) and 
positive controls (Ciprofloxacin, 3.0 µg/ml) were run in each plate. The experiment 
was repeated three times and the reported results are means of three individual 
readings. Fig.  61 shows the effect of the eleven compounds on the growth of E. 
coli, K. pneumoniae and M. smegmatis in liquid medium, as determined by 
monitoring optical density at 612 nm. The assayed compounds only inhibited E. coli 
and K. pneumoniae growth by 10%. For M. smegmatis, compounds showed growth 
inhibition between 30%-83 %, except for compound 8, which showed no effect on 
growth of M. smegmatis. 
 
 
Fig.  61 Growth inhibition of K. pneumoniae, E. coli and M. smegmatis  by compounds 1-11 (10 µM). 
The percentage of inhibition was determined with relation to the control 3.0 µg/mL ciprofloxacin 
(Cipro). 
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1.8.3 Compounds selectivity- cytotoxicity assays 
Selectivity of compounds is a major determinant in selecting agents for further 
inhibitors development. The analysis of the in vitro cytotoxicity of each compound 
on human hepatocytes HepG2 cells and Chinese hamster ovary CHO-K1 cells was 
performed using the CellTiter-Glo® Luminescent Cell Viability Assay. This is a 
homogeneous method to determine the number of metabolically active viable cells 
in culture which correlates  the ATP present in the sample. The amount of ATP is 
directly proportional to the number of cells present in culture in agreement with 
previous reports (Crouch et al., 1993). The assay was used to analyse each 
compound. HepG2 cells (2500 cells/well) and CHO-K1 cells (2000 cells/well) were 
seeded in MTP-384 assay plates and incubated for 24 h at 37°C with 5% carbon 
dioxide. Control wells containing medium without cells to obtain a value for 
background luminescence were prepared. As a control, tamoxifen was used. The 
test compounds (final concentration:  10 µM, 30 µM, 100 µM ) were added to 
experimental wells and incubated for 24 h at 37°C with 5% carbon dioxide. 15 µl 
Celltiter- Glo 3/7 was added to each well and incubated at RT for 1h, before reading 
the luminescence. 
The HepG2 cells viability was >80% for all the assayed compounds. death was not 
induced by any compound at any concentration, causing only a slightly decrease in 
cell viability. Very small reduction of CHO-K1 cells viability was observed when the 
cells were incubated with compounds at 10 µM (≥ 80% cell viability). CHO-K1 viability 
was lower than 80% at  100 μM of compounds 1, 2, 5, 8, 9, 11.  
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Fig.  62 Cell viability of HepG2 (A) and CHO-K1 (B) cells. The test compounds (final concentration:  
10µM, 30 µM, 100 µM). 
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DISCUSSION 
 
The core of bacterial two-component system pathways is a phosphotransfer 
reaction between two components, a histidine kinase (HK) and a response 
regulator (RR). Firstly, upon the perception of environmental of cytosolic specific 
signal(s), HK autophosporylates at conserved His residue using ATP as 
phosphodonour. Cis-autophosphorylation (one subunit phosphorylates itself) 
occurs in some HKs while trans-autophosphorylation takes place in others (Casino 
et al., 2010). The HK communicates with a response regulator protein that possesses 
a receiver domain containing a conserved site of aspartate phosphorylation. 
Aspartate phosphorylation of the response regulator acts as a molecular switch to 
control output activity, thus transducing the original signal. 
The DosR regulon is composed of ~48 co-regulated genes essential for Mtb survival 
during latency. The DosR regulon, activated in response to hypoxia, NO, CO or 
ascorbic acid exposure, is regulated by a two-component regulatory system 
consisting of two sensor kinases, DosS and DosT, and a response regulator DosR. 
One of the main objectives of this study was the structural and functional 
characterization of the activation mechanism of DosR response regulator of the 
DosRST two-component system. 
 
1 Activation mechanisms of DosR 
1.1 Activation of DosR through in vitro phosphorylation  
The ability to phosphorylate is essential for response regulators to activate gene 
expression and allow adaptation of bacteria to their natural habitats. 
Phosphorylation of the active site aspartate residue in a receiver domain of RR is 
coupled to conformational changes that regulate the function of its output domains 
(Ninfa & Magasanik, 1986), many of which activate or repress transcription 
(Parkinson& Kofoid, 1992; Stock et al., 1995). 
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The crystal structure of unphosphorylated inactive DosR has been reported 
(Wisedchaisri et al., 2008) showing that full length DosR is composed of an N-
terminal receiver domain, a C-terminal DNA-binding domain and the linker region 
and revealing several features never seen before in other response regulators.  The 
N-terminal domain of DosR lacks one α/β segment compared to the canonical (αβ)5 
arrangement. The C-terminal domain contains four α-helices named α7, α8, α9, and 
α10. This domain has an unusual conformation where the first α-helix in the N-
terminal domain packs against helix α10 which moves away from the core 
constructed by helices α7 to α9. The linker region consists of helices α5 and α6 with 
high flexibility of the second one. Sequence similarity analysis of DosR with other 
RRs, for example RR468 from Thermotoga maritima, confirmed that M. tuberculosis 
DosR lacks one αβ segment. The structural characterization of phosphorylated 
active form of DosR was one of the objectives during this research. This information 
would allow to gain detailed structural information of the active site and would 
consequently help in the design of target based inhibitors of DosR. Therefore, 
crystallization trials of wild-type and variants of DosR protein were performed. 
Phosphorylation-mediated conformational changes in the response regulator pre-
treated with BeF3
- have been reported. Comparison of the structures of receiver 
domains that are phosphorylated or bound to BeF3
- with their nonphosphorylated 
counterparts revealed key differences between the active and inactive 
conformations (Lee et al., 2001, Wassmann et al., 2007). In CheY, the response 
regulator of bacterial chemotaxis, BeF3
- bound to Asp57, the normal site of 
phosphorylation, forming a hydrogen bond and salt bridge with Thr87 and Lys109, 
respectively (Lee et al., 2001).The BeF3− modification of receiver domain of 
response regulator PleD from Caulobacter crescentus causes rearrangement with 
respect to an adaptor domain, which, in turn, promotes dimer formation, allowing 
for the efficient encounter of two symmetric catalytic domains (Wassmann et al., 
2007). Consequently, in this study, the proteins were pre-treated with BeF3
- prior to 
being submitted to crystallization trials. Although many crystals with different 
geometries were obtained, they diffracted poorly. This might be due to the small 
size and low-quality crystals, or problems with aberrations coming from 
cryoprotectant treatment. The potential formation of multimers of wild-type DosR 
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might be one of the reasons for unsuccesfull diffraction. The mutant proteins may 
have a high degree of structural flexibility and therefore structural heterogeneity, 
which results difficult to obtain rigid conformation of proteins. 
Although RRs are typically phosphorylated by HK-catalysed phosphotransfer in vivo, 
RRs can be phosphorylated in vitro using suitable small molecule phosphodonors, 
such as acetyl phosphate (AcP) or carbamoyl phosphate (CmP). The 
phosphorylation of DosR protein by [ɣ-32P]AcP was shown before and also in this 
study.  
To analyse how the DosR phosphorylation correlate with the interaction of DosR 
with its cognate DNA, EMSAs were carried out using purified wild-type DosR protein 
with or without pre-treatment with different phosphoryl donors, AcP or CmP to 
induce protein phosphorylation or phosphate analogue, BeF3
-, to mimic 
phosphorylation.  
DosR bound to the DNA probe in the absence of phosphorylation. In fact, the 
unphosphorylated response regulators are still able to recognize promoters (Cariss, 
et al., 2008); however, it is unlikely for microbes to over-produce the response 
regulators to activate or repress transcription. In causing the disease, the activation 
of response regulator is important largery, for instance by coordination of virulence 
factors (Leday, et al., 2008). Therefore, when DosR was pre-treated with AcP or 
CmP, DosR binding enhancement was observed confirming the positive effect of 
DosR phosphorylation in DNA binding. There was no enhancement of DosR binding 
to DNA when the protein was previously pre-treated with BeF3
-, although it was 
previously demonstrated by gel shift assays that BeF3
- stimulates the DNA binding 
properties of RRs. The problems with DosR protein precipitation after BeF3
- might 
have interfered in the DNA- binding capacities of protein.  
 
1.2 DosS-dependent phosphorylation of DosR Asp54 is affected by 
DosR Thr198 and Thr205 mutations 
Two functional histidine kinases, DosS and DosT, phosphorylate DosR response 
regulator specifically at aspartic acid residue Asp54 and form a bona fide two-
component system (Saini et al., 2004a). DosR, DosS and DosT proteins of M. 
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tuberculosis exhibited properties typical of TCS´s proteins, namely 
autophosphorylation of a conserved histidine residues in the cytoplasmic domain of 
the histidine kinase DosS and DosT and phosphotransfer of phosphoryl moiety from 
HK to a conserved aspartic acid residue (Asp54) in the response regulator DosR. 
In this study, full length of DosS was expressed and purified as C-terminal His6-tag 
protein and used for in vitro assays. To exclude possible transmembrane (TM) 
regions that flank predominantly at the N-terminus of the protein and used to result 
in problems with proteins purification, diverse truncated forms of histidine kinases 
DosS and DosT were constructed. In each truncated form of the protein, a HisKA 
domain, which contains the phosphoryl group-accepting histidine residue, and a 
HATPase domain, which is the ATP binding site, were preserved. 
Full-length N-terminal His-tagged DosS was able to autophosphorylate in the 
presence or [γ-32P]ATP, which proved its catalytic autophosphorylation activity and 
subsequently  was used for the enzymatic phosphorylation of DosR variants. DosS 
autophosphorylated in the presence of [γ-32P]ATP and transferred the 
phosphomoiety to full-length C-terminally His-tagged DosR. The stability of DosS~P 
was modulated by DosR; the phosphorylated DosS protein had a very short half-life 
(<1 min) in the presence of DosR but was very stable in its absence (the entire 
radioactivity retained in DosS~P at 2 h). In vivo, the rapid phosphotransfer from 
DosS to DosR would enable the rapid adaptation to hypoxic conditions and thus 
would increase the bacilli survival by entering into dormancy. The lack of 
phosphotransfer from DosS~P to DosR D54A mutant confirmed the specificity of 
DosS phosphorylation in Asp54. It also points out the essentiality of Asp54 residue 
for the phosphorylation of RR and for protein–protein interactions between RR and 
HK, as it was demonstrated for DosR-DosS TCS of M.smegmatis, Mtb homolog, (Lee 
et al., 2013). In their study, the replacement of Asp54 with Ala in DosR completely 
abolished protein interactions of DosR with DosS in yeast two-hybrid assay, which 
was further confirmed in the pull-down assay. 
Bacterial homologues of eukaryotic type serine/threonine kinases have been found 
to be necessary for cellular functions such as growth, differentiation, pathogenicity, 
and secondary metabolism (Kennelly, 2002; Deutscher & Saier, 2005; Jayakumar et 
al., 2008). They have been described to be kinases of response regulators in specific 
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threonines. For instance, VirS, a transcriptional regulator of Mtb that controls the 
transcription of the mymA operon, can be phosphorylated by the serine/threonine 
kinase PknK, and this phosphorylation increases the affinity for the mymA promoter 
(Kumar et al., 2009). PknH, a Ser/Thr kinase of Mtb, phosphorylates InhA, a key 
enzyme of the fatty-acid synthase II system involved in mycolic acid biosynthesis 
(Khan et al., 2010), and EmbR, a putative transcriptional regulator of the embCAB 
operon (Sharma et al., 2006). It has been also demonstrated that DosR is a 
substrate of Ser/Thr kinase PknH (Chao et al., 2010). PknH phosphorylates DosR in 
threonine residues 198 (Thr198) and 205 (Thr205).  These phosphorylable residues 
are located in helix α10 at the C-terminal domain of DosR, which has been implicated 
in the activation and binding of the response regulator to DNA. The combination of 
Asp54, Thr198 and Thr205 phosphorylation has been described to cooperatively 
enhance the ability of DosR to bind its cognate promoter sequences in one of the 
two dosR boxes of hspX. For the exposed reasons, mutants mimicking Thr198 and 
Thr205 phosphorylated state were designed. Expected results (i.e. increase in DNA 
binding affinity), were not achieved, which partially contradicted Chao and 
collaborators work. This unexpected results are discussed in detail here. Response 
regulators are in equilibrium between inactive and active conformations, with 
phosphorylation acting as a molecular switch towards the active form (Cho et al., 
2001; Ames et al., 1999; Simonovic et al., 2001; Volkman et al., 2001) and vice versa. 
For E. coli CheY, four states of activation and inactivation of clockwise signaling have 
been identified. The four states correspond to the combinations of phosphorylated 
and unphosphorylated, active and inactive conformations (Silversmith & Bourret, 
1999). 
In this study, the particular interest was to understand the role of DosR amino acid 
residues Thr198 and Thr205 in its activation mechanism. Previous studies 
established that PknH phosphorylation of DosR in Thr198 and Thr205 together with 
DosS-catalysed phosphorylation in DosR Asp54 enhanced DosR binding to its 
cognate DNA promoter sequences (Chao et al., 2010).  
A set of mutants in Thr198 and Thr205 were constructed (DosR [T198A, T205A], 
DosR [T198D, T205D], DosR [T198E, T205E], DosR [D54A, T198D, T205D]) and their 
behavior regarding phosphorylation, DNA binding, and dephosphorylation analysed.  
DISCUSSION 
 
127 
 
Phosphotransfer from DosS to DosR [T198A, T205A] had a similar pattern to that of 
wild-type DosR, indicating that the introduction of silencing neutral mutations did 
not affect largely the conformation of the regions surrounding Asp54 of the 
response regulator. However, phosphotransfer from DosS to DosR [T198D, T205D] 
and DosR [T198E, T205E] was clearly enhanced compared to wild-type and DosR 
[T198A, T205A], increasing the quantity and speed of the HKRR phosphorelay and 
the stability of the phosphor signal in the RR. This result seems to indicate that the 
change from threonines to the negatively charged residues induced a 
conformational change in DosR which made Asp54 more accessible to 
phosphorylation by DosS. This result is in accordance with the DosR helix 
rearrangement activation mechanism proposed by Wisedchaisri et al., where, at 
neutral pH, helix α10 is likely to be in equilibrium between different conformations 
including one with no contact with the N-terminal domain (Wisedchaisri et al., 
2008). The electrostatic repulsion between electronegative charges of Asp54, 
Asp198 and Asp205 or Asp54, Glu198 and Glu205 could displace the equilibrium of 
the conformations towards the one where there are no contacts between helix α10 
and Asp54, thus exposing Asp54 to the solvent and making it more accessible to 
DosS active His395 thus enhancing phosphotransfer. The lack of phosphotransfer 
from DosS~P to triple mutant DosR [D54A, T198D, T205D] confirmed Asp54 
necessity for phosphotransfer from DosS to DosR. 
Prolonged phosphorylation of DosR by mutagenesis of one of its residue was 
published recently (Cho et al., 2014). In this study, DosR S83A mutant showed 
slower autodephosphorylation than the wild type. Ser83 was proposed to play a 
role in DosR transition from an activated, phosphorylated state to an inactive, 
unphosphorylated state. 
In vitro phosphorylation experiments were performed with wild-type DosR and its 
mutant variants using acetyl phosphate to see if the observed increase in 
phosphorylation of the mutant variants was DosS dependent. The results were 
comparable to those of DosS catalysed phosphotransfer, suggesting that an 
increase in accessibility of phosphor donors to active phosphorylable Asp54 residue 
may be the reason why mutants DosR [T198D, T205D] and DosR [T198E, T205E] 
were more rapidly and stably phosphorylated. This result indicates that the effect of 
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the introduction of mutations in Thr198 and Thr205 is independent of the type of 
phosphorylation, whether it is a chemical process or a DosS-catalysed reaction.  
 
1.3 DosS is a phosphatase of DosR~P  
In addition to acting as phosphoryl donors of aspartic acid residues located in the 
receiver domain of response regulators, some sensor histidine kinases have been 
described to display phosphatase activity toward their cognate phosphorylated 
regulators. Willett and Kirby (2012) dissected the autokinase and the phosphatase 
activity of histidine kinases of diverse origin. This mechanism of control is a means 
of auto-regulation of the TCS activation and has been described for a number of HK-
RR pairs such as in WalRK of Bacillus anthracis (Dhiman, 2014). Saini et al suggested 
the presence of phosphatase activity in the cytoplasmic portion of DosS. In our 
phosphotransfer experiments with wild-type and mutants of DosR, DosS~P seemed 
to have a certain phosphatase activity as DosR dephosphorylated when the Dos~P 
was present. To probe DosS phosphatase activity and rule out a possible 
autophosphatase activity by DosR, whether full-length DosS was capable of 
dephosphorylating [32P]-acetyl phosphate phosphorylated DosR was tested. 
Dephosphorylation of wild-type DosR was observed in the presence of DosS.  
Contrary, the radiolabel signal on DosR [T198D, T205D] and DosR [T198E, T205E] 
remained stable in the presence of the histidine kinase, indicating that DosS could 
not exert its phosphatase activity against these proteins. It is tempting to speculate 
that the structural modifications induced in helix α10 in the mutant proteins have a 
pleiotropic effect on the protein structure which renders it unable to be substrate 
of DosS phosphatase activity. Once phosphorylated, the protein structure would 
rearrange in such a way that Asp54~P is no longer available for DosS and is 
protected from dephosphorylation. It would be highly interesting to repeat the 
experiment incorporating PknH protein and investigating the effect of specific 
phosphorylation of  Thr198 and Thr205. This has been attempted in this work but 
the production of PknH, either full-length of truncated forms of the protein, has 
proved unsuccessful.   
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1.4 The role of DosR Thr198 and Thr205 in DosR dimerization and 
DNA binding 
Non-phosphorylated response regulators can bind their cognate DNA sequences, 
although phosphorylation increases their binding affinity.  In views of this 
statement, the ability of wild-type and mutant versions of DosR to bind a DNA 
fragment comprising a consensus promoter sequence in the hspX gene was 
analysed. Precise 3D crystallographic  information from co-crystals of DosR C-
terminal and this DNA sequence is available; for this reason the very same DNA 
sequence was used as probe in the EMSAs. The results  showed that wild-type DosR 
bound specifically to DNA, and this binding was stronger than in the case of DosR 
D54A as it had been shown before (Park et al., 2003; Saini et al., 2004a). Surprisingly, 
the results of the EMSAs with mutant versions of DosR were contradictory with our 
hypothesis: mutant DosR [T198A, T205A], phosphorylated at Asp54, was able to 
bind DNA although with much less affinity than wild-type DosR. Even more striking 
was the observation that no band shift appeared with DosR [T198D, T205D] and 
DosR [T198E, T205E]. The change of threonines to aspartic acid and glutamic acid 
residues was chosen because these negatively charged amino acids are considered 
to function as phosphomimetic substitutions. The mutation to alanines was 
selected as control of silencing substitutions (Wang & Klemke, 2008). The mutant’s 
inability to bind DNA could not be attributable to a less efficient phosphorylation at 
Asp54 as we had previously showed that phosphorylation was enhanced in the 
mutants. Thus the effect may be due to inappropriate interactions between the 
DNA and the C-terminal binding domain of DosR mutants. 
The effect of the double mutation at positions Thr198 and Thr205 on the structural 
stability of the DosR dimerization and DosR-DNA complex was analysed by 
molecular dynamics simulations and shed light on the unexpected results of the 
DNA-binding experiments. The solved structure of C-terminal DosR in complex with 
DNA (Wisedchaisri et al., 2005) and a model of mutant DosR [T198E, T205E] were 
used in this simulation. Conventional protein-DNA interfaces showed a positive 
electrostatic potential all along the interaction surface of the protein, as was 
presented for WT DosR. The structure of the wild-type DosR-DNA complex 
remained stable fluctuating around the initial X-ray coordinates for the total 
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simulation period. By mutation from threonines to glutamic acids, this positive 
electrostatic potential was disrupted in the center of the binding pocket and two 
important effects occurred. Firstly, the DosR dimer started bending and breaking 
apart, which is mainly due to the fact that position 198 and 205 are actually located 
at the dimerization interface formed by alpha-helix 10. A small threonine to a 
voluminous and negatively charged glutamate substitution in these positions 
notably disfavours the protein-protein interactions. Second important observation 
was a progressive loss of the DosR-DNA interaction, which is a consequence of the 
DosR dimer rearrangement. This shows the necessity of stable dimerization of DosR 
for full activation and DNA-binding. Furthermore, the DosR [T198E,T205E]-DNA 
complex was further destabilized by the T198E substitution because a strong 
negative electrostatic potential was formed at the deeper site of the DNA binding 
pocket. 
Mutations in threonines 198 and 205 have two clear and confronted effects on DosR 
activity: on one hand they enhance Asp54 phosphorylation but on the other impair 
the protein ability to bind DNA. 
The observations made in this study are somehow contradictory with the work of 
Chao et al., where it was postulated that phosphorylation of DosR threonines Thr 
198 and 205 enhanced the binding of DosR to cognate DNA sequences. Chao 
observed this phenomenon in one of the two DNA probes used in their EMSA 
experiments. Little differences in the DNA sequence used as probes and DosS 
constructs (full-length in this study and truncated DosS in Chao et al) may be the 
cause of the different observations. Additional studies with DNA promoters 
belonging to other DosR regulated genes would be worth to analyse if the observed 
cooperative effect of Asp54, Thr198 and Thr205 phosphorylation is general for all 
the genes of the Dos regulon or just applicable to hspX regulation. 
The results altogether help increase our understanding of the molecular events 
leading to the activation of DosR and its interactions with DNA.  They also support 
the thesis that stable dimerization of DosR is essential for correct DNA binding  and 
that any disruption of this process may result in dosR regulon inhibition. 
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Further experiments in M. tuberculosis under inducing conditions (hypoxia or nitric 
oxide exposure, for example) will help delineate the role of Thr198 and Thr205 
residues in regulating the activity of DosRST two-component system. 
The knowledge of the certain residues significance among DosR response regulator 
protein will provide enormous insight into modularity and robustness of a given 
system. It will also find great value in applications such as identification and 
validation of drug targets, prediction of critical points, which when perturbed lead 
to system failure.  
 
2. DosRST as potent therapeutic target 
This thesis was initiated because of the attractiveness of DosRST as a novel 
antitubercular drug target against latent tuberculosis infections. In particular, DosR 
response regulator was analysed as potential target for the development of novel 
antimicrobials. A number of inhibitors of DosR were designed and biochemical and 
cellular assays for the evaluation of novel inhibitors were implemented. 
Dormant Mtb may persist for decades in a non-replicating state in the infected host, 
with an estimated 10% lifetime risk of developing active TB. Existing anti-TB 
therapies are directed against actively replicating bacteria, while there is no 
particular treatment for LTBI (latent TB infection). Moreover, the development of 
new antibiotics is not keeping pace with the rapid evolution of resistance to almost 
all clinically available drugs, and novel strategies are required to fight bacterial 
infections. One such strategy is the control of pathogenicity as opposed to inducing 
bacteria death directly. In this case, by forcing Mtb to leave the non-replicative 
state, bacilli would be made susceptible to currently available antimycobacterial 
treatments. 
In recent decades important advances have been made in deciphering the role of 
TCSs in a variety of physiological processes in bacteria, such as virulence, biofilm 
formation and antibiotic resistance. Several properties of TCSs have made them 
attractive targets for the discovery of new antibacterial agents (Introduction, 
chapter 4.2) and the efforts to develop small molecules that inhibit TCSs are on-
going. Some approaches have targeted specific TCSs, such as AgrCA (Lyon et al., 
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2000), whereas other approaches have been aimed at identifying inhibitors that 
target a broad collection of TCSs (Matsushita & Janda, 2002; Stephenson & Hoch, 
2002). During this study one of the main aims focused on the optimization of 
biochemical assays used for target-based drug development. Identification and 
validation of appropriate targets for designing drugs are critical steps in drug 
discovery. 
Several sites have been identified in TCSs that are amenable to disruption by the 
action of inhibitors and that may interfere with the intracellular signalling activities 
of these systems (Fig.  63). Interference by chemical compounds could occur at key 
junctions in the cascade including perception of the triggering signal, binding of ATP 
and consequent HK autophosphorylation (HK~P), HK-RR interaction, 
phosphotransfer from HK~P to RR, and binding of phosphorylated RR (RR~P) to the 
promoter of its target genes. 
 
 
Fig.  63 Two-component system signalling pathway. Black triangles indicate potential targets sites 
amenable to inhibition by molecules generated in drug discovery projects (Watanabe et al., 2008). 
 
Certain screening campaigns for small-molecule inhibitors targeting TCSs have been 
directed towards autophosphorylation of histidine kinases or phosphotransfer from 
histidine kinases to response regulators (Matsushita & Janda, 2002; Stephenson & 
Hoch, 2002). One of the reasons for having chosen these targets is the possibility of 
running the screening assays in a high-throughput mode. Initial hits that target the 
histidine kinases have been discovered, although most of them have shown poor 
selectivity (Hilliard et al., 1999; Stephenson & Hoch, 2004). 
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Response regulators have been suggested to be preferable targets because the 
HK’s activity may be overcome by small molecule phosphate donors and because 
they are the effector molecules in the signaling transduction pathway (Stephenson 
& Hoch, 2002; Gotoh et al., 2010a). 
A significant number of molecules targeting response regulators as a strategy for 
the development of novel broad-spectrum anti-infectives have been reported. One 
example of this is the identification of compounds that inhibit alginate gene 
expression by inhibiting response regulator AlgR1-DNA binding in Pseudomonas 
aeruginosa (Roychoudhury et al., 1993). Another example presents Rap proteins 
from B. subtilis, named after the founding members of the family, which were 
shown to be response regulator aspartate phosphatases (Perego et al., 1994). The 
essential WalK/WalR (YycG/YycF) two-component system is highly conserved and 
specific to low-GC percentage of Gram-positive bacteria. The development of a high-
throughput screening assay for WalR inhibitors and the identification of two novel 
inhibitors targeting the WalR response regulator have been reported (Gotoh et al., 
2010b). 
Structure-based design of DosR inhibitors against non-replicating M. tuberculosis 
has been reported (Gupta et al., 2009). A phenylcoumarin derivative (named 
compound 10 by Gupta and also this study) inhibited DosR binding to target DNA, 
downregulated dormancy genes transcription and drastically reduced survival of 
hypoxic organisms. Consistent with those results, ten structurally similar and 
commercially available compounds were purchased. These small molecules were 
selected for biological and chemical screenings in order to search for potential 
DosR-DNA binding inhibitors. 
The thermodynamic information of the interactions of protein-small molecule 
obtained from ITC facilitates the understanding of the binding modes and is helpful 
to the development of novel drugs for some diseases (Yang et al., 2007; Engel et al., 
2006; Lorca et al., 2007; Thompsett et al., 2005). ITC has been used for evaluation of 
many proteins studied as targets for pharmaceutical drug development. In most 
cases, ITC has been used to study the contribution of enthalpy and entropy to 
binding, which is important when designing the ligands. Furthermore, a significant 
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correlation of the thermodynamic (ITC) and structural (X-ray crystallography, 
models) data was observed suggesting that ITC measurements provide valuable 
information for optimizing inhibitor binding in drug discovery (Perspicace et al., 
2013). 
One of the interests of the present work was to investigate whether ITC could be 
used as screening assay to quantify the interactions between DosR and thus to 
screen for potential inhibitors. 
ITC was carried out to determine the binding ability of each compound to wild-type 
DosR. The ITC results of compound 10, which showed affinity to DosR, are in 
accordance with previous findings about this compound, where it was suggested 
that compound 10 interacts with DosR by locking it in a conformation that cannot 
bind to cognate DNA (Gupta et al., 2009). Another examined compound,  2-chloro-
N-(3,4-dimethoxyphenyl) benzamide (named compound 2 in this study) also 
showed affinity to DosR, pointing at the regions in compound 10 that may be 
essential for interaction with DosR. The binding to DosR was abolished for 
compounds 3, 4, 6, 7, 8 and 11, while compounds 1, 5 and 9 displayed very weak 
binding. Despite the wide application of the ITC method, it has some inherent 
limitations, which makes it difficult to explore data generated with this technique 
for the DosR protein. The routine problems were encountered during ITC attempts, 
such as alterations in protein and ligand pH final solutions, a common issue when 
working with high concentrations of ligand, e.g. 500 µM.  It is unclear why no heat 
was observed in some trials. This may be linked to the weak binding or low affinity, 
but also could be possible due to the problems with dilution, or protein 
aggregation. Another trouble encountered in this study was high sensitivity of the 
method on any environmental changes coming from poor dialysis, for instance. 
From the experience gained with the DosR system, ITC does not seem to be ideal as 
primary screening technique due to the difficulties in its standardisation. 
Nevertheless, it could be used as secondary screening in the hit to lead phase 
(Introduction, chapter 4.1.3).  ITC could be used as secondary screening technique 
with a reduced number of molecules for gathering thermodynamic information 
about the interaction of DosR and the evaluated compounds.  
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In addition to ITC, all the compounds were screened with the electrophoretic 
mobility shift assay (EMSA). EMSA can be used to validate the inhibitory properties 
of screening compounds and could provide additional criteria for selecting the most 
promising ones. In fact, EMSA trials have been shown to be a good experimental 
approach to test potential inhibitors of response regulators such as DosR (Gupta et 
al., 2009) or PhoP response regulator from Salmonella enterica (Tang et al., 2012). 
EMSA was used to evaluate if the screened compounds could bind to DosR and 
prevent this protein from binding to cognate DNA promoter.  Most of the tested 
chemicals had no significant effect on the DNA-binding properties of the response 
regulator DosR. Compound 2 displayed poor inhibitory effects in DosR-DNA binding. 
The results confirmed the inhibitory activity against DosR-DNA binding of 
compound 10 at 500 µM and an increase in compound concentration (1 mM), 
measured for compound 10 caused an increase in binding inhibition.  
These results confirmed the inhibitory activity against DosR-DNA binding of 
compound 10 at 500 µM and an increase in compound concentration (1 mM), 
measured for compound 10 caused an increase in binding inhibition.  
Surprisingly, the affinity of compound 10 was not potent enough to inhibit the 
binding when DosR was pre-treated with AcP. These results are not in correlation 
with previous study (Gupta et al., 2009), where compound 10 inhibited pre-treated 
with AcP DosR-DNA binding. This disagreement might derive from the differences in 
DNA fragments used as DNA probles in both studies. Gupta et al., used the whole 
fragment of fdxA promoter, while in this experiment the short fragment of hspX 
promoter was employed. Furthermore, fluorescein labelled DNA probe might result 
in lower signal comparing to radioactive labelled DNA fragments, that is why 500 
µM (compound 10) and 1 mM (compound 2) was required for noticeable inhibition. 
It is interesting to note the significant inhibitory effect of 2,3-dichloro-N-[3-methyl-4-
(2-oxo-2H-chromen-3-yl)phenyl]benzamide (compound 5) already at lower 250 µM 
in the binding when DosR was pre-treated with AcP. Compound 5 was, in this 
experiment, the unique molecule able to inhibit binding of DosR-DNA with the 
protein previously phosphorylated. Compound 5 did not inhibit the binding when 
the protein DosR was not phosphorylated. It is tempting to speculate that 
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compound 5 interferes with DosR conformational changes by inhibiting the 
phosphorylation of DosR.  
This result is in accordance with other study, where Lactoferricin B (Lfcin B), a 
natural antimicrobial peptide, did not affect the DNA binding ability of the 
unphosphorylated response regulators, BasR and CreB. Instead, Lfcin B was 
observed to attach to the receiver domains of BasR and CreB to inhibit their 
phosphorylation activity. As it was mentioned before, the unphosphorylated 
response regulators are still able to recognize promoters; however, it is unlikely for 
microbes to over-produce the response regulators to activate or repress 
transcription. 
The screening for antimicrobial activity of the chemical compounds as potential 
drug candidates represents an additional strategy in the development of novel 
drugs. The acquired information may assist in the optimisation of a lead 
compound’s activity, provide a focus for toxicological attention and aid in the 
anticipation of resistance. Characterization of the interaction between antimicrobial 
compounds and their target sites could potentially allow the design of second 
generation inhibitors. Antibacterial activity has been reported in the literature with 
diverse sets of methodologies, degrees of sensitivity, amount of test–compounds 
and microbial strains. 
In this study, the growth inhibition assay was used to estimate the activity of the 
inhibitors to arrest bacterial growth. Compounds were screened for antibacterial 
activity against Escherichia coli, Klebsiella pneumoniae and Mycobacterium 
smegmatis. Susceptibility testing was performed using Müeller-Hinton agar (E. coli 
and K. pneumoniae) or nutrient agar medium (M. smegmatis). 
It was observed that the broadest activity of the screened compounds was against 
M. smegmatis while lower activity was noticed against E. coli and K. pneumoniae. 
This different behaviour may be a consequence of the specificity of the assayed 
compounds towards DosR. An identified response regulator of M. smegmatis, which 
plays an important role in adaptation to oxygen-starved stationary phase, has 
exhibited a strong sequence similarity to DosR of M. tuberculosis and is also named 
DosR (O’Toole et al., 2003). It has been determined that the response regulator 
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DosR plays an important role in stationary-phase gene expression, adaptation to 
oxygen stavation-induced growth arrest, and resistance to environmental stress in 
M. smegmatis. It can be hypothesised that the compounds activity against M. 
smegmatis in this study could be due to affinity of those molecules to DosR.  
Differences in compounds activities in the different bacterial species assayed could 
also be explained by the different classification of evaluated bacteria according to 
Gram stain (Gram-positive M. smegmatis against Gram-negative E. coli and K. 
pneumoniae). For most antimicrobial molecules that are not active against Gram-
negative bacteria, the outer membrane is believed to be a major barrier (Matsuzaki 
et al., 1999; Nikaido, 1994). However, the details of the interactions of the molecules 
with these membranes are still not fully known. The outer membrane of Gram-
negative bacteria mostly (>90%) contains the glycolipid lipopolysaccharides (LPS) on 
its surface, which is generally thought to be a protective wall, rendering bacteria 
resistant to a variety of host defense molecules. This may be one of the reasons for 
the negative results with the compounds screened with Gram-negative bacteria. 
In vitro profiling of compounds encouraged the study of in vitro toxicological 
profiles that may be valuable for prioritizing compounds for more intensive 
toxicological investigation, and ultimately, predicting in vivo toxicity. 
In order to measure the selectivity of the compounds, the examination of the in 
vitro cytotoxicity on human hepatocytes HepG2 cells and Chinese hamster ovary 
CHO-K1 cell lines was studied. The percentage of cell viability was quantified in the 
presence of each compound. 
The HepG2 cell death was not induced by any compound at any concentration, 
causing only a slightly decrease in cell viability (>80% cell viability). The compounds 
tested with CHO-K1 showed different mortality rate at different concentrations. 
Previous studies (Xia et al., 2008) demonstrated that in vitro cytotoxicity is often 
cell-type specific and that cytotoxicity in one cell type does not necessarily predict 
cytotoxicity in another. In this study, commonly used in cell viability assays HepG2 
and CHO-K1 cell lines were used due to their genuine toxicity predictions in animal 
models. 
DISCUSSION 
 
138 
 
The good antimicrobial activity of compounds 2, 5 and 10 against M. smegmatis and 
low toxicity against HepG2 and CHO-K1 cells, together with their target based 
inhibition profile, suggest that they may be regarded as potential hits for drug 
development of novel antimycobacterial drugs against dormant forms of M. 
tuberculosis.
CONCLUSIONS 
 
139 
 
CONCLUSIONS 
 
1. The DosR response regulator and the DosS histidine kinase of Mycobacterium 
tuberculosis cloned, expressed and purified in this work, conform a bona fide two-
component system. 
2. The predicted molecular model of DosS-DosR interactions reveals a genuine 
overlap between hydrophobic and polar amino acids. The analysis of the complex 
interface shows that exposed hydrophobic amino acids Phe403 and Leu407 in DosS 
and Val12 and Leu20 in DosR are key in maintaining the complex stability. 
3. DosR D54A mutant is not phosphorylated by DosS, showing the specificity of 
the DosS-catalysed phosphorylation of DosR in its active aspartic acid residue. 
4. The truncated form of DosS histidine kinase, DosS350-578, has the ability to 
autophosphorylate with ATP similarly to wild type full-length DosS in vitro.  
5. The truncated forms of DosT histidine kinase, DosT349-573 and DosT380-573, have 
the ability to autophosphorylate with ATP in vitro. 
6. Phosphorylation on Asp54 of DosR enhances its ability to bind specifically to 
its cognate promoter sequences. 
7. Mutant DosR [T198A, T205A] shows a slight increase in chemical and DosS-
mediated phosphorylation compared to wild type DosR. However, this mutant 
binds to DNA less efficiently than wild type DosR. 
8. Mutants DosR [T198D, T205D] and DosR [T198E, T205E] show a notorious 
increase in chemical and DosS-mediated phosphorylation compared to wild type 
DosR. However, these mutants are completely unable to bind their cognate 
promoters. 
9. Molecular dynamics calculations of the interactions between C-terminal 
domain of DosR and DNA show stability of the protein-DNA complex along time. 
10. Molecular dynamics calculations of C-terminal DosR [T198E, T205E]-DNA 
interactions, based on the available 3D structure of this complex with wild type 
DosR, reveal an increase in the distance between protein and DNA along time. This 
result explains the observed lack of protein-DNA complex formation because of the 
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inability to form a dimer with the appropriate conformation compatible with DNA 
interactions. 
11. Molecular modelling of DosR [T198E, T205E]-DNA shows repulsion between 
negatively charged DNA and glutamate 198, contributing to the lack of DNA binding 
observed in this mutant. 
12. DosS is a phosphatase of wild type DosR~P. However, DosS has limited 
phosphatase activity on mutant DosR [T198A, T205A] and is unable to 
dephosphorylate mutants DosR [T198D, T205D] and DosR [T198E, T205E]. 
13. Compound 10 (a phenylcoumarin derivative), together with compound 2 
show affinity to DosR. Compound 5 inhibits binding of phosphorylated DosR to 
DNA. Compound 5 does not interfere with DNA-binding when DosR is not 
phosphorylated as is the case of compound 10. These molecules have good activity 
profile in the bacterial growth inhibition assay and low toxicity against HepG2 and 
CHO-K1 cells. These findings suggest that they may be interesting hits for the 
development of novel antimycobacterial drugs. 
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Annex 1 
1 Tuberculosis  
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(M.tuberculosis, Mtb), which most commonly affects the lungs. The World Health 
Organization (WHO) estimates that one third of world’s total population is currently 
infected with Mtb and approximately 10% of these people are expected to develop 
active TB at some point in their lifetime. A new individual is infected every second 
whilst another one dies from the disease every 15 seconds. Furthermore, the 
development of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-
resistant tuberculosis (XDR-TB) strains, together with the spread of risk factors such 
as human immunodeficiency virus (HIV), acquired immunodeficiency syndrome 
(AIDS) and diabetes (Corbett et al., 2003, Restrepo et al., 2007), continue making 
Mtb a health concern in developed countries and strengthened the urge to develop 
new treatment infection strategies. 
TB has been historically known by different names, such as consumption, phthisis, 
wasting disease, Pott’s disease or scrofula and has infected humans for millennia.  
Evidence of TB has been found in Egyptian mummies of several thousand years BC 
and also in antique Babylonian and Chinese writings. Recent molecular genetic 
studies have shown that M. tuberculosis is ∼3 million years old (Zink et al., 2003, 
Gutierrez  et al., 2005).  
The tuberculosis epidemic in Europe, which probably started in the 17th century and 
lasted two hundred years, was known as the Great White Plague and caused more 
than 1 billion deaths (Dormandy et al., 1999). 
Until mid-1800s, many people believed that TB was hereditary. In 1865 Jean Anoine-
Villemin demonstrated that TB was contagious. In 1882 Robert Koch discovered 
Mtb, the bacterium that causes TB. These two findings changed the medical 
community's understanding of how to prevent and treat the disease. 
Another important development in the 19th century were sanatoriums, a special 
type of hospitals, where infectious persons were isolated from society, treated and 
provided with supervised recuperation and convalescence. The sanatoriums, usually 
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located in the countryside, demonstrated the value of rest, fresh air, good nutrition 
and isolation to prevent the spread of infection. Initially started in Silelsia in 1859 by 
Hermann Brehmer, sanatoriums became widespread by the late 19th and early 20th 
centuries being used also as centers of discovery (Schwartz et al., 2009). 
One of the great advances in TB treatment, commenced in the nineteenth century, 
was the development of the vaccination. In the 1880s, Louis Pasteur began his 
studies on immunization against anthrax, chicken cholera, and, later, rabies. Koch 
hoped to develop an effective vaccine from an extract of the protein coat of the 
tuberculin organism. In 1908, the French scientists Albert Calmette and Camille 
Guerin grew Koch’s bacillus in a variety of media in an attempt to decrease their 
virulence and increase the capacity to produce immunity. This led to the 
development of one of the worldwide most popular vaccine called Bacille Calmette-
Guérin (BCG) introduced in 1921 for the first time (Schwartz et al., 2009). 
In 1944 Albert Schatz, Elizabeth Bugie, and Selman Waksman isolated streptomycin 
from Streptomyces griseus, the first antibiotic and first bacterial agent effective 
against Mycobacterium tuberculosis. This finding is generally considered the 
beginning of the modern era of tuberculosis, although the true revolution began 
some years later, in 1952, with the development of isoniazid, the first oral 
mycobactericidal drug (Daniel et al., 2006). The discovery of rifampin in the 1970s 
significantly reduced the number of tuberculosis cases until the 1980s. 
The expansion of drug-resistant strains in the 1980s tempered the complete 
elimination of TB . 
 
1.1 Mortality, incidence, prevalence and HIV co-infection 
The burden of disease caused by TB can be measured in terms of mortality, 
incidence or prevalence. 
WHO Global Tuberculosis Report 2013 (WHO 2013) indicates that in 2012 almost 1,3 
million people died of TB, new cases were estimated at 8.6 million, and the number 
of total TB cases worldwide is about 14 million.  
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1.1.1 Mortality 
The global TB mortality rate dropped 45% between 1990 and 2012. In 2012, 1.3 million 
people died from TB, including almost one million deaths among HIV-negative 
individuals and 320,000 among people who were HIV-positive. TB is one of the top 
killers among women, with 250,000 deaths in HIV-negative women population and 
160 000 deaths among HIV-positive women in 2012. An estimated 530,000 children 
were infected with TB and 74,000 children who were HIV-negative died of TB in 
2012. Although globally the numbers of HIV-associated TB deaths were similar 
among men and women, there are regional variations. In the African Region, more 
deaths occurred among women than men, while in other regions more deaths were 
estimated to occur among men. The male:female ratio of HIV-associated TB deaths 
ranged from 0.83 in the African Region to 3.1 in the Western Pacific Region.  
 
1.1.2 Incidence 
In 2012, there were an estimated 8.6 million new cases of TB globally, equivalent to 
122 cases per 100,000 population (Fig.  64). Most of the estimated number of cases 
in 2012 occurred in Asia (58%) and Africa (27%); smaller proportions of cases occurred 
in the Eastern Mediterranean Region (8%), the European Region (4%) and the South 
America, Central America and North America (3%). 
The five countries with the largest number of incident cases in 2012 were India (2.0 
million–2.4 million), China (0.9 million–1.1 million), South Africa (0.4 million–0.6 
million), Indonesia (0.4 million–0.5 million) and Pakistan (0.3 million–0.5 million). 
India and China alone accounted for 26% and 12% of global cases, respectively. 
Of the 8.6 million new cases in 2012, 1.0 million– 1.2 million (12–14%) were among 
people infected with HIV. 
 
ANNEX 1 
 
169 
 
 
Fig.  64 Estimated TB incident rates, 2012 (WHO, 2013) 
 
1.1.3 Prevalence 
There were estimated 12 million prevalent cases (range, 10 million–13 million) of TB 
in 2012, equivalent to 169 cases per 100,000 population. The prevalence rate has 
fallen by 37% globally since 1990. 
Geographically, most of the TB cases occur in Southeast Asia’s most populous 
countries, with the highest number in China and India with 1.3 million and 1.2 million 
new cases respectively (almost 40% of the world’s TB cases), followed by Indonesia. 
The heaviest TB burden is observed in Sub-Saharan Africa, with South Africa, 
Zimbabwe and DR Congo showing prevalence rates higher than 500 cases/100,000 
population (Fig.  65). About 60% of cases are in the South-East Asia and Western 
Pacific regions. 
Conversely, the TB prevalence in Western countries is dramatically lower, ranging 
from 10 to 50 cases per 100,000 populations, and it has been estimated that in 
Western European countries half of the TB cases occur in foreign-born citizens who 
migrated from countries with high TB prevalence. 
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India, the Russian Federation and South Africa have more than half of the world’s 
cases of MDR-TB. The highest proportions of TB patients with MDR-TB are in 
eastern European countries.  
 
 
Fig.  65 The 22 high burden TB countries. Source: Kaiser Family Foundation, based on WHO Global 
Tuberculosis Report; 2013 (www.GlobalHealthFacts.org). 
 
1.1.4 Tuberculosis and HIV 
HIV infection is the most potent risk factor for the development of TB disease. 
Following acquisition of HIV-1 infection (the most common and pathogenic strain of 
the virus), the risk of TB in individuals with Mtb infection increases from an 
approximately 10% lifetime risk to over 10% each year (Corbett et al., 2003). The risk 
in those living with HIV depends on the degree of immunodeficiency, the prevailing 
socioeconomic conditions, and the TB infection pressure in the community. HIV 
leads to disease as a result of the depletion of CD4+ T4 helper cells and the 
consequent inability to fight opportunistic infections. T4 cells are the major cell type 
that is infected by the virus. Infected CD4+ T4 helper cells become targets for HIV-
specific CD8+ killer cells. Furthermore, the HIV virus has the ability to make a copy of 
itself which can integrate with the DNA of the T4 helper cell and result in a latent 
infection (Schlossberg 1983, Lawn et al., 2010).  
In addition, the risk of TB disease continues to rise as CD4+ cell counts decrease 
(Badri et al., 2002, Holmes et al., 2006) The velocity with which risk increases 
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following HIV seroconversion is striking, rising 2-3-fold within the first 2 years of 
infection (Sonnenberg et al., 2005, Glynn et al., 2008). 
A major step forward is the development by the World Health Organization and the 
Centers for Disease Control and Prevention of a high sensitivity symptom screening 
tool for use in HIV-infected patients (Getahun et al., 2010). In contrast to the existing 
strategy of screening for cough of 2-3 weeks duration, this new screening tool 
identifies any HIV-infected patient with cough (any duration), fever, night sweats, 
or weight loss, and such patients should be further evaluated for TB disease. 
In 2012, 1.1 million (13%) of the 8.6 million people who developed TB worldwide were 
HIV-positive; 75% of these HIV-positive TB cases were in the African Region (WHO 
2013) (Fig.  66). 
 
Fig.  66 Estimated HIV prevalence in new TB cases, 2012 (WHO, 2013). 
 
1.2 Pathogenesis  
The immune mechanisms that protect the individual against tuberculosis are 
extremely complex. Infection occurs when a person inhales droplet nuclei 
containing tubercle bacilli that reach terminal alveoli in the lungs.  
The first step is the recognition of mycobacteria as invading pathogens, followed by 
activation of innate host defense responses. Cell-mediated immunity is usually 
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developed within approximately two to eight weeks from the initial infection, 
followed by initiation of adaptive immune responses. 
The activated T lymphocytes, macrophages, and other immune cells form 
granulomas that wall off the growing necrotic tissue limiting further replication and 
spread of the tubercle bacilli. 
Granulomatous inflammation is a distinctive pattern of chronic inflammation and 
adaptive immunity, and the granuloma is the hallmark of many human diseases 
among which tuberculosis is embraced (Thurlbeck et al., 1995; Algood et al., 2003). 
Its formation is firmly linked to the type IV (delayed type) hypersensitivity reaction 
(DTH), which is a form of adaptive cell- mediated immunity that is mediated by 
activated T lymphocytes and their products, called cytokines (Boyd 1995). Activated 
immune mechanisms lead to destruction of the bacilli and disease progression is 
arrested (Ahmad et al., 2011). 
If the infection proceeds, bacilli begin to multiply rapidly and cause TB. This process 
can occur in different parts in the body. The infection starts with phagocytosis of 
the bacilli by phagocytic antigen-presenting cells in the lung including alveolar 
macrophages and dendritic cells. 
Macrophages are central in chronic inflammation because of the vast number of 
substances they produce (Beutler, 2004) and different mechanisms through which 
they can eliminate mycobacteria, such as production of reactive oxygen and 
nitrogen (VanCrevel et al., 2002). Autophagy, a cellular process through which 
cytoplasmic components, including organelles and intracellular pathogens, are 
detached in a double-membrane-bound autophagosome and delivered to the 
lysosome for degradation, also determines the fate of intracellular mycobacteria 
(Kundu et al., 2008). 
Dendritic cells play an important role in antigen capture and the induction of T cell 
responses, especially in naïve T cells (Hart 1997). 
M. tuberculosis is recognized by the host through Toll-like receptors (TLRs), 
nucleotide-binding oligomerization domain- (NOD-) like receptors (NLRs), and C-
type lectins (Jo et al., 1998; Harding et al., 2010). 
The mycobacterial structures, such as lipoproteins and glycolipids, associated with a 
subset of immune receptors initiating phagocytosis and mediating specific host cell 
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responses, interact with TLRs. Signaling cascades are triggered with the significant 
role of adaptor molecule myeloid differentiation primary response protein 88 
(MyD88) (Underhill et al., 1999). Later, IL-1 receptor-associated kinases (IRAK), TNF 
receptor-associated factor 6 (TRAF6), TGFβ-activated protein kinase 1 (TAK1), and 
mitogen-activated protein (MAP) kinase are enrolled in a signaling pathways with 
the consequence of activation and nuclear translocation of transcription factors 
such as the nuclear transcription factor (NF)-κB (Takeda et al., 2004). This 
introduces transcription of genes engaged in the activation of the innate host 
defense, mainly the production of proinflammatory cytokines as TNF, IL1β, and IL-12 
and nitric oxide (Akira et al., 2003). 
NOD2 is an intracellular receptor, mediating stimulation of proinflammatory 
cytokine production by Mtb. It is a receptor for bacterial peptidoglycans (Girardin et 
al., 2003) and plays role in the recognition of mycobacteria (Ferwerda et al., 2005, 
2007). 
The mannose receptor (MR), belonging to the C-type lectins family, is involved in 
the recognition of polysaccharide structures of pathogen and is highly expressed on 
alveolar macrophages (Gordon et al., 2003). Mycobacterial stimulation through MR 
leads to production of IL- 4 and IL-13, inhibition of IL-12 production, and failure to 
activate oxidative responses (Nigou et al., 2001; Geijtenbeek et al., 2003). 
Produced inflammatory cytokines and chemokines serve as a signal for infection 
and are involved in many crucial outcomes. 
The CD4+ T cells control infection in the granuloma through several functions, such 
as apoptosis of infected macrophages, production of other cytokines (e. g. IL-2 and 
TNF-α), induction of other immune cells (macrophages or dendritic cells) to produce 
other immunoregulatory cytokines such as IL-10, IL-12, and IL- 15, and activation of 
macrophages through direct contact via CD40 ligand (Chan and Flynn et al., 2004, 
Cooper et al.,  2009, Oddo et al., 1998). 
The IFN-γ is the key cytokine in the defence against mycobacteria, as individuals 
revealing a genetic defect in IFNγ production or receptors, develop severe systemic 
infection (Frucht et al., 1996; Dorman et al., 1998). 
Introduction of M. tuberculosis into the lungs leads to infection of the respiratory 
system; however, bacilli may reach any part of the body or spread from lungs to 
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other organs, such as the lymph nodes, pleura, bones/joints, or meninges, and cause 
extrapulmonary tuberculosis. Systemic (also called military) TB occurs when bacilli is 
being carried to all parts of body, through bloodstream. 
 
1.3 Clinical symptoms 
Mycobacterium tuberculosis mainly infects the lungs and causes a bad coughing. The 
clinical manifestations of tuberculosis can vary depending on the stage of 
tuberculosis, which include latency, primary disease, primary progressive (active) 
disease, and extrapulmonary disease. 
Latency, which is minutely described in Chapter 3, does not display any signs or 
symptoms of the disease. Individuals do not feel sick and are not infectious.  
Primary pulmonary tuberculosis is also often asymptomatic; however some self-
limiting findings might be noticed in an assessment. Associated paratracheal 
lymphadenopathy may occur due to bacilli spread from the lungs through the 
lymphatic system. If the primary lesion enlarges, pleural effusion is a distinguishing 
finding. Whilst the bacilli infiltrate the pleural space from an adjacent area, the 
effusion develops and it may remain small and resolve spontaneously, or it may 
become large enough to induce indications such as fever, pleuritic chest pain, and 
dyspnea. Dyspnea is a consequence of faint gas exchange in the areas of affected 
lung tissue. 
Active tuberculosis, which develops in 5% to 10% of persons infected with Mtb, 
produces nonspecific symptoms at early period. Manifestations often include 
progressive fatigue, malaise, weight loss, and a low-grade fever accompanied by 
chills and night sweats. Loss of weight, a classic feature of tuberculosis, is provoked 
by lack of appetite and the altered metabolism associated with the inflammatory 
and immune responses. It involves the loss of both fat and lean tissue, which leads 
to the fatigue as an effect of the decreased muscle mass (Paton et al., 2004) and 
subsequently together with the weakness to the anemia. Finger clubbing, a late 
sign of poor oxygenation, may occur; however, it does not indicate the extent of 
disease (Ddungu et al., 2006). A cough eventually develops in most patients and, 
although initially nonproductive, it advances to a productive cough of purulent 
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sputum with or without blood streak. Hemoptysis can be the result of a dilated 
vessel in a cavity, or the formation of an aspergilloma in an old cavity. Pleuritic chest 
pain may occur due to the inflamed parenchyma. Dyspnea or orthopnea are the 
consequences of the extensive disease when the increased interstitial volume leads 
to a decrease in lung diffusion capacity. 
Due to the immune response to the infection and subsequently large increase of 
leukocytes, leukocytosis may also occur. 
Although lungs are the most common location for tuberculosis, extrapulmonary 
disease is diagnosed in more than 20% of immunocompetent patients, indicating the 
increasing risk with immunosuppression. The most dangerous location is the central 
nervous system, where infection may result in or space occupying tuberculomas or 
meningitis, fatal if not treated (Frieden et al., 2003). Clinical manifestations that 
should prompt consideration of this disease would be headache and change in 
mental status after possible exposure to TB or in high risk groups. Disseminated or 
miliary tuberculosis, where mycobacteria reaches bloodstram, is another fatal form 
of TB and can spread throughout the body, leading to multiorgan involvement 
(Wang et al., 2007). This type of disease progresses rapidly and its systemic and 
nonspecific signs and symptoms, such as fever, weight loss, and weakness make it 
difficult to diagnose. Lymphatic tuberculosis is the most common extrapulmonary 
tuberculosis, in which cervical adenopathy occurs most often. Further possible 
locations of the infection extend include bones, joints, pleura, and genitourinary 
system (CDC). 
 
1.4 Transmission 
Tuberculosis is primarily transmitted through air and spread by small airborne 
droplets, called droplet nuclei. Individuals with pulmonary or laryngeal disease 
aerosolize droplet nuclei when coughin or sneezing tubercle bacilli which may be 
inhaled by others. Individuals at high risk of infection include those who are 
frequently exposed for long period of times to infectious individuals. The minuscule 
droplets can remain airborne for minutes to hours after expectoration. 
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There are four factors that determine the probability of transmission of Mtb: i) 
susceptibility (immune status) of the exposed individual; ii) infectiousness of the 
person with TB disease, which is directly proportional to the number of sprayed 
bacilli; iii) environmental factors that affect the concentration of M. tuberculosis 
organisms; and iv) exposure of the susceptible individual, measured in proximity, 
frequency, and duration. 
Mathematical models of TB transmission classify individuals as either susceptible, 
exposed, infectious, recovered or vaccinated (Castillo-Chavez et al., 2004). Since the 
first model, built for the transmission dynamics of TB (Waaler et al., 1962), many 
others have been proposed. They consider diverse constituents, such as multiple 
strains of TB (Blower et al., 1996; Castillo-Chavez et al., 1997, 1998), density 
dependent demography (Levin et al., 1981; Lin et al., 1993; Lowell et al., 1969), co-
infection with HIV (Kirschner et al., 1999; Schmitz et al., 2000), and multiple levels of 
macrophages (Herrera et al., 1996). 
Two vaccine models, preexposure and postexposure (Lietman et al., 2000) and one 
that examines both multiple strains and variable latent period have been described 
(Feng et al., 2002). 
 
1.5 Diagnosis 
The most frequent method for diagnosing TB worldwide is sputum smear 
microscopy (Hopewell et al., 2006). This test is relatively simple and rapid to 
perform, but it is not specific for tuberculosis as other mycobacteria give the same 
results. However, it does provide a quick method to determine if prevention should 
be taken while more definitive testing is performed. 
For the test, sputum is smeared on a slide, stained, dried, and then treated with 
alcohol. Any bacilli that are present will remain red because they will not destain 
(Fig.  67). Results of sputum smears should be available within 24 hours of the 
sample collection. 
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Fig.  67 Mycobacterium tuberculosis. Acid-fast stain, extracted from 
http://textbookofbacteriology.net/tuberculosis.html. The arrow indicates Mtb smear, stained with 
carbol-fuchsin. 
 
Beside sputum samples, cerebrospinal fluids are required for the diagnosis of 
meningitis. Blood culture has become more important in the diagnosis of 
disseminated mycobacterial infections following the HIV epidemic. 
Other material that can be used for TB diagnosis contains: gastric aspirate, effusion 
fluids, early-morning urine specimens, pus, faeces, fine-needle lymph-node aspirate, 
bronchoalveolar lavage (BAL) specimen, lymph-node biopsy, liver biopsy, pleural 
biopsy, uterine curettings, biopsy of affected skin, bone marrow (Bannister et al.,  
2006). 
Purified tuberculin protein derivative is used in tuberculin skin test (TST, Mantoux 
test). When injected intracutaneously into hypersensitive individuals, tuberculin 
evokes an intense inflammatory reaction (delayed hypersensitivity) at the site of 
injection. The degree of induration at the site of injection is an indication of the 
individual´s present or past association with the TB bacillus. The test is considered 
positive if the diameter of the resulting lesion, which is characterized by erythema 
(redness) and swelling, is 10 mm or bigger. 90% of people that have a lesion of 10-
15mm are currently infected with Mtb or have been previously exposed to bacteria. 
Each invidual that has a lesion of ≥15 mm is actually infected with Mtb or has been 
previously exposed to Mtb. 
ANNEX 1 
 
178 
 
To counteract some of the problems with the TST, such as false positives due to the 
prior BCG vaccination (Pouchot et al., 1997), a new group of tests, the interferon-
gamma release assays (IGRAs), have been developed. There are currently two 
commercially available tests: the QuantiFERON®-TB Gold In-Tube (Cellestis Limited, 
Chadstone, Australia) and the T-SPOT®.TB (Oxford Immunotec, Limited, Abingdon, 
UK). Both are whole-blood assays that measure interferon-gamma levels after in 
vitro exposure to TB-specific antigens (Norton et al., 2012). They have been shown 
to predict TB at least as well (Bakir et al.,  2008) or better (Diel et al., 2008,Leung et 
al., 2010) than the TST, with much greater specificity in patients previously 
immunized with BCG (Pai et al.,  2008). 
Several molecular typing methods, including a standard Southern blotting protocol 
based on insertion sequence IS 6110, are used internationally to investigate possible 
outbreaks and track the spread of strains of Mtb. Other important Mtb typing 
methods include spoligotyping, MIRU typing and variable tandem repeat (VNTR) 
(Inglis et al., 2008). Spacer oligonucleotide typing (spoligotyping) is an 
ampliﬁcation-based method for genotyping Mtb isolates that detects variability in 
the direct repeat region in the DNA of Mtb. The traditional spoligotyping method 
detects the presence or absence of 43 different spacer sequences. The test is often 
used as a ﬁrst-line genotyping method due to its low cost, rate and robustness. 
 
1.6 Current prevention and treatment of TB 
1.6.1 Vaccination 
Bacille Calmette-Guerin is an avirulent strain of Mycobacterium bovis that was 
attenuated by serial passages in potato slices imbibed with glycerol for 13 years 
(Calmette et al., 1927).  
BCG vaccines are the oldest of the vaccines currently used throughout the world 
(Starke et al., 1991). BCG vaccination does not prevent infection with Mtb but may 
prevent dissemination of disease (Plotkin et al., 2004). They have been given to 4 
billion people and have been used routinely since the 1960s in almost all countries 
of the world, with the exception of few industrialized countries. The USA and 
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Netherlands are the only countries that have never routinely recommended BCG 
vaccination (Lugosi et al., 1992). 
The success of BCG is principally due to its efficacy in preventing TB meningitis in 
children (Colditz et al., 1995), which is frequent in TB-endemic areas, where BCG 
immunization is mandatory nowadays. As BCG is live attenuated vaccine, it might 
lead to disseminated TB disease in people living with HIV and further 
immunosuppressive conditions (Colditz et al., 1994). 
 
New vaccination strategies against TB include:  
• Prime: BCG replacement with either live recombinant BCG (rBCG) that may be 
more effective than the parental strains or genetically attenuated Mtb mutants.  
Since BCG lacks many genes found in Mtb (>120 genes), it has been proposed that a 
live attenuated strain which contains a more complete antigen repertoire may be 
more protective than BCG.  
• Prime-boost: enhance the limited immunity transmitted by BCG (or boost specific 
antigens presented by recombinant BCG or attenuated Mtb) adapting either viral-
vectored or adjuvanted subunit vaccines.  
The rationale for the development of a subunit-based vaccine against TB is linked 
with the induction by immunization of a Th-1 type immune response against Mtb 
antigens. Antigents secreted and abundant in the early steps of infection results in a 
more rapid and more effective mobilization of T cells at the site of bacteria 
multiplication. This would contain the infection and reduce the risk of developing 
active TB (Delogu et al., 2009). This type vaccine would be administered as boosters 
to a BCG prime to infants or in adolescents when BCG’s protection begins to 
disappear. 
• Immunotherapeutic: The therapeutic vaccines might associate with 
chemotherapy resulting in shorten treatment for TB. Those under development 
include whole-cell and fragmented mycobacteria, although several of these 
candidates also demonstrate prophylactic potential. 
New TB vaccines are an urgent part of a comprehensive plan to control and 
ulimately eliminate TB. Over the past decade, researchers have made significant 
progress in TB vaccine development. Out of current 14 vaccine candidates 
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undergoing or preparing to enter human clinical trials, 4 have reached phase I trials 
to demonstrate safety, and eight have reached phase II trials to evaluate their 
safety and immunogenicity. M. vaccae, the whole-cell mycobacteria vaccine 
candidate, has successfully completed phase III trials (Table 10). 
 
Table 10 The development pipeline for new vaccines (The TB Vaccines Pipeline, Mike Frick, July 2013). 
Agent Strategy Type Sponsors Status 
M. vaccae 
Immunother
apeutic 
Whole-cell M. 
vaccae 
AnHui Longcom Phase III 
MVA85A/ 
AERAS-485 
Prime-boost Viral vector Oxford University, Aeras Phase IIb 
M72 + AS01 Prime-boost 
Adjuvanted 
subunit 
GSK, Aeras Phase IIb 
Crucell 
Ad35/ 
AERAS-402 
Prime-boost Viral vector Crucell, Aeras 
Phase II 
(formerly 
phase IIb) 
VPM1002 Prime 
Live 
recombinant 
rBCG 
 
Vakzine Projekt Management 
GmbH, Max Planck Institute 
for Infection Biology, 
TuBerculosis Vaccine Initiative 
(TBVI), Serum Institute of India 
Phase IIa 
RUTI 
Immunother
apeutic 
Fragmented 
Mtb 
Archivel Farma Phase IIa 
Hybrid 1 + 
IC31 
Prime-boost 
Adjuvanted 
subunit 
Statens Serum Institut (SSI), 
TBVI, Intercell, European & 
Developing Countries Clinical 
Trials Partnership 
Phase IIa 
Hybrid 56 + 
IC31 
Prime-boost 
Adjuvanted 
subunit 
SSI, Aeras Phase IIa 
Hybrid 4 + 
IC31/ AERAS-
404 
Prime-boost 
Adjuvanted 
subunit 
Aeras, Sanofi Pasteur 
 
Phase IIa 
ID93 + GLA-
SE 
Prime-boost 
Adjuvanted 
subunit 
Infectious Disease Research 
Institute, Aeras 
Phase I 
Ad5Ag85A Prime-boost Viral vector McMaster University, CanSino Phase I 
MTBVAC 
 
Prime 
Live 
genetically 
attenuated 
Mtb 
University of Zaragoza, 
Biofabri, TBVI 
Phase I 
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Dar-901 Prime-boost 
Whole-cell M. 
vaccae 
Geisel School of Medicine at 
Dartmouth University 
Phase I 
pending 
Note: For each candidate under the prime-boost strategy, trials are evaluating the 
experimental vaccine in the left-hand column given as a boost to a BCG prime. 
 
1.6.2 Pharmacological treatment 
Antitubercular drugs can be divided into first-line drugs, those that generally have 
the greatest bactericidal activity when used for TB treatment, the second-line 
therapeutic-drugs, which are less effective, more expensive and have higher 
toxicities, and experimental drugs. First-line drugs include isoniazid, rifampin, 
pyrazinamide, ethambutol, and streptomycin. Second-line drugs contain ƿ-
aminosalicylicacid, ethionamide, cycloserine, kanamycin, capreomycin, amikacin, 
ciproflaxin, ofloxacin and viomycin. 
 
1.6.2.1 First line drugs 
 Isoniazid (INH) (CAS 54-85-3) was first introduced as a therapy against Mtb in 
the 1950s and was first recommended in US guidelines for LTBI treatment in 
1965. INH interferes with mycolic acid synthesis, resulting in disruption of the 
bacterial cell wall (Takayama et al., 1972, Winder et al., 1970) (Fig.  68). INH is a 
prodrug and is converted to an active form by catalase peroxidase (KatG) 
(Peloquin et al., 2002; Zhan et al., 1992). Activated INH inhibits the action of 
enoyl-acyl carrier protein reductase (InhA), which is an important enzyme 
component of the fatty acid synthetase II (FAS-II) complex. FAS-II is involved in 
the synthesis of long-chain mycolic acids. It is bactericidal against rapidly dividing 
bacteria, but has limited activity against slow growing populations (Budha et al., 
2009). 
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Fig.  68 Site of action of isoniazid. Extracted from www.immunopaedia.org 
 
 Rifampin (RIF) (CAS 13292-46-1), a product of Streptomyces sp., is the mainstay of 
current antituberculosis therapy. RIF inhibits bacterial DNA-dependent RNA 
polymerase by binding to its β-subunit (Norton et al., 2012) (Fig.  69). Preventive 
treatment with rifampin-pyrazinamide causes severe hepatotoxicity more often 
than does preventive treatment with isoniazid or curative treatment for 
tuberculosis (van Hest et al., 2004), which limits rifampin usage for long-term 
therapy. 
 
 
Fig.  69 Site of action of rifampicin. Extracted from www.immunopaedia.org 
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 Pyrazinamide (PZA) (CAS 98-96-4) is uniquely effective in eliminating potential 
persisters and is used during the first 2 months of chemotherapy to reduce the 
total length of therapy. PZN is a prodrug and is converted to active form 
(pyrazinoic acid) by a nicotinamidase-peroxidase enzyme known as 
pyrazinamidase mycolic acids (Fig.  70). PZA does not show any activity against 
mycobacteria under normal culture conditions at neutral pH but shows in vitro 
activity in acidic cultures (Wade et al., 2004, Zhang et al., 2002) and 
demonstrates high in vivo sterilizing activity (Tarshis et al., 1953). Being effective 
at acidic pH makes it ideal drug for killing tuberculosis residing in acidic 
phagosomes within infected macrophages (Mandell et al., 1996).  
 
 
Fig.  70 Site of action of pyrazinamide. Extracted from www.immunopaedia.org 
 
 Streptomycin (STR) (CAS 3810-74-0), first introduced by Waksman (Waksman et 
al., 1946), was the first clinically effective antibiotic available for the treatment 
of TB. STR is an aminoglycoside that interferes with translation of messenger 
RNA transcripts in Mtb. STR binds to a ribosome protein (S12) that is a 
component of the 30S subunit of the ribosome complex and inhibits the 
synthesis of mycobacterial proteins (Fig.  71). Streptomycin is effective only 
against actively growing extracellular organisms and because of high rates of 
resistance sometimes it is not considered as a first line drug.  
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Fig.  71 Site of action of streptomycin. Extracted from www.immunopaedia.org 
 
 Ethambutol (EMB) (CAS 74-55-5) interferes with cell wall biosynthesis in Mtb 
(Fig.  72). EMB inhibits the action of arabinosyl transferase (EmbB), which is a 
membrane-associated enzyme involved in the synthesis of arabinogalactan 
(Takayama et al., 1989). 
 
 
Fig.  72 Site of action of ethambutol. Extracted from www.immunopaedia.org 
 
1.6.2.2 Second line drugs 
The targets of second-line drugs against Mtb are cell wall biosynthesis, DNA 
supercoiling and protein synthesis. 
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Ethionamide (CAS 536-33-4) and cycloserine (CAS 68-41-7) interfere with cell wall 
biosynthesis by inhibiting mycolic acid synthesis and peptidoglycan synthesis, 
respectively. 
Ciproflaxin (CAS 85721-33-1) and ofloxacin (CAS 82419-36-1) are fluoroquinolone 
drugs that inhibit DNA supercoiling by inhibiting the DNA gyrase enzyme. 
Kanamycin (CAS 8063-07-8) and amikacin (CAS 37517-28-5) are aminoglycoside 
drugs that interfere with protein synthesis by inhibiting the action of ribosomes. 
Similarly, viomycin (CAS 32988-50-4) and capreomycin (CAS 11003-38-6) are peptide 
drugs that also inhibit the action of ribosomes. 
1.6.2.3 Experimental drugs 
Existing therapy against tuberculosis is cumbersome, due to its length of ~6 months 
and often leads to prior patient compliance. There is an urgent need for more 
effective and tolerable treatment of drug-susceptible and drug-resistant disease, 
latent TB infection, and dosing strategies for children. 
New drugs are required to shorten and simplify treatment, to improve the efficacy 
and tolerability of treatment for resistant strains of Mtb and to improve the 
treatment of TB among people living with HIV. 
The status of the pipeline for new anti-TB drugs is shown in Table 11. 
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Table 11 The development pipeline for new TB drugs. Source: Stop TB Partnership Working Group on 
New TB Drugs; WHO, 2013. GLP: Good labolatory practice. 
Lead optimization 
Preclinical 
development 
GLP 
toxicity 
P
h
as
e
 I 
Phase II Phase III 
Diarylquinoline 
DprE Inhibitors 
GyrB inhibitors 
InhA Inhibitors 
LeuRS Inhibitors 
MGyrX1 inhibitors 
Mycobacterial 
Gyrase 
Inhibitors 
Pyrazinamide 
Analogs 
Riminophenazines 
Ruthenium (II) 
complexes 
Spectinamides 
Translocase-1 
Inhibitors 
CPZEN-45 
DC-159a 
Q-201 
SQ-609 
SQ-641 
SPR-10199 
BTZ-043 
TBA-354 
 
AZD-5847 
Bedaquiline 
(TMC-207) 
Linezolid 
Novel 
Regimens 
PA-824 
Rifapentine 
SQ-109 
Sutezolid 
(PNU- 
100480) 
Delamanid 
(OPC-67683) 
Gatifloxacin 
Moxifloxacin 
Rifapentine 
 
 
Chemical classes: fluoroquinolone, rifamycin, oxazolidinone, nitroimidazole, 
diarylquinoline, benzothiazinone 
 
1.7 MDR-TB and XDR-TB 
Multi-drug resistant tuberculosis (MDR-TB) is defined as resistance to the first-line 
drugs isoniazid and rifampin. 
ANNEX 1 
 
187 
 
Extensively drug resistant TB (XDR-TB) is defined as MDR-TB plus resistance to a 
fluoroquinolone, and at least one of three injectable second-line drugs. Treating 
XDR-TB is difficult and requires tailored individual care. 
Drug-resistant TB disease can develop in two different ways, called primary and 
secondary resistance. Primary resistance occurs in people who are initially infected 
with resistant organisms. Secondary resistance, or acquired resistance, develops 
during TB therapy, either because the patient was treated with an inadequate 
regimen, did not take the prescribed regimen appropriately, or because of other 
conditions such as drug malabsorption or drug-drug interactions that led to low 
serum levels. 
Regimens for MDR-TB treatment currently recommended by WHO imply 20 months 
of treatment with second-line drugs for most patients, and are associated with 
multiple side-effects and lower cure rates (Who 2013). 
 
 
Fig.  73 Percentage of new tuberculosis cases with MDR-TB (WHO, 2013). 
 
1.8 TB global initiatives 
There are many government, multi-lateral and also non-governmental organizations  
focused on TB. Their role is to accelerate progress on access to TB diagnosis and 
treatment, research and development for new TB diagnostics, drugs and vaccines, 
and tackling drug resistant- and HIV-associated. 
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World Health Organization carries global leadership on matters critical to TB by 
monitoring TB situation in the world, including new strategies and standard 
implementation and measuring progress in TB care, control, and financing. WHO 
shapes the TB research agenda and stimulates the generation, translation and 
dissemination of valuable knowledge. 
STOP TB PARTENRSHIP is a collection of nearly 1000 partners that is transforming 
the fight against TB in more than 100 countries. They include international and 
technical organizations, government programmes, research and funding agencies, 
foundations, non-governmental organizations, civil society and community groups 
and the private sector. 
There are many non-profit organization dedicated to the discovery and 
development of new, globally accessible and affordable tuberculosis medicines, 
such as TB Alliance, Bill & Melinda Gates Foundation, Aeras and TuBerculosis Vaccine 
Initiative (TBVI). 
Main target that unites all TB organizations is The Millennium Development Goal 
(MDG) under which by 2015 the global burden of TB disease (deaths and 
prevalence) will be reduced by 50% relative to 1990 levels, and further, by 2050, the 
global incidence of TB disease will be less than 1 per million population. By 2012, the 
prevalence rate fell 37% globally since 1990. Current forecasts suggest that the Stop 
TB Partnership target of halving TB prevalence by 2015 compared with a baseline of 
1990 will not be met worldwide (WHO 2013). 
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Annex 2 
Comparison of the annotated Mycobacterium tuberculosis H37Ra genome sequence 
with that of H37Rv (GenBank accession no. AL123456) did not reveal any differences 
in DosR, DosS, DosT aminoacid sequences (Fig. 74, Fig. 75, Fig. 76). For this reason, 
the Mtb DosRST proteins were cloned using H37Ra genomic DNA as template. 
 
 
Fig. 74 Sequence alignment of two-component transcriptional regulatory protein DosR 
[Mycobacterium tuberculosis H37Rv] (NCBI Reference Sequence:NP_217649.1)  (query) with two-
component transcriptional regulatory protein DosR [Mycobacterium tuberculosis H37Ra] (NCBI 
Reference Sequence: YP_001284510.1) (Sbjct). 
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Fig. 75 Sequence alignment of two-component sensor histidine kinase DevS [Mycobacterium 
tuberculosis H37Rv] (NCBI Reference Sequence: NP_217648.1) (query) with two-component sensor 
histidine kinase DevS [Mycobacterium tuberculosis H37Ra] (NCBI Reference Sequence: 
YP_001284509.1) (Sbjct). 
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Fig. 76 Sequence alignment of two-component system sensor histidine kinase DosT [Mycobacterium 
tuberculosis H37Rv] (NCBI Reference Sequence: YP_006515439.1) (Query) with histidine kinase 
response regulator [Mycobacterium tuberculosis H37Ra] (NCBI Reference Sequence: YP_001283364.1) 
(Sbjct). 
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Annex 3 
Table 12 Cross-references for most important proteins in this thesis. 
Protein 1. TubercuList 2. UniProt 4. Pfam 5. TB Database 
DosR Rv3133c.  P9WMF9 PF00072 
PF00196 
Rv3133c 
DosS Rv3132c.  P9WGK3 PF01590 
PF02518 
PF07730 
Rv3132c 
DosT Rv2027c.  P9WGK1 Rv2027c 
PknH Rv1266c.  P9WI71 PF00069 Rv1266c 
 
1. http://genolist.pasteur.fr/TubercuList/genome.cgi 
2. http://www.uniprot.org/ 
3. http://pfam.xfam.org/ 
4. http://www.tbdb.org/ 
 
 
